Studies on aspects of autonomic neuropathy in non insulin dependent Diabetes by Levitt, Naomi Sharlene & Levitt, Naomi Sharlene
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
STUDIES ON ASPECTS OF AUTONOMIC NEUROPATHY IN 
NON INSULIN DEPENDENT DIABETES 
by 
Naomi Sharlene Levitt, M.B., Ch.B. 
thesis submitted to the University of Cape Town in fulfilment 
of the requirements for the degree of Doctor of Medicine 
October, 1980 
  
 
 
 
 
 
 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
For my mother and father and to the memories of my 
brother David and my grandmother. 
ABSTRACT 
Autonomic neuropathy (AN) is a well-recognized complication of diabetes mellitus. 
It has multiple clinical features and is often associated with debilitation and 
an increased mortality. However, there appears to be a paucity of knowledge with 
regard to its effects on hormone release and its biochemical sequelae. Recent 
evidence has accumulated suggesting a role for the autonomic nervous system in 
regulating release of a number of gastrointestinal hormones. It is therefore 
possible that autonomic dysfunction may be associated with altered gastro-
intestinal hormone relea se and indeed various studies have revealed abnormalities 
in t he release of these peptides in diabetes mellitus. 
The prime purpose of this thesis was to provide evidence which might contribute 
to an understanding of t he interrel ationship between non insulin dependent 
diabetes (NIDDM), gastrointestinal hormone release and the autonomic nervous 
system. Thus studies to evaluate basal and stimulated release of the gastro-
intestinal hormones glucagon (IRG), pancreatic polypeptide (PP), gastrin, gastric 
inhibitory polypeptide (GIP) and somatostatin (SRIF~LI) have been undertaken in 
NIDDM. Studies were also carried out to assess whether AN may be implicated in 
abnormal release of these five gut hormones in diabetes and to determine if one 
of the hormones, PP, might be used as a marker for AN. Finally the effect of 
dietary fibre on glucose tolerance was studied to assess whether its effect 
would be altered in the presence of AN in NIDDM. 
All studies were undertaken in NIDDM with and without AN and matched controls 
whenever possible. The studies were designed to determine basal concentrations 
.of the hormones on three separate occasions: after a 12 hr overnight fast; after 
a 12 hr insulin infusion to induce fasting normoglycaemia; and after overnight 
gastric aspiration to ensure complete emptying of the stomach. Concentrations 
of the five hormones were measured in response to insulin hypoglycaemia, with 
and without prior induction of fasting normoglycaemia and after ingestion of a 
mixed meal. The effects of dietary fibre supplementation on glucose tolerance 
were evaluated following the ingestion of two test meals, one with 5 g guar and 
5 g pectin added and the other without. 
The results of the studies on basal hormone release revealed that in the 
diabetics with AN,an elevated basal plasma IRG concentration was present,which 
could not be corrected by the prior establishment of fasting normoglycaemia or 
by complete gastric emptying. Basal serum PP levels were also elevated, but 
only after the establishment of fasting normoglycaemia. Abnormalities in 
-/ 
stimulated hormone release in the presence of AN were demonstrated as follows: 
impairment of the plasma IRG response to hypoglycaemia which could be corrected 
by the prior establishment of fasting normoglycaemia; a non-correctable uniform 
impairment of the serum PP response to hypoglycaemia; a delayed early serum PP 
peak following ingestion of the mixed meal and a delayed and impaired plasma 
GIP response to the meal. The addition of fibre to a test meal did not affect 
glucose or gut hormone responses to the meal in the diabetics with AN in 
contrast to those without AN who showed im~roved glucose tolerance. 
When the diabetics were regarded as a single group abnormalities in basal and 
stimulated hormone release were present. These were: elevated basal plasma IRG 
concentrations, impaired serum PP responses to hypoglycaemia and impaired 
plasma GIP responses to ingestion of a mixed meal. 
These findings suggest that AN in NIDDM may be associated with altered release 
of certain gastrointestinal hormones and indicate that AN may be relevant in 
the abnormal hormone release observed in NIDDM. Further the findings suggest 
that serum PP responses to insulin hypoglycaemia may have a role as a bio-
chemical marker for AN and that dietary fibre is ineffective in improving 
glucose tolerance in NIDDM with AN, at least in the short term. 
These studies, therefore, provide early evidence of an interrelationship 
between NIDDM, gastrointestinal hormone release and the autonomic nervous 
system and reveal the importance of determining the existence or absence of AN 
in groups of subjects in whom hormone release is to be studied. Furthermore 
the studies suggest that the serum PP response to insulin hypoglycaemia may 
indeed be useful as a marker for AN and that fibre supplementation of diets may 
have a real role in the treatment of diabetes which may however be limited in 
cases complicated by AN. 
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PREFACE 
The work described in this thesis originated from a study on impotence in 
diabetes conducted by investigators of the University of Cape Town/Medical 
Research Council Endocrine and Diabetes Research Group. That study was directed 
towards an evaluation of the incidence and pathogenetic factors of impotence in 
male patients attending the Groote Schuur Hospital Diabetic Clinic. 
On analysis of some of the early data it became apparent that differences 
existed in the release of certain gut hormones (which were measured coinciden-
tally) in diabetics with autonomic neuropathy as compared to diabetics without 
autonomic neuropathy. This observation, together with the realization that 
previously described abnormalities in the release of various hormones had been 
found in patients in whom no reference to the existence of autonomic neuropathy 
had been made, led to the commencement of specific studies to evaluate gastro-
intestinal hormone release in a particular type of diabetic, namely non insulin 
dependent diabetics, in the presence and absence of autonomic neuropathy. In 
addition, the recent surge of interest shown in the effects of dietary fibre on 
glucose tolerance; the suggestions of its use as an adjunct to the therapy of 
diabetes and the observation of altered gastrointestinal hormone release in 
diabetics with autonomic neuropathy led to the question whether the effect of 
dietary fibre on glucose tolerance would be altered in the presence of autonomic 
neuropathy. These are the problems which were researched in this study. 
While these studies were in progress three reports evaluating the effect of 
autonomic neuropathy on the release of the gastrointestinal hormones glucagon, 
gastrin, and pancreatic polypeptide in insulin dependent diabetics were published 
in the literature. The results in the first two reports contrasted with the 
findings in the present study, but the third study is in agreement. Furthermore 
the authors of the last study suggested that impairment of the serum PP response 
to hypoglycaemia might be used as a sign of autonomic neuropathy, a conclusion 
reached in this study. These reports are included in the literature review which 
extends as far as December 1979 on pages 39-41. 
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CHAPTER I 
REVIEW OF LITERATURE 
"Although diabetic neuropathy is probably the most common complication of 
diabetes it remains the least understood, the least explored and the least 
appreciated." 
Max Ellenberg (1976) 
The description by Ellenberg of diabetic neuropathy or neuropathies as he 
preferred to call them, encompassed both autonomic and peripheral neuropathies. 
Whilst the clinical manifestations of both forms of neuropathy are well 
recognized and their pathogenesis, particularly that of peripheral neuropathy 
(PN) has received widespread attention, the hormonal effects and biochemical 
consequences of autonomic neuropathy (AN) remain largely unknown. 
In this work the studies undertaken to investigate diabetic AN and its effect 
on the release of certain of the gastrointestinal hormones are described. In 
view of the paucity of literature pertaining to this relationship, the review 
of the literature has been designed to provide a comprehensive but not 
exhaustive background to the studies undertaken. 
The literature review comprises five sections :-
(1) a brief resume of the five gastrointestinal hormones studied 
namely glucagon (IRG), pancreatic polypept ide (PP), somatostatin 
(SRIF or SRIF-LI), gastric inhibitory polypeptide (GIP) and gastrin. 
(2) autonomic regulation of the release of the five hormones. 
(3) diabetes mellitus and the five hormones. 
(4) diabetic autonomic neuropathy. 
(5) dietary fibre. 
A brief historical note prefaces each part of the review. 
SECTION l : AN OVERVIEW OF THE GASTROINTESTINAL HORMONES 
Introduction 
In 1902 Bayliss and Starling demonstrated that brisk secretion of 
pancreatic juice was elicited by the instillation of hydrochloric acid into a 
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Table I. l 
Table I.2 
Gastrointestinal Hormones 
insulin 
gl ucagon 
gastrin 
cholecystokinin 
secretin 
pancreatic po1ypeptide 
gastric inhibitory polypeptide 
enteroglucagon 
motilin 
somatostatin 
Peptides of the brain and gut 
Substance P 
Somatostatin 
Vasoactive intestinal peptide 
Enkephalin 
Bern bes in 
Gastrin 
Cholecystokinin 
2.i 
denervated loop of small intestine. Realizing the implications of their 
findings, Bayliss and Starling suggested that an unidentified blood-borne 
"chemical messenger'' was released from the acidified intestine to mediate the 
observed response. However, more than fifty years elapsed before the 
significance of the gastrointestinal hormones was realized. The most likely 
reasons for the time lapse were the difficulties encountered in isolating and 
identifying the hormones as we11 as the considerable controversy over the very 
existence of some of them. The situation started to change in the early 
sixties and now almost twenty years later the mucosa of the gastrointestinal 
tract is known to be the largest endocrine gland in the body. 
The gastrointestinal hormones and related peptides are located in endocrine 
ce11s dispersed throughout the mucosa of the gastrointestinal tract. The 
widespread nature of this distribution has made it almost impossible to study 
the actions of the gastrointestinal hormones in the classical manner, i.e. 
surgical removal of the source of hormone release and examination of the 
effect of its absence. Only a few of the numerous peptides localized to the 
gastrointestinal tract however, have been found to fit the criteria for a 
gastrointestinal hormone as indicated in Table 1.1 (Johnson, 1977; Bloom and 
Polak, 1978; Grossman, 1979; Pimstone, Sheppard, Shapiro, et al, 1979; 
Schusdziarra, Harris, Arimura and Unger, 1979). 
The functions of the gastrointestinal hormones are numerous, but fa11 into a 
few major categories : stimulation or inhibition of water, electrolyte, enzyme 
and endocrine secretion from the gut, stimulation or inhibition of gut 
motility, trophic effects, regulation of metabolism and effects on intestinal 
absorption (Johnson, 1977). 
A recent exciting development in the field of gastrointestinal endocrinology 
has been the finding of many peptides initially identified in the gut but 
subsequently found in the brain and conversely peptides of the brain which 
were later found in the gut. The peptides shown in Table 1.2 have been 
localized to nervous tissue in the brain and in the gut as well as to specific 
endocrine cell types in the gut {Bloom and Polak, 1978; Fµxe, Anderson, 
Hokfelt, et al, 1979; Loonen and Soudijn, 1979; Polak and Bloom, 1979). 
Originally gut hormones were thought to exert their actions by passing via the 
bloodstream to a distant site and eliciting a physiological response at their 
destination. However, there appear to be two further major ways in which gut 
hormones or peptides (since they do not all fulfill the criteria for hormones) 
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may act; as a peptidergic neurotransmitter and/or as a locally acting paracrine 
substance (Bloom and Polak, 1978). Thus nervous control, local control and 
control via the circulation may form a triple control system by which gastro-
intestinal functions are regulated (Bloom and Polak, 1978). 
Since only five gut hormones have been selected for study, not all the 
recognized gut hormones are discussed, but the review is limited to those 
chosen for study. They are IRG, PP, gastrin, GIP and SRIF. In this section 
an overview of the literature pertaining to the general characteristics of the 
five hormones is given. 
I (i) GLUCAGON (IRG) 
In 1921 Banting and Best noticed that a mild but reproducible hyper-
glycaemia preceded the hypoglycaemic effect of injecting pancreatic extracts 
into depancreatized dogs. These workers thought that the hyperglycaemic 
phenomenon was due to liberation of epinephrine and did not pursue the subject. 
Shortly afterwards, Murlin, Clough, Gibbs and Stokes, in 1923 reported that 
aqueous pancreatic extracts caused a marked elevation of blood sugar levels in 
depancreatized dogs. They believed this effect was due to a glucogenic 
hormone which they named Glucagon or mobiliser of glucose. 
Glucagon, which initially was considered to occur only in the islets of 
Langerhans in the pancreas, was subsequently also found in extrapancreatic 
tissue. Moreover glucagon was shown to have multiple rather than single form. 
The extrapancreatic glucagons form a heterogenous group of peptides which are 
for the most part, poorly characterized and have been localized primarily to 
the stomach, duodenum, ileum and colon depending on the species studied (Polak, 
Bloom, Coulling and Pearse, 1971; Larsson, Holst, Hakanson and Sundler, 1975; 
Grimelius, Capella, Buffa, et al, 1976). 
The extrapancreatic glucagons are glucagon-like in that they may possess 
glucagon-like immunoreativity (GLI) but may or may not have glucagon-like 
biological activity (Holst, 1978). The availability of specific immunological 
techniques has enabled the differentiatioi of GLI from immunoreactive 
pancreatic-like glucagon (IRG). However, it has been well-established that 
one peptide which is indistinguishable from true pancreatic glucagon, may be 
found in extrapancreatic gastro-intestinal tissue in numerous species (Holst, 
1978). A definite physiological role for these extrapancreatic glucagons has 
not been established as yet. 
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Further discussion of glucagon in this work applies solely to immunoreactive 
pancreatic-like glucagon (IRG) which is itself heterogenous. The predominent 
form of IRG is a straight chained 29 amino acid polypeptide with a molecular 
weight of 3500, but other molecular weight forms have also been found (Valverde, 
Villanueva, Lozano and Marco, 1974; Weir, Knowlton and Martin, 1975; Conlon, 
Ipp and Unger, 1978). By histochemical techniques IRG has been localized to 
the alpha cell, which is generally found on the periphery of · the pancreatic 
islets (Munger, 1972) as well as in the gastric mucosa in certain species 
excluding man (Larsson, Holst, Hakanson and Sundler, 1975; Sundler, Alumets, 
Holst, Larsson and Hakanson, 1976). 
IRG i s a well recognized hormone but perhaps its most important physiological 
action is its role in the maintenance of glucose homeostatis. Its effects are 
opposed by those of insulin. IRG stimulates glucose output from the liver by 
activation of glycogenolysis with resultant 'inhibition of glycogen synthesis 
and stimulation of gluconeogenesis (Park and Exton, 1972). IRG also plays a 
role in lipid metabolism by promoting free fatty acid and glycerol mobilization 
from adipose tissue and the liver (Lefebvre, 1972). In addition IRG is an 
important regulator of amino acid metabolism (Marliss, Aoki and Cahill, 1972). 
In summary, IRG is a well recognized metabolic hormone which is primarily 
localized to the pancreas and has its major role as one of the regulating 
hormones of carbohydrate homeostasis. 
I (ii) PANCREATIC POLYPEPTIDE (PP) 
PP, a 36 amino acid residue, was discovered independently by Kimmel, 
Pollock and Hazelwood (1968) and by Chance (1972). In the course of purifying 
chicken insulin Kimmel and co-workers extracted and purified a polypeptide 
which was named avian pancreatic polypeptide (APP). Chance isolated bovine 
pancreatic polypeptide (BPP) during the purification of bovine insulin and 
subsequently isolated and characterized a similar peptide from pig (PPP), 
sheep (OPP) and man (HPP) (Lin and Chance, 1974). 
By irrununohistochemistry PP has been localized to a population of endocrine 
cells in the islets of Langerhans, distinctive from the IRG (A), insulin (B) 
and SRIF-LI (D) cells. Further in most species PP cells also occur in the 
exocrine parenchyma of the pancreas (Larsson, Sundler and Hakanson, 1976; 
Heitz, Polak, Bloom and Pearse, 1976; Pelletier and Leclerc, 1977), and 
predominate in a specific lobe thereof (Larsson, Sundler and Hakanson, 1976; 
Orci, Malaisse-Lagae, Baetens and Perrelet, 1978). In addition small 
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quantities of PP have been found throughout the gastrointestinal tract {Adrian, 
Bloom, Bryant, et al, 1976). 
At present the physiological function of PP is not known. However studies with 
APP in the chicken and with BPP in the dog have led to suggestions that it may 
have gastrointestinal and possibly metabolic functions. In the chicken infused 
APP induced reductions in liver glycogen, plasma glycerol, free fatty acids and 
amino acids, an increase in plasma triglyceride and a striking stimulation of 
H+ and pepsin secretion. Although large doses of APP were used in the studies 
it has been assumed that the findings may have some meaning with rega~ to 
physiological activity (Kimmel, Pollock and Hayden, 1978). In the dog low 
pharmacological doses of BPP suppressed pancreatic secretion, enhanced gastric 
emptying and intestinal transit and initially stimulated but later inhibited 
gut motility (Lin and Chance, 1978; Taylor, Solomon, Walsh and Grossman, 1979). 
BPP has also been infused in man when suppression of plasma motilin levels, 
pancreatic exocrine secretion and bilirubin output were noted and the promotion 
of gallbladder storage {Floyd, 1979). 
Thus PP has been localized primarily to endocrine cells and the exocrine 
parenchyma of the pancreas. While the physiological function of PP ·in man is 
not known it would appear that its biological actions are directed towards 
moderation of the rate or amount of pancreatic exocrine secretion and bile that 
reach the duodenum. 
I (iii) GASTRIN 
As early as 1905 Edkins reported that extracts of antral mucosa 
stimulated acid secretion when injected intravenously into anaesthetized cats 
(Edkins, 1905a) and named the active principal gastrin (Edkins, 1905b), His 
. 
extracts however, contained histamine as well as gastrin and for many years 
there was controversy as to whether they contained an acid stimulant other than 
histamine. Finally in 1964, all doubts were dispelled when Gregory and Tracey 
isolated pure gastrin from the antral mucosa of the dog. The compounds 
isolated by Gregory and Tracey were two identical 17 amino-acid polypeptides 
named Gastrin I and II, differing only in the presence of a sulphate group on 
the tyrosine of Gastrin II. These gastrin heptadecapeptides have since been 
isolated from the antral mucosa of other species including man {Gregory, 
Tracey and Grossman, 1966). Subsequently further molecular forms of gastrin in 
tissues and serum have been isolated (Ya!ow and Berson, 1972; Rehfeld, Stadil, 
Malmstr~m and Miyata, 1975; Walsh and Grossman, 1975) but the heptadecapeptide 
appears to be the most potent form (Wa1sh and Grossman, 1975). 
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By immunohistochemistry gastrin containing cells (G cells) have been localized 
largely to the pyloric glands of the antrum, particularly to the mid-portion 
of these glands (McGuigan and Greider, 1971). An extensive quantitative study 
on the gastrin content of tissues in the gut has been carried out and in man it 
has been estimated that the duodenum, due to its greater bulk may contain as 
much gastrin as the antrum (Nilsson, Yalow and Berson, 1973). Controversy 
exists as to whether gastrin is found in the pancreas. Very small amounts of 
gastrin have been extracted from human pancreas by some investigators, and 
some workers have found G cells in the pancreas by immunohistochemistry, 
whereas other investigators have failed to confirm these observations using 
extraction and immunohistochemical techniques (Walsh and Grossman, 1975). 
Gastrin in pharmacological doses has been found to have numerous and diverse 
actions on water, electrolyte and enzyme secretion, absorption of nutrients, 
bowel motility, release of hormones, gastric blood flow and stimulation of 
protein synthesis in gastrointestinal tissues (Walsh and Grossman, 1975). 
However, few of these actions have been demonstrated at physiological 
concentrations of gastrin. The accepted physiological actions of gastrin are 
limited to : stimulation of gastric acid and pepsin secretion, a stimulatory 
effect on the lower oesophageal sphincter and stimulation of DNA, RNA and 
protein synthesis in the stomach, duodenum, ileum and colon (Walsh and 
Grossman, 1975; Johnson, 1977). 
In summary, gastrin is a gastrointestinal hormone localized primarily to the 
gastric antrum and the duodenum in man. Its major functions are promotion of 
gastric acid and pepsin secretion and a trophic action on certain gastro-
intestinal tissues. 
I (iv) GASTRIC INHIBITORY POLYPEPTIDE (GIP) 
The possible existence of a polypeptide derived from porcine duodenum 
and jejunum with the biological actions of inhibiting acid and pepsin secretion 
and inhibiting motor activity was postulated by Brown and Pedersen (1970). 
Support for this hypothesis was provided by the isolation of a polypeptide 
during the purification of cholecystokinin-pancreozymin which inhibited acid 
and pepsin secretion from the canine stomach. The polypeptide named GIP was 
found to be a straight-chain, containing 43 amino acids and to have a molecular 
weight of 5105 (Brown, Mutt and Pedersen, 1970; Brown, 1971; Brown and 
Dryburgh, 1971). GIP has been found to circulate in two forms, one with a 
molecular weight of 5105 and the other as a larger molecular weight species 
(Brown, Dryburgh, Ross and Dupre, 1975). The N (amino) terminal amino acid 
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sequence of GIP appears to be similar to that of glucagon, secretin and 
vasoactive intestinal polypeptide (VIP) (Brown, Dryburgh, Ross and Dupre, 1975). 
By immunohistochemistry GIP has been localized to cells situated predominantly 
in the midzone of the glands in the duodenum and to a lesser degree in the 
jejunum in man (Polak, Bloom, Kuzio, Brown and Pearse, 1973). This 
distribution of GIP containing cells has been confirmed following radio-
immunoassay of tissue extracts (Thomas, Shook, O'Domsio, et al, 1977). 
The known actions of GIP in man and animals are diverse. Effects on the 
gastrointestinal tract and on hormone secretion have been demonstrated. In 
the dog GIP causes inhibition of pentagastrin- and histamine- induced gastric 
acid secretion (Pederson, Brown, 1972). In man however, the role of GIP on 
gastric secretion is not as well documented. GIP infused at doses calculated 
to achieve supraphysiological concentrations inhibited pentagastrin-stimulated 
gastric acid secretion (Brown, Dryburgh, Frost, Otte and Pederson, 1978). 
Thus the relevance of this finding in physiological terms is uncertain. GIP 
is a well accepted insulinotropic hormone. In vitro, in isolated islets, and 
in vivo in man, GIP is a potent stimulator of insulin release (Dupre, Ross, 
Watson and Brown, 1973; Crockett, Cataland, Falko and Mazzaferri, 1976; 
Pederson and Brown, 1976). Indeed GIP was originally postulated to be the 
incretin ie. an enteric peptide released during glucose absorption and a 
stimulator of insulin secretion (McIntyre, Holdsworth and Turner, 1965), but 
it is now held that GIP may be only one of numerous incretins (Creutzfeldt, 
1979). In addition GIP has been shown ·to induce IRG release in the isolated 
perfused rat and canine pancreas (Pederson, Dryburgh, Brown and Dupre, 1978; 
Adrian, Bloom, Hermansen and Iverson, 1978). 
Thus GIP is a polypeptide hormone found in the duodenum and jejunum. It has 
numerous biological actions involving motility and secretion in the gastro-
intestinal tract and may have physiological relevance as an incretin. 
I (v) SOMATOSTATIN (SRIF) 
In 1973 whilst searching for growth hormone releasing factor, Brazeau, 
Vale, Burgus, et al, isolated and structurally identified a peptide capable of 
inhibiting growth hormone release from the ovine hypothalamus. The peptide 
was named somatotrophin release inhibiting factor or somatostatin and was 
shown to be a cyclic tetradecapeptide (Brazeau, Vale, Burgus, et al, 1973). 
Following the original extraction of SRIF from the hypothalamus, it was subse-
quently found in other sites in the rest of the nervous system, ie. in 
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various areas of the brain, in the spinal cord and spinal ganglia (HHkfelt, 
Schultzberg, Johansson, et al, 1978; Luft, Efendic and HHkfelt, 1978) as well 
as in peripheral sympathetic ganglia (HHkfelt, Elfvin, Elde, et al, 1977). 
Outside the nervous ~stem, SRIF has been found in various sites in the gastro-
intestinal tract; in the antrum of the stomach where the largest number of 
SRIF cells are seen in man, in the D cells at the periphery of the islets in 
the pancreas, in the duodenum, jejunum and to a lesser extent in the colon 
(Arimura, Sato, Du Pont, Nichi and Schally, 1975; Dubois, 1975; HHkfelt, 
Efendic, HellerstrHm, et al, 1975; Orci, Baetens, Dubois and Rufener, 1975; 
Polak, Pearse, Grimelius, Bloom and Arimura, 1975). 
The widespread distribution and actions of SRIF have led to suggestions that 
it may act as both a neuromodulator and a hormone (Luft, Efendic and HHkfelt, 
1978; Pimstone and Berelowitz, 1978). While SRIF has multiple physiological 
actions, only its effects in the gastrointestinal tract will be referred to. 
SRIF has actions on endocrine and exocrine pancreatic and gastric secretion, 
gastrointestinal hormone secretion, gut motility and gut absorption (Konturek, 
1976; Gomez-Pan and Hall, 1977; Gerich and Patton, 1978). Basal and 
stimulated insulin and IRG secretion is reduced by somatostatin as are plasma 
glucose levels (Gomez-Pan and Hall, 1977; Gerich and Patton, 1978). The 
hypoglycaemic effect of SRIF is transitory and is thought to be a consequence 
of IRG suppression (Sakurai, Dobbs and Unger, 1974). Unger and Orci (1977) 
have postulated that paracrine inter-relationships between insulin, IRG and 
SRIF in pancreatic islets may modify the resultant secretion of insulin and 
IRG and may thus account for some of the abnormalities seen in the secretion 
of these hormones in diabetes. 
Somatostatin also impairs the release of a number of gastrointestinal peptides; 
GIP, CCK, secretin, motilin, GLI, IRG, VIP, PP and gastrin (Gomez-Pan and 
Hall, 1977; Gerich and Patton, 1978). Further, SRIF inhibits absorption of 
xylose, glucose and certain mono- and disaccharides (Wahren and Felig, 1976; 
Wagner, Hengst, Jansen and Gerlach, 1978) leading to the suggestion that 
SRIF may regulate nutrient homeostasis by modulating the absorption of 
nutrients from the intestine (Schusdziarra, Harris, Arimur~ and Unger, 1979). 
In addition SRIF reduces gut motility and inhibits gastric acid and pepsin 
secretion (Gomez-Pan and Hall, 1977; Gerich and Patton, 1978). 
Thus SRIF is a peptide found primarily in central and peripheral nervous 
tissue and in endocrine cells of the gastrointestinal tract. This localization 
of SRIF together with its multiple actions have given rise to suggestions that 
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it may act as a hormone as well as a neuromodulator. In the gastrointestinal 
tract the major functions of SRIF are thought to be regulation of nutrient 
homeostasis and co-ordination of endocrine and exocrine secretion. 
In this section a brief review of the literature was given to provide an over-
view of the 5 gastrointestinal hormones selected for study, Special emphasis 
was placed on the localization of the endocrine cells of origin of the 
hormones and the physiological functions of the honnones, In the next 
section the literature regarding regulation of the release of the 5 gastro-
intestinal honnones by the autonomic nervous system is reviewed. 
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SECTION 2 : AUTONOMIC NERVOUS CONTROL OF GASTROINTESTINAL HORMONE SECRETION 
11 I propose the term autonomic nervous system for the sympathetic system and 
applied nervous system of the cranial and sacral nerves and for the local 
nerves of the gut. 11 
Langley, 1898 
Introduction 
Present knowledge has considerably extended the confines of the 
original description of the autonomic nervous system. Although sympathetic and 
parasympathetic pathways are probably the major components of the autonomic 
nervous system recent work has identified neuropeptides other than the classic 
neurotransmitters in nerves and ganglia of this system (Uvnas-Wallensten, 
Efendic and Luft, 1978; Larson and Rehfeld, 1979; Loonen and Soudijn, 1979; 
Lundberg, Hokfelt, Kewenter, et al, 1979; Polak and Bloom, 1979). In addition 
immunocytochemical studies have revealed nerves in the gut containing neuro-
peptides in their entire length e.g. VIP, substance P (Loonen and Soudijn, 1979; 
Polak and Bloom, 1979). These observations together with others have led to 
the suggestion of peptidergic pathways as a component of the autonomic nervous 
system (Daniel, 1978; Polak and Bloom, 1979). 
The autonomic nervous system provides a dual supply to the gastrointestinal 
tract, similar to other systems. The parasympathetic innervation of the 
oesophagus through to the pelvic colon derives from the subdiaP,hragmatic vagal 
·trunks and the pelvic splanchnic nerves. The former supplying fibres to the 
gut as far as the splenic flexure of the colon and the latter fibres to the 
rest of the colon. The sympathetic innervation of the gut from the oesophagus 
through to the pelvic colon arises from the sympathetic trunks, the greater, 
lesser and lumbar splanchnic nerves. Fibres from the greater and lesser 
splanchnic nerves pass to the gut, from the oesophagus to the splenic flexure 
of the colon and fibres from the lumbar s~anchnic nerves innervate the rest of 
the colon. Fibres from these nerves, particularly the sympathetic fibres, 
generally pass to ganglia such as the coeliac, superior and inferior mesenteric 
ganglia from which fibres extend to the various organs. However, vagal fibres 
also pass directly to the organs concerned and tenninate in plexuses within 
their walls, e.g. myenteric and submucosal plexuses in the intestine (Pick, 
. 1970; Barr, 1979; Chusid, 1979). 
Thus it is apparent that there is a rich supply of nerves to the stomach, 
pancreas and small intestine, the primary sites of origin of the endocrine 
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cells of the 5 gut peptides. The parasympathetic fibres generally pass from 
plexuses within the walls of the organs and end shortly on smooth muscle and 
mucosal cells. However, sympathetic fibres generally follow the blood vessels 
to the organs, thereafter extending to the mucosal cells and smooth muscle 
(Lockhart, Hamilton and Fyfe, 1974). In addition to the fibres described 
above, which are all motor, sensory fibres also pass via the vagus and 
splanchnic nerves and subserve pain and distension in the gut (Lockhart, 
Hamilton and Fyfe, 1974; Barr, 1979). 
Although there can be little doubt regarding the rich neural innervation of the 
gut, little information is available on direct neural innervation of gastro-
intestinal endocrine cells. However there is some suggestive evidence with 
regard to the pancreas. Indeed a rich innervation of the pancreatJc islets was 
recognized by Langerhans himself (1869), More recent work has revealed nerve 
fibres at the periphery of the islets and within the centre of the islets. 
Further nerve terminals of three types have been demonstrated in close 
association with islet endocrine cells (Woods and Porte, 1974) and microscopy 
has revealed nerve terminals applied to the surface of the alpha cell 
(Munger, 1972; Renold, 1972). In addition serotonin and dopamine, both amines, 
have been found within islet alpha (A) and beta (B) cells (Woods and Porte, 
1974). These data indicate that the gut is plentifully supplied with neural 
fibres and that the pancreatic endocrine cells too are richly innervated, It 
is feasible that further studies would reveal a similar situation with regard 
to other endocrine cells of the gut. In addition the innervation of the 
endocrine cells of the gut by the peptidergic nerve fibres, which are likely 
to be in plentiful supply, remains to be elucidated. 
Having reviewed the autonomic nervous innervation of the gut, at this stage it 
is pertinent to discuss the neurotransmitters and their agonists and 
antagonists, for without neurotransmitters nerve impulses could not reach 
their destination. Neurotransmitters are the chemical mediators of nerve 
impulse transmission at synapses and a number of criteria should be fulfilled 
before a substance may be classified as a transmitter (Fahrenkrug, 1979). 
Although it is perhaps appropriate to mention that few of the classical neuro-
transmitters fulfil most of the criteria which are listed below: 
(1) The substance must be present in neur,ons. 
(2) The neurons must possess the necessary mechanisms to synthesize the 
transmitter. 
(3) The presence of the various precursors and intermediaries in the 
synthetic pathway should be demonstrable. 
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(4) There should be systems for the inactivation of the transmitter. 
(5) During stimulation the substance proposed as transmitter must be 
released from the neurons. 
(6) The effect of the transmitter should be mimicked by exogenous 
application of the substance. 
(7) Pharmacological agents which interact with the synaptically released 
transmitter should interact with the suspected transmitter in an 
identical manner. 
(8) The demonstration of specific receptors for the transmitter substance 
on postsynaptic membranes. 
The principle neurotransmitters at most sympathetic postganglionic endings are 
adrenaline and noradrenaline. Acetylcholine is the mediator at synapses 
between pre- and post-ganglionic fibres while dopamine and occasionally 5-
hydroxytryptamine are mediators at some postganglionic endings in the 
sympathetic pathways. The ganglia, both pre- and postganglionic, of the 
parasympathetic pathways are mediated by acetylcholine (Johnson and Spalding, 
_1974; Ganong, 1979). In addition, an increasing number of neuropeptides are 
being found which comply with most of the stringent criteria for neuro-
transmitters e.g. VIP and substance P (Fahrenkrug, 1979; Loonen and Soudijn, 
1979). Thus the autonomic nervous system may in future be separated into 
cholinergic, adrenergic and also peptidergic divisions based on the chemical 
mediator released. 
However, further subdivision in the adrenergic system has been recognized. 
These subdivisions were revealed by Ahlquist (1948) when he found that various 
catecholamines had two types of responses in physiological systems. He 
postulated the existence of two types of receptors; namely alpha-adrenergic 
and beta-adrenergic receptors and classified them according to the order of 
potency with which they were affected by sympathomimetic drugs. Subsequent 
developments have demonstrated that each of the types of receptors exist in 
more than one form (Lands, Arnold, McAuliff, Luduena · and Brown, 1967; Wood, 
Arnett, Clarke, Tsai and Lefkowitz, 1979). The adrenergic receptors are still 
classified by their different sensitivities to certain drugs. Thus it is 
apparent tt-at there are various subtypes of adrenergic receptors which mediate 
distinct physiological functions. 
There are two further terms which require discussion. 
affect acetylcholine as well as adrenergic receptors. 
as agonists and antagonists. Agonist drugs are those 
Various drugs may 
These drugs are known 
capable of inducing the 
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response of the particular neurotransmitter while an antagonist reduces the 
effect of the neurotransmitter or its agonist. These terms have relevance to 
the discussion in this section. 
The innervation of the gut by the autonomic nervous system has been described 
earlier. While disorders of the alimentary tract due to autonomic lesions may 
be suspected, few investigations are available which might confirm the existence 
of dysfunction of autonomic nervous innervation of the gut. However, one of 
these may prove to be of value in the investigation of the effect of AN on 
hormone secretion. The standard test of integrity of vagal innervation to the 
stomach is the gastric acid secretory response to insulin hypoglycaemia, as 
hypoglycaemia will only cause acid secretion if the vagal supply to the stomach 
is intact (Hollander, 1946; Johnson and Spalding, 1974). However, hypo-
glycaemia has subsequently been found to increase circulating catecholamine 
levels too (Vendsalu, 1960; Garber, Cryer, Santiago, et al, 1976). Thus it 
might appear that insulin hypoglycaemia activates both the sympathetic and 
parasympathetic nervous systems and in this way is known to stimulate the 
release of certain hormones e.g. PP (Adrian, Bloom, Besterman, et al, 1977; 
Schwartz, Holst, Fahrenkrug, et al, 1978). 
Thus investigation of the effect of insulin hypoglycaemia on hormone secretion 
in AN may shed some light on the possible existence of altered hormone 
secretion in AN. 
A further possible means of assessing dysfunction of the autonomic innervation 
of the gut relates to the fact that the autonomic nervous system reguiates 
secretion of the gut. Indeed gastric acid secretion in response to a meal is 
induced by a number of mechanisms, one of which is neuronal (Soll and 
Grossman, 1978). Cephalic stimuli via the vagus nerves and gastric distension 
which also activates neural reflexes produce gastric acid secretion (Soll and 
Grossman, 1978) but also causes secretion of certain hormones e.g. gastrin 
(Soll and Grossman, 1978) and PP (Taylor, Feldman, Richardson and Walsh, 1978; 
Schwartz, Stenquist and Olbe, 1979). Ingestion of a meal is a known stimulus 
for the release of a number of gut hormones e.g. gastrin - (Karmen, Soveny and 
Hansky, 1971), PP (Adrian, Bloom, Bryant, et al, 1976) and IRG (Gerich, 
Lorenzi, Karam, Schneider and Forsham, 1975). However, whether the release of 
these hormones relates to the meal per se or solely to activation of the 
autonomic nervous system, or possibly to a combination of these two factors, 
is not known. Thus it is conceivable that alterations in the release of certain 
hormones in the presence of AN may become apparent in their response to meal 
ingestion. Hence it would appear that both insulin hypoglycaemia and ingestion 
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of a mixed meal may provide valuable information regarding the effect of AN on 
gut hormone secretion. 
The functions of the autonomic nervous system are numerous and diverse. In 
the gastrointestinal tract, the area of interest in this work the major actions 
are on motility and secretion. This action extends throughout the gastro-
intestinal tract and the actions of the parasympathetic and sympathetic 
divisions often promote opposite effects. The major functions of the para-
sympathetic innervation of the gut are the following : to increase peristalsis 
in the oesophagus, stomach, gall bladder, small and large intestines; to cause 
relaxation of sphi.ncters in the oesophagus, stomach, small and large 
intestines; to increase exocrine secretion from the stomach, small and large 
intestine and possibly from the pancreas, and the conduction of pain impulses 
from the lower colon. The major functions of the sympathetic innervation of 
the gut are : diminution of motility in the oesophagus and small intestinel 
reduction of peristalsis in the stomach, gall bladder, bile ducts and large 
intestine; relaxation of sphincters in the oesophagus and small intestine; 
inhibition of exocrine secretion from the stomach, small and la--ge intestines 
and possibly from the pancreas and conduction of pain impulses from multiple 
organs (Johnson and Spalding, 1974). 
Although the functions of the peptidergic nerves remain unknown they too are 
likely to be involved in regulation of motility and secretion of the gut. 
Furthermore it is possible that a major function of peptidergic nerves in 
regulation of the release of gut hormones may come to light. Nevertheless it 
is known that sympathetic and parasympathetic pathways have an effect on gut 
hormone release. In this section literature regarding autonomic nervous 
regulation of the release of the five gut hormones is reviewed, 
2 (i) GLUCAGON 
In vivo and in vitro experiments in animals have provided evidence for 
a neuroregulatory role of IRG release. However, conflicting reports on studies 
conducted in man have led to uncertainty with regard to the importance of 
autonomic nervous regulation of IRG release, 
Neuroregulatory effects on IRG release have been studied in animals, in vitro in 
the isolated perfused pancreas and in vivo and support a neuroregulatory role in 
IRG release. Perfusion of epinephrine and norepinephrine, providing combined 
alpha and beta adrenergic receptor stimulation, induced a significant increase 
in plasma IRG levels in the isolated perfused canine pancreas, Stimulation of 
beta adrenergic receptors by isoproterenol induced a marked increase in plasma 
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IRG levels which was completely abolished by propranolol, a beta adrenergic 
receptor antagonist. However, alpha adrenergic blockade did not alter IRG 
release (Iversen, 1973a). Acetylcholine in the isolated perfused pancreas also 
induced IRG release which could be abolished by atropine (Iversen, 1973b). 
These data indicate that adrenergic and cholinergic influences mediate IRG 
release in vitro. 
Animals studied in vivo further support a neuroregulatory role in IRG release. 
Electrical stimulation of the mixed autonomic nerves innervating the pancreas 
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in unanaesthetized dogs resulted in almost a doubling of the pancreaticouduodenal 
vein IRG output (Marliss, Girardier, Seydoux, et al, 1973). Electrical 
stimulation of the peripheral ends of the thoracic vagus nerve in adrenal-
ectomized calves, in whom the splanchnic nerves had been sectioned, produced a 
significant rise in plasma IRG levels. In the normal calf atropine lowered 
basal plasma IRG levels and also delayed the rise in plasma IRG levels in 
response to insulin hypoglycaemia (Bloom, Edwards and Vaughan, 1974). In dogs 
sham feeding increased plasma IRG levels which could be markedly reduced by 
atropine (Nillson and Uvnas-Wallensten, 1977). These observations tend to 
support a role for parasympathetic mediation of IRG release. Studies investi-
gating the effects of the sympathetic nervous system on IRG release in animals 
have also been reported. Splanchnic nerve stimulation in the adrenalectomized 
calf, dog, cat and sheep induced a prompt increase in plasma IRG levels (Bloom, 
Edwards art! Vaughan, 1973; Bloom and Edwards, 1975). Further studies in the 
calf showed that alpha or beta adrenoreceptor blockade did not suppress this 
elevation (Bloom and Edwards, 1978). In addition electrical stimulation of the 
ventromedial hypothalamus, the central sympathetic centre, induced an increase 
in IRG release in the rat (Frohman and Bernardis, 1968). These data thus support 
a role for neural mediation, both sympathetic and parasympatheti~ of IRG release 
in animals. 
The regulation of IRG release by the parasympathetic nervous system has been 
studied in man but conflicting reports have resulted in a lack of clarity on the 
subject. Atropine was originally reported to decrease basal plasma IRG levels 
and to reduce arginine-induced IRG release. Further truncal vagotomy was 
associated with a reduced rise in plasma IRG levels during insulin hypoglycaemia 
but did not alter basal plasma IRG levels (Bloom, Vaughan and Russell, 1974). 
However, a study by Palmer, Werner, Hollander and Ensinck (1979) contradicted 
these findings. In their study truncal vagotomy too did not alter basal plasma 
IRG levels. However neither bethanocol chloride, which mimics the effects of 
acetylcholine at cholinergic nerve terminals, nor edrophonium, a cholinesterase 
blocking agent, which results in accumulation of acetylcholine at cholinergic 
nerve terminals, caused any change in basal plasma IRG concentrations. In 
addition the plasma IRG response to insulin hypoglycaemia was not influenced by 
atropine administration or by truncal vagotomy. The reasons for the contra-
dictory observations in the reports by Bloom et al and Palmer et al are not 
clear as the criteria used in their vagotomized subjects were similar. 
Although a major point of difference in the two studies was the use of different 
IRG antisera, it is uncertain whether this factor could be responsible for the 
discrepancies reported. However, Mcloughlin, Hayes, Buchanan and Kelly (1978), 
using two different glucagon antisera also found that atropine did not alter the 
IRG response to hypoglycaemia, tending to mitigate against antisera differences 
as the cause for the discrepant results reported. The effect of parasympathetic 
blockade on the hyperglucagonaemia induced by exercise was determined by the use 
of atropine, which caused no alteration in exercise-induced IRG release (Galbo, 
Christensen and Holst, 1977). While it might seem presumptuous to comnent on 
the role that the parasympathetic nervous system may have on IRG release in man, 
it seems likely that its role would only be a minor one. 
Adrenergic influences on IRG release have also been studied in man and have 
indeed been found to have an effect, Epinephrine infusion, producing combined 
alpha and beta receptor stimulation, was associated with a 50% rise in plasma 
IRG levels (Gerich, Karam and Forsham, 1973). Infusion of isoproterenol, a 
pure beta receptor agonist, induced a similar elevation of plasma IRG levels 
which was prevented by propranolol, a beta receptor antagonist, although 
propranolol itself had no effect on basal IRG release. In addition infusion of 
methoxamine, an alpha receptor agonist significantly reduced plasma IRG levels 
while phentolamine, an alpha receptor antagonist increased plasma IRG levels 
(Gerich, Langlois, Noracco, et al, 1974; Schneider and Forsham, 1974). 
However, adrenergic agents had no effect on stimulated plasma IRG concentrations 
induced by insulin hypoglycaemia or exercise. Propranolol and phentolamine did 
not alter insulin hypoglycaemia-induced IRG release (Walter, Dudl, Palmer and 
Ensinck, 1974; Mcloughlin, Hayes, Buchanan and Kelly, 1978), Further, neither 
adrenalectomy (Ensinck, Walter, Palmer, Brodaws and Campbell, 1976) nor cervical 
cord transaction (Palmer, Henry, Benson, Johnson and Ensinck, 1976) reduced the 
plasma IRG response to hypoglycaemia. In addition · IRG rel~ased during exercise 
was not altered by phentolamine administration (Galbo~ Christensen and Holst, . 
1977), Thus while adrenergic mechanisms appear to have an effect on basal IRG 
release no associated effect was apparent on stimulated IRG release induced by 
exercise or insulin hypoglycaemia in man. 
Dopaminergic agents have also been shown to effect IRG release (Rayfield, 
George, Eichner and Hsu, 1975; Leblanc, lachelin, Abu-Fadil and Yen, 1977). 
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L-Dopa is a catecholamine precursor and could thus alter IRG release via cate-
cholamine stimulation or may itself have a direct action on dopaminergic 
receptors. Dopamine in man increased plasma IRG levels and this increase was 
not antagonized by alpha or beta adrenergic receptor blocking agents (Lorenzi, 
Karam, Tsalikian, et al, 1979). Thus dopaminergic mechanisms too may play a 
part in the mediation of IRG release. 
In animals there is fairly conclusive evidence of a neuroregulatory role via 
both the sympathetic and parasympathetic nervous systems of IRG release. 
However, in man the parasympathetic nervous system appears to play only a 
minor role, sympathetic influences appear to be involved only in basal IRG 
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release and dopaminergic pathways may also play a part in mediation of IRG release. 
2 (ii) PANCREATIC POLYPEPTIDE 
Considerable evidence has accrued that the autonomic nervous system 
and in particular vagal cholinergic pathways play an important part in the 
regulation of PP release. 
The following data derived from animal and human experiments provides evidence 
of a major role for the parasympathetic nervous system in the regulation of PP 
release. Electrical stimulation of the vagus nerves in anaesthetized pigs 
induced a ninefold increase in portal serum PP concentrations within 30 seconds. 
This response was inhibited by atrop5ne and eliminated by hexamethonium, but 
unaltered by either alpha or beta adrenergic blockade (Schwartz, Holst, 
Fahrenkrug, et al, 1978). In addition acetylcholine stimulated the secretion 
of PP from the isolated perfused procine and canine pancrea~ and this 
secretion could be blocked by atropine (Schwartz, Holst, Fahrenkrug, et al, 
1978; Adrian, Bloom, Hermansen and Iversen, 1978). In man the prominent rise 
in serum PP levels observed in response to insulin hypoglycaemia was totally 
abolished following vagotomy (Adrian, Bloom, Besterman, et al, 1977; Schwartz, 
Holst, Fahrenkrug, et al, 1978) and strongly inhibited by atropine (Schwartz, 
Holst, Fahrenkrug, et al, 1978). 
Moreover there is considerable evidence that a part of th~ stimulus for PP 
release following food ingestion in animals and man is vagally mediated. In 
dogs after truncal vagotomy there was no early or late rise in serum PP levels 
after food ingestion (Taylor, Impicciatore and Walsh, 1977). In man Schwartz, 
Rehfeld, Stadil, et al (1976) found that there was a true biphasic serum PP 
response to food ingestion and that after truncal vagotomy the first phase was 
eliminated and the second significantly reduced. After truncal vagotomy and 
pyloroplasty patients were found to have greatly diminished early and late 
serum PP responses to food {Hansky, Ho, Korman and Stern, 1978). Although data 
in two other reports showed a reduction in serum PP levels after food ingestion 
in· patients with truncal vagotomy, the PP responses were adjudged to have been 
unaffected by vagotomy (Adrian, Bloom, Besterman, et al, 1977; Taylor, Feldman, 
Richardson and Walsh, 1978). 
Further studies have attempted to evaluate more clearly the role of the vagus 
nerves in the first early phase of the PP response to food ingestion. Cephalic 
stimulation has been studied by adequate sham and modified sham feeding 
experiments. These experiments evoked a rapid rise in serum PP levels which 
was reduced by truncal vagotomy and abolished by atropine and benzilonium, an 
antimuscarinic agent with minimal cerebral effects (Taylor, Feldman, Richardson 
and Walsh, 1978; Schwartz, Stenguist and Olbe, 1979; Feldman, Richardson, 
Taylor and Walsh, 1979). The effect of a gastric stretch neural mechanism was 
evaluated by distension of the stomach by & rubber balloon, intragastric 
saline instillation and intragastric food. A11 induced an early small rise in 
serum PP levels which was reduced following vagotomy or probantheline, an anti-
cholinergic agent (Schwartz and Rehfeld, 1977; Taylor, Feldman, Richardson and 
Walsh, 1978). Gastric distension and food stimuli activate local vagal 
reflexes {Grossman, 1962) to cause PP release. Ingestion of a mixed meal 
induced a much greater early rise in serum PP levels than either cephalic 
stimulation or gastric distension produced individually. It would indeed 
appear that the vagus nerve and in particular vagal cho1inergic pathways play an 
important role in the mediation of PP release and specifically the .early serum 
PP response to food and the serum PP response to insulin hypoglycaemia. 
It is generally accepted that vagal integrity exerts a less prominent effect on 
the second late phase of PP release after a meal (Floyd, 1979). Although 
atropine administered intravenously at intervals up to 120 min after ingestion 
of a protein meal caused a rapid return of markedly elevated serum PP levels to 
near basal concentrations, it is likely that the delayed serum PP response to 
food is mediated by an interaction of chemical, humoral and vagal stimuli 
(Floyd, 197 9) • 
The effects of the adrenergic nervous system on PP release are less prominent 
than those of the parasympathetic nervous system. Stimulation of s~anchnic 
nerves in the anaesthetized pig failed to induce PP release (Schwartz, Holst, 
Fahrenkrug, et al, 1978). Adrenaline induced a sma11 rise in serum PP levels in 
the isolated perfused dog pancreas (Adrian, 81 oom, Hermansen and Iversen, 1978) 
as did isoproterenol, a beta adrenergic agonist. The latter stimulus could be 
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blocked by prior infusion of propranolol, a beta adrenergic antagonist (Samols, 
Wei r , Patel, Loo and Gabbay, 1977). Adrenaline in man also produced a small 
rise in serum PP levels which was significantly increased with alpha adrenergic 
blockade. Further exercise-induced PP release was inhibited by beta adrenergic 
blockade but increased by alpha adrenergic blockade (Floyd, 1979). Hence it 
would appear that there is some adrenergic modulation of PP release. 
From the above evidence there appears to be conclusive evidence that neural 
influences are important mediators of PP release. The serum PP response to 
insulin hypoglycaemia appears to be mediated by vagal mechanisms. The early 
serum PP response to food appears to be mediated by vagal cholinergic factors 
while vagal stimuli together with those of chemical and humoral factors 
probably mediate the delayed PP response to food. Furthermore there appears 
to be some degree of adrenergic modulation of PP release. 
2 (iii) GASTRIN 
Neural regulation of gastrin release has been the subject of much 
investigation in man and animals. For the most part the dog has been the 
ani mal studied although certain experiments have also been conducted in the 
cat. 
The following data was derived from animal studies. Electrical stimulation of 
the vagus nerves induced a large increase of serum gastrin levels in 
anaesthetized cats (Uvnas, Uvnas-Wallensten and Nilsson, 1975) and in dogs 
(Smith, Kewenter, Connell, et al, 1975). Also in the dog, vagal stimulation 
by sham feeding and insulin hypoglycaemia induced gastrin release which was 
abolished by vagotomy and blocked by atropine (Nilsson, Simon, Yalow and Berson, 
1972; Tepperman, Walsh and Preshaw, 1972; Csendes, Walsh and Grossman, 1972). 
Also in the dog, application of acetylcholine to the antral mucosa strongly 
stimulated gastrin release (Tepperman, Walsh and Preshaw, 1972), while 
distension of the antrum of the stomach induced gastrin release which could be 
blocked by vagal denervation (Debas, Konturek, Walsh and Grossman, 1974). 
Thus in the dog and to a lesser extent in the cat there is abundant evidence to 
support the importance of cholinergic vagal regulation of gastrin release. 
In contrast to the dog, in man it would appear that there is a vagal cholinergic 
inhibitory mechanism of gastrin release. In man atropine has been shown 
variously to increase, to decrease and not to alter basal serum gastrin 
concentrations (Korman, Soveny and Hansky, 1971; Becker, Reeder and Thompson, 
1974; Feldman, Richardson, Taylor and Walsh, 1979). However, all forms of 
vagotomy resulted in elevated basal serum gastrin concentrations (Stadil, 1974). 
19 
Vagotomy also resulted in greater serum gastrin responses to a meal (Korman, 
Hansky and Scott, 1972) and atropine further enhanced the serum gastrin 
response to a meal in vagotomized subjects (Hansky and King, 1977). In 
addition in healthy men atropine caused an augmented rise in serum gastrin 
levels after a meal (Becker, Reeder and Thompson, 1974) and potentiated gastrin 
release induced by sham feeding (Feldman, Richardson, Taylor and Walsh, 1979), 
Although a significant rise in serum gastrin levels in response to insulin 
hypoglycaemia in healthy men has not been found by all investigators, including 
Mcloughlin, Hayes, Buchanan and Kelly (1978), these workers observed a 
significant increase in serum gastrin levels after prior atropinization. The 
investigators who have noted significant gastrin release with insulin hypo-
glycaemia reported that serum gastrin levels still rose during insulin hypo-
glycaemia in vagotomized subjects (Stadil, 1974). Thus it seems likely that 
there is a vagal-cholinergic pathway in man which normally acts to inhibit 
gastrin release. 
The effect of dopaminergic stimulation on gastrin release has also been studied 
in animals. Using the acute antral pouch in the cat, Uvnas-Wallensten, 
Efendic and Luft, (1978) demonstrated gastrin release in response to apo-
morphine, a dopamine receptor stimulant, which could not be inhibited by 
atropine. Although the apormorphine-induced effect on gastrin release might 
have been mediated by activation of dopaminergic receptors, mediation via the 
vagal nerves and via adrenergic pathways might also have been taken place. 
~rther work is required before the proposed dopaminergic effect on gastrin 
release can be evaluated. 
The effect of sympathetic nervous stimulation on gastrin release has also been 
studied and the data has revealed that adrenergic pathways too mediate gastrin 
secretion. Splanchnic nerve stimulation in anaesthetized cats after separation 
of acid and gastrin-secreting parts of the stomach resulted in a significant 
reduction in gastrin release (Blair, Grund, Reed, et al, 1975), The meaning of 
this finding is uncertain however, as the observed effects might have been due 
to altered blood flow as well as due to direct effects of nerve stimulation on 
gastrin release. 
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In man an important role has been suggested for the sympathetic nervous system 
in the mediation of gastrin release. Indeed elevated serum gastrin levels which 
returned to normal with surgical removal of the tumour, have been reported in 
tv,o patients with phaeochromocytoma (Hayes, Ardill, Kennedy, Shanks and 
Buchanan, 1972). In addition epinephrine infusion in man induced a prompt 
increase in serum gastrin levels (Stadil and Rehfeld, 1973; Christiansen and 
Stad i l, 1976) which could be completely suppressed by prior administration of a 
beta adrenergic blocking agent (Stadil and Rehfeld, 1973). Infusion of iso-
proterenol, a beta receptor stimulant, resulted in a rise in serum gastrin 
levels which was prevented by prior beta adrenergic .blockade (Brandsborg, 
Brandsborg and Christensen, 1976).. These data indicate that there is beta 
adrenergic modulation of basal gastrin secretion. 
The effect of beta adrenergic modulation of stimulated gastrin secretion has 
been investigated by evaluating the effect of beta adrenergic blockade on serum 
gastrin responses to stimuli. Oral or intravenous propranolol administered 
before ingestion of a meal did not alter the serum gastrin response to the meal 
(Kronberg, 1975). Infusion of a beta agonist produced a slight enhancement of 
the meal-induced gastrin release, this enhancement was prevented by prior 
infusion of a beta adrenergic antagonist (Brandsborg, Brandsborg and 
Christensen, 1976). Christiansen and Stadil (1976) assessed the effects of 
three beta adrenergic blocking agents on the serum gastrin response to hypo-
glycaemia. They found that propranolol eliminated, pindolol reduced and 
practolol caused no alteration in the serum gastrin response. In another study 
in which no significant rise in serum gastrin levels was observed in response 
to insulin hypoglycaemia, propranolol did not alter the serum gastrin response 
(Mcloughlin, Hayes, Buchanan and Kelly, 1978). These data indicate that beta 
adrenergic pathways may be partly involved in the mediation of insulin hypo-
glycaemia-induced gastrin release but not in meal-induced gastrin release. 
However, there is little data on alpha adrenergic modulation of gastrin 
secretion. In the two patients with phaeochromocytana the elevated basal serum 
gastrin levels returned to normal with alpha adrenergic receptor blockade 
(Hayes, Ardill, Kennedy, Shanks and Buchanan, 1972). This data is suggestive 
but not conclusive of alpha adrenergic modulation of gastrin secretion. 
The evidence presented above indicates that .. neural regulation plays an 
important part in mediation of gastrin release. There is considerable data to 
suggest that vagal cholinergic pathways normally provide an inhibitory effect 
on gastrin release, both basal and stimulated, As regards the adrenergic 
nervous system, it would appear that alpha and beta adrenergic pathways are 
involved in regulation of basal gastrin release. Further beta adrenergic 
receptor stimulation may play a part in the mediation of insulin hypoglycaemia-
induced gastrin release, but not in meal-induced gastrin release. Further 
studies are required before an accurate assessment of the effect of dopa-
minergic stimu1ation on gastrin release can be made. 
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2 (iv) GASTRIC INHIBITORY POLYPEPTIDE 
Little is known regarding possible neural regulation of GIP release. 
Basal plasma GIP levels and glucose-stimulated GIP release have been reported 
after vagotomy and vagotomy and plyoroplasty respectively. While the other 
reported studies involved the use of atropine. 
A threefold elevation in basal plasma GIP levels has been reported in patients 
after truncal vagotomy, leading Ebert and Creutzfeldt (1978) to suggest that an 
intact autonomic innervation seemed to be important for the basal state of the 
GIP producing cells. Following truncal vagotomy and pyloroplasty, exaggerated 
plasma GIP responses to glucose ingestion were observed (Thomford, Sirinek, 
Crockett, Mazzaferri and Cataland, 1974). This observation might have been due 
to a direct effect of vagotomy or alterations in small intestinal transit time 
and altered gastric emptying. In view of the fact that GIP hypersecretion 
might be an intrinsic defect in patients with duodenal ulcers (Cataland, 
01 Dorisio, Brooks and Mekhijian, 1977) the effect of atropine administration on 
GIP release induced by intraduodenal perfusion of glucose was assessed in 
healthy subjects (Larrimer, Mazzaferri, Cataland and Mekhijian, 1978). Atropine 
was found to blunt the plasma GIP response to intraduodenal glucose, which 
could not be related to reduced gastrointestinal absoprtion of glucose and was 
thought to be due to an effect on the GIP cells. The effect of atropine on 
food-stimulated GIP release in the dog has also been studied (Baumert, Cataland, 
Tetirick, Pace and Mazzaferri, 1978). In this study the plasma GIP response to 
food ingestion was almost completely inhibited. Suggested mechanisms for this 
latter inhibitory effect of atropine on GIP release were a delay in gastric 
emptying of the meal or a dependence of GIP release on the vagus nerve. 
Thus elevated basal plasma GIP levels have been observed in patients after 
truncal vagotomy and exaggerated plasma GIP responses were found in patients 
after truncal vagotomy and pyloroplasty. These observations may possibly be 
related to altered GIP release in duodenal ulcer. However atropine-induced 
inhibition of plasma GIP responses to intraduodenal glucose in man and to a 
meal in dogs might possibly suggest a cholinergic dependence of GIP release. 
Alternatively the atropine effect might have been related to other known 
actions of this drug such as altered gastric empiying. 
2 (v) SOMATOSTATIN (SRIF-LI) 
Few reports are available in which autonomic regulation of gastro-
intestinal release of somatostatin-like immunoreactivity (SRIF-LI) has been 
investigated. However, the effect of cholinergic agonism and adrenergic 
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modulation of pancreatic SRIF-LI has been reported, while the effect of vagal 
activation and cholinergic control of gastric SRIF-LI release and the effect of 
electrical vagal stimulation of SRIF-LI release have also been studied. 
Samols and Weir (1979) and Samols, Weir, Ramseur, Day and Patel (1978) found 
that there was adrenergic but little cholinergic modulation of pancreatic 
SRIF-LI secretion. Using the isolated perfused canine pancreas they infused 
various adrenergic agents to provide specific alpha and beta receptor 
stimulation and inhibition. They found that beta adrenergic stimulation induced 
a significant increase of SRIF-LI secretion which was abolished by beta 
adrenergic antagonism. Alpha adrenergic stimulation moderately decreased 
SRIF-LI secretion and this effect was abolished by infusion of alpha adrenergic 
antagonists. Thus SRIF-LI secretion from the D cell in the pancreas was 
inhibited by alpha adrenergic agonism and stimulated by beta adrenergic agonism 
(Samols and Weir, 1979). The effect of cholinergic agonism on the pancreatic 
D cell was also studied in the isolated perfused canine pancreas by Samols, 
Weir, Ramseur, Day and Patel (1978). Acetylcholine infused into the pancreas 
induced a mild suppression while atropine alone did not alter SRIF-LI release. 
The effect of vagal activation on SRIF-LI release in animals has also been 
studied. Vagal stimulation in cats has been shown to release SRIF-LI into the 
antral lumen (Uvnas-Wallensten, Efendic and Luft, 1978). Electrical vagal 
stimulation in the dog produced a rise in portal plasma SRIF-LI levels, which 
peaked after the end of the stimulation period (Guzman, Chayvaille, Banks, 
Rayford and Thompson, 1979). In addition truncal vagotomy in the dog was 
associated with an increase in basal plasma SRIF-LI levels and like atropine, a 
reduced rise in plasma SRIF-LI levels in response to an intragastric meal 
(Schusdziarra, Roufller, Harris and Unger, 1979). Furthermore, SRIF-LI released 
from the stomach in response to intraduodenal infusion of food in the dog was 
altered by vagotomy as well as by an atropine infusion (Schusdziarra, Rouiller, 
Pietri, et al, 1979). These data suggest that there is vagal and cholinergic 
mediation of gastrointestinal SRIF-LI release, although not necessarily by a 
direct effect. In addition dopamine receptor stimulation by apormorphine 
induced SRIF-LI release into the antral lumen. This SRIF-LI release was 
atropine-resistant (Uvnas-Wallensten, Lundberg and Efendic, 1978). However, it 
is not known whether the apormorphine-induced SRIF-LI release was mediated via 
catecholamine, vagal or dopaminergic stimulation. 
Thus it would appear from the literature available, that there is some degree 
of autonomic regulation of gastrointestinal SRIF-LI release. Vagal, 
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adrenergic and dopaminergic stimulation were associated with alterations in 
SRIF-LI secretion. However, the relevance of these mechanisms in the regulation 
of basal and stimulated SRIF-LI secretion remains unknown. 
In this section literature pertaining to autonomic nervous regulation of the 
release of the five gastrointestinal hormones has been reviewed. It is apparent 
that only in the cases of PP is there . conclusive evidence that neural factors 
and in particular vagal cholinergic influences are important mediators of its 
release. With regard to IRG, parasympathetic pathways appear to play only a . 
minor role in its release in man, while sympathetic influences do appear to be 
involved in the regulation of basal IRG release. There is considerable data to 
support a continuous inhibitory effect of vagal cholinergic pathways on gastrin 
release and a regulatory role for adrenergic influences on the basal release of 
gastrin. There is data to suggest that vagal influences may partly mediate GIP 
release while early work has indicated that vagal, adrenergic and dopaminergic 
pathways effect SRIF-LI release. 
Thus in this section the existence of at least a partial regulatory role for 
autonomic nervous pathways on the release of the five hormones has been 
determined. In addition the release of many hormones including these five gut 
hormones may also be affected in diabetes mellitus. Thus at this stage it is 
pertinent to review the literature of the effect of diabetes on the secretion 
of the five hormones. 
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SECTION 3 : DIABETES MELLITUS AND HORMONE RELEASE 
The history of diabetes dates back many centuries. In the Ebers Papyrus in 
Egypt at about 1500 BC, reference was made to a condition which might have been 
diabetes. Later, in 400 BC "honey urine" was noted by Sushrutha in India. The 
first good clinical description of the disease came from Celsus and the name 
diabetes was introduced by Aretaeus, both Roman physicians living in the 1st 
century AD. However, it was not until the nineteenth century that major 
contributions to the understanding of the biochemistry, pathology and clinical 
features of diabetes were made. Indeed in this century considerable advances in 
the understanding of all aspects of diabetes have been made. 
By definition, diabetes is 11 a chronic hereditary disease characterized by an 
abnormally high level of glucose in the blood and the excretion of that sugar in 
the urine. The basic defect is an absolute or relative lack of insulin which 
leads to abnormalities of metabolism, not only of carbohydrate but also of 
protein and fat 11 (Marble, White, Bradley and Krall, 1971). This definition is 
not completely satisfactory since some forms of diabetes are not hereditary, not 
all diabetics have glucosuria and insulin deficiency is not always the basic 
defect. Indeed it is unlikely that any definition of diabetes would receive 
universal acceptance. 
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A new classification of diabetes has been formulated by an international work group 
and was recently published by the National Diabetes Data Group (1979). This 
classification was based on contemporary knowledge of diabetes and included three 
clinical classes. Only two of these classes have relevance for the present 
studies, insulin dependent diabetes (IDDM) and non insulin dependent diabetes 
(NIDDM). IDDM is usually characterized clinically by a rapid onset of symptoms, 
insulinopenia, dependence on exogenous insulin to sustain life and proneness to 
ketosis. Classically this form of diabetes occurs in juveniles and was previously 
termed juvenile diabetes. However it may occur at any age. Thus diagnosis based 
on age at onset is inappropriate. Genetic and environmental factors may precipitate 
the disease and altered immune responses and autoimmunity are thought to play an 
etiological role. 
NIDDM frequently present with minimal or no symptoms referable to the metabolic 
abnormalities of diabetes. Patients with NIDDM are not prone to ketosis and are 
not dependent on insulin for the prevention of ketonuria, but may require insulin 
for correction of symptomatic or persistent fasting hyperglycaemia that is 
resistant to dietary or oral hypoglycaemic management. Such patients may develop 
ketosis under special circumstances. In NIDDM insulin levels may be normal, above 
normal or low. NIDDM usually occurs in patients over 40 years of age and was 
previously known as adult or maturity onset diabetes. However NIDDM may also 
occur in young people. NIDDM also has a genetic basis but environmental factors 
too are considered important in the onset of the disease. NIDDM may be 
separated into two sub-types, obese and non obesa Although each of the types of 
diabetes described above has a set of features that distinguish it from the 
other, on occasion it may be difficult to assign an individual to one class 
because insufficient information is available on that patient. However it 
should be possible to classify the patient once the information is obtained 
(National Diabetes Data Group, 1979). 
Although there is general agreement that altered insulin secretion is basic to 
the aetiology of diabetes the role of other hormones, particularly pancreatic 
IRG and SRIF-LI, in the causation of diabetes has not been fully elucidated. At 
present there is tremendous controversy with regard to the role of pancreatic 
IRG (Unger, 1978; Lefebvre and Luyckx, 1979), while recent evidence has tended 
to suggest that SRIF-LI too may play a part in the development of diabetes 
(Unger and Orci, 1977). · Setting the controversy regarding the relationship of 
gastrointestinal hormones and insulin secretion in · the development of diabetes 
aside, diabetes per se has been shown to be associated with altered secretion of 
a number of hormones, both pituitary and gastrointestinal in or1g1n. In this 
section literature referring to the effect of diabetes on the 5 gastrointestinal 
hormones chosen for study, will be reviewed. 
3 (i) GLUCAGON 
IRG secretion in diabetes has been the subject of many studies and 
there is evidence of disturbed secretion of the alpha cell in this disorder. 
In the first place abnormalities in basal plasma IRG concentrations have been 
reported in various forms of diabetes in man. Significantly elevated basal 
plasma IRG concentrations have been demonstrated in IDDM (Gerich, Tsalikian, 
Lorenzi, et al, 1975), NIDDM (Pek, Fajans, Floyd, et al, 1972; Day and Anderson, 
1973; Alford, Bloom and Nabarro, 1977) and in patients with diabetes secondary 
to chronic pan~reatitis (Kalk, Vinik, Paul, Keller and Jackson, 1975). However 
in other reports basal plasma IRG concentrations have been similar in NIDDM, 
IDDM and healthy subjects (Aguilar-Parada, Eisentraut and Unger, 1969; MUller, 
Faloona, Aguilar-Parada and Unger, 1970; Unger, Aguilar-Parada, Mulle,r and 
Eisentraut, 1970). The striking feature of these studies was that absolute 
elevation of basal plasma IRG levels as well as similar levels to those of 
healthy controls occurred, despite the presence of hyperglycaemia. In contrast, 
in healthy non -diabetic subjects in whom glucose was infused to produce hyper-
glycaemia comparable to that observed in diabetics, a fall in basal plasma IRG 
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levels occurred (Unger, Aguila-Parada, MUller and Eisentraut, 1970). Thus the 
terms absolute and relative fasting hyperglucagonaemia have been used. 
The mechanism of the fasting hyperglucagonaemia, both relative and absolute, is 
not known but there are suggestions of an insulin-related defect. Marked 
elevation in basal plasma IRG concentrations has been observed in diabetic 
ketoacidosis with reversion to normal levels after institution of treatment 
(MUller, Faloona and Unger, 1973). In addition supraphysiological doses of 
insulin reduced basal plasma IRG levels to within the normal range in NIDDM but 
not in IDDM (Raskin and Unger, 1978). However, restoration of normal basal 
plasma IRG levels has been reported following prolonged insulin infusion in 
IDDM (Gerich, Tsalikian, Lorenzi, et al, 1975; Raskin, Fujita and Unger, 1975). 
Furthermore, insulin treatment reduced the elevated basal plasma IRG levels to 
normal in newly diagnosed diabetics (Matsuyama, Hoffman, Dunbar, Foa and Foa, 
1975). These observations seem to indicate that insulin lack per se, or 
metabolic derangements related to insulin lack induce the relative or absolute 
elevation of basal plasma IRG concentrations in NIDDM and IDDM. However, Unger 
~nd Orci (1977b) have suggested that altered intra-islet SRIF-LI secretion may 
also be involved in the development of fasting hyperglucagonaemia. 
In diabetes in man numerous forms of stimulation have resulted in abnormalities 
in the release of IRG. Ingestion of a carbohydrate meal by healthy subjects 
was associated with a fall in plasma IRG levels. In contrast no reduction in 
plasma IRG levels was observed in IDDM and NIDDM after ingestion of this meal 
(MUller, Faloona, Aguilar-Parada and Unger, 1970). In the same report ingestion 
of a protein meal induced a similar rise in plasma IRG levels in healthy 
controls, NIDDM and IDDM despite hyperglycaemia in the diabetics. When 
comparable hyperglycaemia was induced in the healthy subjects, no rise in 
plasma IRG levels was observed in response to protein ingestion. Two to three-
fold higher plasma IRG responses to ingestion of a mixed meal was also observed 
in IDDM (Gerich, Lorenzi, Karam, Schneider and Forsham, 1975). Furthermore an 
exaggerated rise in plasma IRG levels was noted in response to arginine and 
alanine stimulation in IDDM and NIDDM (Unger, Aguilar-Par3da, MUller and 
Eisentraut, 1970; Wise, Hendler and Felig, 1973). Impaired plasma IRG responses 
to hypoglycaemia have been observed in IDDM (Gerich, Langlois, Noacco, Karam and 
Forsham, 1973), in unstable IDDM (Reynolds, Molnar, Horwitz, et al, 1977) and in 
IDDM with AN (Maher, Tanenberg, Greenberg, et al, 1977). The cause of the 
impaired IRG responses to hypoglycaemia is not clear, but may relate to the 
presence of AN and as such, will be discussed later. However, the data 
presented above clearly demonstrates abnormalities of stimulated IRG. secretion 
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in diabetes in man. 
The effects of insulin and SRIF infusions have been evaluated on some of the 
abnormalities in stimulated IRG release in diabetes. Insulin infusion during a 
carhohydrate meal reduced the abnormal plasma IRG response in both NIDDM and 
IDDM, decreasing it to the level in healthy subjects in the latter group alone, 
and then only when supraphysiological levels of insulin and high glucose levels 
were attained (Aydin, Raskin and Unger, 1977). Similarly supraphysiological 
quantities of insulin and prolonged insulin infusion respectively normalized 
the plasma IRG response to arginine in IDDM (Gerich, Tsalikian, Lorenzi, et al, 
1975; Raskin, Aydin and Unger, 1976). However supraphysiological doses of 
insulin had no effect on the plasma IRG response to arginine in NIDDM (Raskin, 
Aydin and Unger, 1976). Nevertheless, insulin administration alone did not 
normalize the excessive plasma IRG response to ingestion of a mixed meal in 
IDDM, but SRIF infusion alone and when administered with insulin prevented a 
rise in plasma IRG levels (Gerich, Lorenzi, Karam, Schneider and Forsham, 1975). 
Aggressive insulin therapy providing improved control in NIDDM and IDDM, induced 
a significant reduction in mean daily plasma IRG levels in both groups, compared 
to a period of poor control, but in the latter group, the mean plasma IRG con-
centration was still significantly higher than in healthy subjects (Raskin and 
Unger, 1978). SRIF infused for five or 24 hours suppressed plasma IRG levels in 
NIDDM (Tamborlane, Sherwin, Hendler and Felig, 1977; Christensen, Hansen and 
Lundbaek, 1978), and caused the same effect in IDDM when infused for 24 hours 
(Christensen, Hansen, Weeke and Lundbaek, 1978). These data indicate that 
abnormalities in stimulated IRG secretion in IDDM and NIDDM may on occasion be 
corrected by insulin while SRIF may generally correct the abnormalities in both. 
The mechanisms whereby hyperglucagonaemia occurs in diabetes are unclear as 
indicated previously, although there are several possibilities. Metabolic 
clearance rate and plasma acute disappearance times have been studied in IDDM 
{Alford, Bloom and Nabarro, 1976). Despite a similar metabolic clearance rate 
in healthy subjects and diabetics, the acute plasma disappearance time was 
prolonged in the latter. Thus it is possible that sluggish clearance of 
released IRG may be in part responsible for the basal and stimulated hyper-
glucagonaemia of IDDM, but it is not known if the same would apply to NIDDM. No 
studies are available to confirm this hypothesis. Other possible mechanisms 
involve abnormal release of IRG from the alpha cell, which may be an independent 
defect, may be secondary to insulin deficiency or loss of contact between A and 
B cells in the islets {Pek, 1977; Unger and Orci, 1977a). The inability of 
supraphysiological insulin infusions to totally correct the various forms of 
hyperglucagonaemia as described earlier, tends to mitigate insulin deficiency 
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per se being the only mechanism involved. A final possible mechanism postulated 
by Orci and Unger (1977b) suggests that SRIF-LI may alter IRG release from the 
pancreatic alpha cell by it's paracrine influence. This last postulate may 
indeed be responsible for at least part of the hyperglucagonaemia of diabetes 
but further studies are required to fully evaluate the role of somatostatin. 
Various mechanisms have been proposed to explain the impaired IRG responsiveness 
to hypoglycaemia observed in IDDM, including an alpha cell gluco-receptor defect 
(Gerich, Langlois, Noacco, Karam and Forsham, 1973) and AN (Maher, Tanenberg, 
Greenberg, et al, 1977). In view of the latter suggestion, further discussion 
will follow in the next section. 
In summary, elevated basal plasma IRG concentrations relative and absolute, have 
been found in all forms of diabetes. Furthermore marked derangement in 
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stimulated plasma IRG concentrations have also been demonstrated in diabetes thus a 
number of mechanisms have been suggested which might explain the abnormal IRG 
release of diabetes, but the precise mechanism remains unknown. 
3 (ii) PANCREATIC POLYPEPTIDE 
PP secretion in diabetes has received less attention than was the case 
with IRG. 
One of the reasons for this lesser attention may be related to problems 
encountered in the measurement of serum PP levels in diabetics. First, serum 
PP levels increase with age in healthy subjects as well as diabetics (Berger, 
Crowther, Floyd, Pek and Fajans, 1978), thus unless groups are age-matched, the 
validity of the levels measured are questionable for comparison. Second, 
conventional insulin treatment is associated with the development of circulating 
antibodies to PP in up to 64 per cent of patients. Such circulating PP anti-
bodies invalidate the levels of PP obtained when measured by a conventional 
radioimmunoassay for PP (Floyd, Fajans, Pek and Chance, 1977; Bloom, West, 
Polak, Barnes and Adrian, 1978). 
Basal serum PP levels have been determined in diabetics and the levels observed 
appear to be related to the degree of hyperglycaemia. Floyd, Fajans, Pek and 
Chance (1977) found significantly higher basal serum PP levels in IDDM and 
insulin treated NIDDM compared to healthy subjects, but NIDDM treated with oral 
agents or diet had similar basal serum PP levels to controls. Amongst the four 
groups of diabetics studied by Floyd, et al, the mean basal serum PP level rose 
in relation to the mean fasting blood glucose level. Elevated basal serum PP 
levels which were twice that of age-matched healthy controls were reported by 
Villanueva, Heda, Castillo-Olivares and Marco (1978) in diabetics with marked 
fasting hyperglycaemia and presumably IDDM. In contrast a group of IDDM well 
stabilized on monocomponent insulin therapy had similar basal serum PP levels 
to those of age-matched controls (Adrian, Bloom, Besterman and Bryant, 1978). 
Introduction of insulin therapy in previously untreated NIDDM reduced their 
basal serum P~ with one exception, to levels which could not t:econsidered 
elevated (Berger, Floyd, Pek and Fajans, 1978). These data suggests that 
diabetes is more often associated with elevated basal serum PP levels if the 
diabetes is uncontrolled. 
The following data suggests that stimulated PP secretion is altered in diabetes. 
Villanueva, Heda, Castillo-Olivares and Marco (1978) round that diabetics had 
exaggerated serum PP responses to ingestion of a protein meal compared to 
controls. Although Villanueva and associates did not specify the type of 
diabetic subject studied, they had marked fasting hyperglycaemia and were 
probably IDDM. In contrast Sive, Vinik, Van Tonder and Lund (1978) found 
impaired serum PP responses to insulin hypoglycaemia in patients with chronic 
pancreatitis and pancreatic diabetes. Impaired PP release after a meal was also 
found in patients with chronic pancreatitis and steatorrhoea of whom a small 
proportion were diabetic (Adrian, Besterman, Mallison, Garalotis and Bloom, 
1979). The mechanism of the impaired serum PP responses is likely to be· related 
to the reduced PP cell mass in the destroyed fibrotic pancreas, or alternatively 
to defective PP release resulting from gross distortion of the architecture of 
the pancreas due to the disease process of chronic pancreatitis. The mechanisms 
of the exaggerated serum PP responses in the diabetics reported by Villanueva 
et al are unclear, but may be related to altered intra-islet paracrine 
relationships and insulin deficiency. 
Serum PP responses to insulin hypoglycaemia have also been studied in diabetic 
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AN (Krarup, Schwartz, Hilsted, et al, 1979) and impaired responses have been found 
in IDDM with AN as compared with IDDM without AN. In the latter group however, 
impaired serum PP responses, although not to the same extent as in the former, 
were observed in the patients with a long duration of diabetes. In addition the 
impairment in the PP response in hypoglycaemia even on those without AN, was found 
to correlate inversely with the threshold of vibration sense. This suggests the 
existence of undiagnosed AN in the patients without AN and also reveals abnormal 
PP secretion in diabetic AN. This report is also discussed in the next section. 
Thus it is apparent that abnormalities in basal and stimulated PP secretion in 
diabetes have been reported in the literature. The mechanisms whereby most of 
these abnormalities occur are unknown, but suggestions have been made in each 
case. Nevertheless further work is required to fully elucidate the mechanisms 
underlying the various abnormalities reported. 
3 (iii) GASTRIN 
Gastrin secretion in diabetes mellitus has been the subject of one 
study. Feldman, Corbett, Ramsay, Walsh and Richardson (1979) studied gastrin 
secretion in IDDM; their patients were divided into two groups on the basis of 
the presence of the symptoms nausea and vomiting. Basal and food stimulated 
gastrin concentrations were found to be similar in both groups of diabetics, 
but were two- to threefold higher than in normal subjects. In addition 
features of PN and AN as well as delayed gastric emptying rates were present 
.in both groups of diabetics. These data tend to suggest that the observed 
abnormal gastrin secretion was the consequence of AN and not diabetes per se. 
In view of this conclusion the data will be discussed in more detail in the 
next section. 
3 (iv) GASTRIC INHIBITORY POLYPEPTIDE 
GIP secretion, both basal and stimulated, has been studied in all forms 
of diabetes in man and there is some evidence to suggest abnormal secretion in 
this condition. 
In the first instance fasting plasma GIP levels have been reported in various 
forms of diabetes. Normal basal plasma GIP levels have been found in non-obese 
NIDDM with fasting hypoglycaemia treated with dietary restriction alone (Ross, 
Brown and Dupre, 1977). Elevated basal plasma GIP levels were reported in obese 
subjects who had a pathological glucose tolerance test (Ebert and Creutzfeldt, 
1978) while still higher basal levels were found in obese NIDDM (Crockett, 
Mazzaferri and Cataland, 1976; Ebert and Creutzfeldt, 1978). These data suggest 
that fasting plasma GIP concentrations are related to either obesity per se or to 
the hyperinsulinaemia which accompanies obesity. In addition elevated basal 
plasma GIP levels were found in subjects with mild acquired pancreatic diabetes 
(Botha, Vinik and Brown, 1976). In subjects with more severe diabetes secondary 
to chronic pancreatitis, insulin withdrawal induced a further rise in basal 
plasma GIP levels which returned to normal on reinstitution of insulin treatment, 
suggesting that insulin treatment lowers basal plasma GIP levels, possibly via a 
metabolic effect related to insulinopenia (Botha, Vinik and Child, 1978). In 
untreated ketotic IDDM, five-fold higher basal plasma GIP levels than those of 
controls have been observed, suggesting that insulin deficiency or elevated blood 
ketones may lead to higher basal plasma GIP levels (Ebert and Creutzfeldt, 1978). 
Stimulated plasma GIP concentrations ha.e also been reported in diabetics and 
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various abnormalities have been found. However, neither in untreated ketotic 
IDDM nor in well controlled IDDM did the plasma GIP responses to ingestion of a 
test meal differ from those in healthy controls (Ebert, Frerichs and Creutzfeldt, 
1976; Ebert and Creutzfeldt, 1978). Contrariwise in poorly controlled IDDM 
there was a significantly reduced plasma GIP response to oral glucose compared 
to controls (Reynolds, Tronsgard, Gibbons, Blix and Rubenstein, 1979). In 
contrast, obese and non-obese NIDDM with fasting hyperglycaemia had exaggerated 
plasma GIP responses to an oral glucose tolerance test and a mixed meal 
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(Crockett, Mazzaferri and Cataland, 1976; Ebert, Frerichs and Creutzfeldt, 1976; 
Ross, Brown and Dupre, 1977). However no enhancement of plasma GIP responses to 
oral glucose or oral corn oil were observed in obese and non obese NIDDM who did 
not require oral hypoglycaemia therapy and who did not have fasting hyperglycaemic 
(May and Williams, 1978). Thus abnormalities in stimulated GIP secretion have 
been found in obese and non obese NIDDM with fasting hyperglycaemia and in certain 
IDDM but not in obese and non obese NIDDM with fasting normoglycaemia. These data 
in the NIDDM suggest that .abnormal stimulated GIP secretion is related to the 
combination of fasting hyperglycaemia and NIDDM regardless of the presence of 
obesity. The discrepant results obtained in the IDDM are difficult to explain and 
do not appear to be related solely to insulin deficiency. Furthermore the precise 
mechanism of the altered stimulated GIP secretion observed in certain IDDM and 
NIDDM is unknown. 
Hence abnormal GIP secretion occurs in the major forms of diabetes in man. In 
addition differences exist in the form of the altered GIP secretion in these 
various types of diabetes. These differences might be explained by some of the 
characteristics of the types of diabetes such as the presence of insulinopenia 
and obesity. It is apparent however that studies are required to elucidate the 
mechanisms underlying the observed alterations in GIP secretion in IDDM and 
NIDDM. 
3 (v) SOMATOSTATIN 
The effect of diabetes on SRIF-LI secretion in man is largely unknown 
due to the fact that the measurement of circulating SRIF-LI levels in this 
species is in it's infancy. Although considerable controversy has been raging 
over the estimation of circulating SRIF~LI levels in man, the recent description 
of a number of assay systems for this measurement should result in a flurry of 
reports including some on secretion in diabetes. 
The reported studies on SRIF-LI secretion in diabetes have primarily involved 
evaluation of SRIF-LI secretion in the insulin-deficient dog and immunohisto-
chemistry and radioimmunoassay of pancreatic tissue extracts of various species. 
In the insulin-deficient alloxan diabetic dog, marked abnormalities in SRIF-Ll 
secretion have been demonstrated. Significantly elevated basal plasma SRIF-LI 
levels have been ·observed in alloxan diabetic dogs compared to control dogs 
(Schusdziarra, Dobbs, Harris and Unger, 1977; Schusdziarra, Rouiller, Harris, 
Conl on and Unger, 1978). Despite insulin treatment lowering the elevated basal 
plasma SRIF-LI levels, the lowered concentrations were still significantly 
higher than those of control dogs (Schusdziarra, Dobbs, Harris and Unger, 1977). 
In addition in alloxan diabetic dogs plasma SRIF-LI responses to intragastric 
low and high fat protein meals were initially attenuated but ultimately exceeded 
those in control dogs. Further, insulin administration abolished the rise in 
plasma SRIF-LI levels in response to the intragastric meal in the diabetic dogs 
{Schusdziarra, Rouiller, Harris, Conlon and Unger, 1978). These data indicate 
the presence of altered SRIF-LI secretion in alloxan diabetic dogs and tend to 
suggest that insulin deficiency may play a part in this altered secretion. 
In other forms of insulin-deficient diabetes, alterations in the SRIF-LI (D) 
cell mass and in SRIF-LI content of the pancreas have been reported. In IDDM 
in man and in streptozotocin-induced diabetes in rats, hypertrophy and hyper-
plasia of D cells and in the latter increased islet content of SRIF-LI, have 
been found (Orci, Baetens, Rufener, et al, 1976; Patel and Weir, 1976). 
However, in spontaneously diabetic mice, conflicting reports have appeared. 
In the insulinopenic spontaneously diabetic mouse, Baetens, Coleman and Orci 
(1976) found an increase in the number of D cells while in the same mice, not 
as yet insulinopenic, Patel, Orci, Bankier and Cameron (1976) found decreased 
pancreatic SRIF-LI content. The reason for the discrepancy in the latter two 
reports probably related to different ages of the animals studied, as in the 
former the mice were insulinopenic and were thus presumably older than those in 
the former study. Nevertheless it would appear that insulin deficient forms of 
diabetes are associated with altered SRIF-LI secretion and abnormalities in 
SRIF-LI content and D cell mass in the pancreas. 
Little is known with regard to SRIF-LI secretion in non insulin-deficient forms 
of diabetes, although alterations in numbers of pancreatic D cells and in 
pancreatic SRIF-LI content have been reported in spontaneously diabetic animals. 
An increased pancreatic SRIF-LI content was observed in hyperinsulinaemic 
spontaneously diabetic mice (Dolais-Kitabchi, Marchand-Brustel and Freychet, 
1979), but there was no associated increase in the number of D cells (Makino, 
Matsushima, Kanatsuka, et al, 1979). Conversely in the same hyperinsulinaemic 
spontaneously diabetic mice, a decreased pancreatic SRIF-LI content was noted 
(Patel, Orci, Bankier and Cameron, 1976) and further a reduced release of . 
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SRIF-LI from the islets was observed (Petersson, Ludgvist and Andersson, 1979). 
Once again age differences in the animals studied may explain the discrepant 
results reported, although it is possible that varying laboratory techniques 
too may be responsible. Despite the conflicting reports, it is clear th-at 
alterations exist in pancreatic SRIF-LI content and release in hyperinsulinaemic 
forms of diabetes in animals. Whether the same applies to man remains to be 
assessed. 
The sequelae of the aforementioned alterations in SRIF-LI secretion and pancreatic 
SRIF-LI content in the various forms of diabetes are unclear, but the importance 
of the reduced release of SRIF-LI from the pancreatic islets of hyperinsulinaemic 
mice as reported by Petersson and co-workers cannot be overlooked. Indeed it is 
feasible that altered islet SRIF-LI release in insulin deficient and non insulin-
deficient forms of diabetes may produce changes in the normal intra-islet 
paracrine interrelationships and may in some way be related to the abnormalities 
in islet hormone release in diabetes (Unger and Orci, 1977). 
In summary in this section literature regarding the effect of diabetes on the 
five gastrointestinal hormones has been reviewed. It ·is apparent that 
abnormalities in IRG, PP and GIP secretion are a common feature of diabetes. 
However little work is available on SRIF-LI secretion in diabetes and that which 
is available stems from animal work. Nonetheless the animal studies have 
provided evidence of abnormalities in SRIF-LI secretion which may also occur in 
diabetes in man. In addition it is possible that altered SRIF-LI secretion may 
in some way be related to the abnormalities in the islet hormones in diabetes. 
The finding of altered gastrin secretion in diabetes in the only report 
available was probably related to altered neural innervation of the G cell rather 
than to diabetes per se. 
Thus diabetes may be associated with altered hormone secretion. In addition 
diabetes may be complicated by the presence of AN and by the same token hormone 
secretion in diabetes may be affected if AN is present. Hence in the next 
section literature relating to AN and its pathogenesis, clinical tests of its 
integrity and known hormonal effects, will be reviewed. 
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SECTION 4 : DIABETIC AUTONOMIC NEUROPATHY 
Introduction 
Prior to 1850 the high frequency of neurological abnormalities in 
diabetes mellitus led many workers to believe that diabetes was caused by a 
lesion in the nervous system. However, De Calvi in 1864 suggested that 
diabetes might be the cause, rather than the result of the neurological 
lesions. Almost without exception, early reports of neurological involvement 
in diabetes referred to peripheral neuropathy (PN), but in two reports 
involvement of autonomic fibres of peripheral nerves was described (Auche, 
1890; Pryce, 1893). A detailed description of the features of AN did not 
appear until 1945 when Rundles, in a review of 125 cases with diabetic neuro-
pathy, documented the presence of gastrointestinal and genito-urinary dis-
turbances and abnormalities in the regulation of blood pressure, sweating and 
temperature of the skin in a proportion of the diabetics studied. 
To date the numerous clinical manifestations of AN have been well documented. 
Moreover the fact that the symptoms of AN may be severe and incapacitating 
and that an increased mortality rate may be associated with AN (Ewing, Campbell 
and Clarke, 1976) are still well accepted. In this section literature 
pertaining to the pathogenesis and the clinical features of AN and the use of 
tests to confirm the presence of AN is covered. The known biochemical and 
hormonal sequelae of AN are discussed in more detail. 
4 (i) PATHOGENESIS OF AUTONOMIC NEUROPATHY 
Studies on the pathogenesis of diabetic neuropathy have focussed on 
PN and there is no comparable data on AN. In addition morphological studies 
of nerves in diabetic neuropathy have generally been limited to PN. However, 
there is evidence of similar morphological changes in peripheral and autonomic 
nerves in PN and AN, particularly with regard to segmental loss of myelin and 
axonal degeneration (Clarke, Ewing, Campbell, 1979). Thus it is possible that 
PN and AN may share a common pathogenesis. For this reason literature 
pertaining to the pathogenesis of PN will be reviewed briefly. The main 
hypothesis with regard to the pathogenesis of PN may be grouped as metabolic 
and vascular. 
(a) Metabolic theories 
Abnormalities in carbohydrate and lipid metabolism have been reported in 
peripheral nerves particularly within the myelin sheath and the Schwann cell, 
the metabolically active cell of peripheral nerves. 
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The Polyol Pathway 
The first abnormality was described in the polyol pathway which is present in the 
Schwann cell and is the pathway in which free glucose is converted to fructose 
(Gabbay, Merola and Field, 1966). In diabetic peripheral nerves the pathway is 
very active leading to accumulation of large amounts of glucose, fructose and the 
intermediate product sorbitol. In studies by Ward (1972) and Gabbay (1973), the 
accumulation of sorbitol was related directly to the level of blood glucose and 
fell with improved control of blood sugar concentrations by insulin administration. 
Furthermore, increased sorbitol concentrations in peripheral nerves were associated 
with slowing of motor nerve conduction velocity, which improved when the blood 
sugar levels were lowered (Gabbay, 1973). 
Myoinositol Metabolism 
Abnormalities in myoinositol metabolism ha.e also been demonstrated in diabetes and 
several studies ha.e suggested that chronic depletion of myoinositol may occur in 
diabetes. In uncontrolled diabetes in man, .excessive amounts of myoinositol were 
excreted in the urine but the amount diminished toward normal with improved control 
(Anderson, 1976). Myoinositol is a polyol that has an important role in lipid 
metabolism and is essential for normal structural integrity of peripheral nerves. 
Reduced myoinositol content of peripheral nerves in diabetic animals was observed 
in association with impaired motor nerve conduction velocity (Green, de Jesus and 
Winegrad, 1975). The addition of myoinositol to the diet of diabetic animals led 
to an improvement in the motor nerve conduction velocity and an increase in the 
myoinositol content of the nerves. Furthermore the decrease in peripheral nerve 
myoinositol content following induction of streptozotocin diabetes could be 
prevented by good control of the diabetes (Green, de Jesus and Winegrad, 1975). 
In addition in diabetics with neuropathy there was an improvement in motor 
conduction velocities of multiple nerves when high daily myoinositol intakes were 
instituted (Clements, Vourganti and Darnell, 1978). 
Abnormal Glycosylation of Protein 
A further possible metabolic mechanism is abnormal glycosylation of structural 
protein in nerves. Abnormalities in the metabolism of glycoproteins have been 
detected in diabetics and accumulation of excessive amounts of glycoprotein have 
been found on the glomerular basement membrane in this disease. Increased 
glycosylation might involve proteins occurring on basement and cell membranes 
and could conceivably contribute to nerve damage in diabetes (Clarke, Ewing and 
Campbell, 1979). 
(b) Vascular theory 
Changes in vascular supply to peripheral nerves have also been implicated in 
the pathogenesis of diabetic PN. Lundbaeck (1954) proposed a theory of wide-
spread small vessel disease as the underlying factor in most diabetic com-
plications based on clinical observation of the kidney, eye and nerves. 
Histological studies of peripheral nerves have confirmed this theory (Timperley, 
Ward, Preston, Duckworth and O'Malley, 1976). 
In this section metabolic and vascular factors which are thought to be involved 
in the pathogenesis of peripheral neuropathy, have been discussed. The 
relevance of these factors in terms of the pathogenesis of AN is not clear 
although it is possible that the two forms of neuropathy do share a common 
pathogenesis. 
4 (ii) CLINICAL MANIFESTATIONS OF AUTONOMIC NEUROPATHY 
The clinical features of AN are multiple and diverse, involving a number 
of organ systems. The symptoms are often unpleasant, may be life-threatenting 
and are usually associated with PN. 
(a) Gastrointestinal Tract 
Oesophagus: Symptoms of autonomic dysfunction affecting the oesophagus are 
rare. However, investigators have shown that disordered oesophageal motility 
may be detected by manometry or cineradiography in diabetics symptomatic of AN 
(Mandelstam, Siegel, Lieber and Siegel, 1969; Silber, 1969). 
Stomach: Autonomic dysfunction of the stomach may induce alterations in 
gastric motility and acid secretion. Delayed gastric emptying has been reported 
in diabetic AN, which may result in gastric stasis (Kassander., 1958; Ellenberg, 
1976; Hosking, Bennett and Hampton, 1978) and a variable degree of sympto-
matology may ensue. Nausea, vomiting, anorexia or a persistent feeling of 
fullness after meals are the usual symptoms. Alteration in gastric acid 
secretion has also been reported in diabetic AN (Hosking, Moody, Stewart and 
Atkinson, 1975). 
Intestine: AN may result in diabetic enteropathy, which is characterized 
by intermittent diarrhoeal attacks with spontaneous exacerbations and remissions 
of varying length. Periods of alternating diarrhoea and constipation may occur 
with diarrhoea usually occurring at night or in the early morning. Nocturnal 
faecal incompetence may also occur (Ellenberg, 1964; Ellenberg, 1976). 
Gall Bladder: A syndrome of neurogenic gall bladder in diabetics has been 
postulated by Gitelson, Schwartz, Fraenkel and Chowers (1963). They reported 
that diabetics with other evidence of autonomic dysfunction had large poorly 
contractile, but asymptomatic, gall bladders. 
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(b) Genitourinary System 
Sexual dysfunction: Abnormality in sexual function is a frequent complaint 
in diabetes. Impotence has been found in 28-59% of diabetic males (Rundles, 
1945; Rubin and Babbott, 1958; Schoffling, Federlin, Ditschuneit and Pfeiffer, 
1963; Ellenberg, 1971; Kolodny, Kahn, Goldstein and Barnett, 1974). AN is 
thought to be an important pathogenetic factor (Keen, 1959; Ellenberg, 1971). 
Retrograde ejaculation as evidenced by infertility may also be a feature of AN 
(Ellenberg and Weber, 1966). Sexual dysfunction in female diabetics with AN 
might also be expected, although Kolodny (1971) was unable to detect any causal 
relationship. 
The Bladder: Bladder dysfunction known as neurogenic vesical dysfunction 
has been reported in AN (Buck, Reed, Siddig, et al, 1976; Ellenberg, 1976). 
Clinically the onset is insiduous with gradual progression of bladder paralysis 
resulting in urinary retention. The symptoms initially are a reduced rate of 
micturition with straining followed by hesitation, dribbling, weakness of the 
stream and a sensation of incomplete bladder emptying. Later in the course 
infection intervenes and the symptoms alter (Ellenberg, 1976). 
(c) Thermoregulation 
Disturbances in sweating have been found in AN. Intolerance to heat 
accompanied by hyperhidrosis of the head, face, neck, axillae, chest and upper 
back with a lack of sweating below the waist has been reported (Goodman, 1966). 
An interesting feature of AN is extensive facial sweating induced by eating 
(Watkins, 1973; Bronshvag, 1978), a similar picture being found after cervical 
sympathectomy (Greenhalgh, Rosengarten and Martin, 1971), and in the auriculo-
temporal or Frey syndrome following parotid surgery (Hemenway, 1960; Friedman 
and Pomarica, 1974). Gustatory sweating in the auriculo-temporal syndrome is 
thought to be due to damaged parasympathetic secretomotor fibres destined for 
the parotid gland being reanastomazed with sympathetic fibres supplying sweat 
glands (Hemenway, 1960). 
Changes in vasomotor tone may also occur in diabetic AN, causing failure 
of circulatory adaption to alterations in environmental temperature. Persistent 
coldness of the feet may be a common symptom thereof (Martin, 1953; Keen, 1959; 
Ellenberg, 1976; Clarke, Ewing and Campbell, 1979). 
·(d) Cardiovascular System 
A resting tachycardia has been observed in diabetics with AN (Page and 
Watkins, 1977), but diabetic subjects as a group have a faster mean heart rate 
than healthy subjects (Ewing, Irving, Kerr, Wildsmith and Clarke, 1974). 
Diabetics with AN were also found to have a fixed heart rate which was 
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unresponsive to manoeuvres that influence it reflexly (Ewing, 1978). In 
addition diminished cycltal variations in heart rate have been demonstrated in 
diabetics with AN (Wheeler and Watkins, 1973; Ewing, 1978). 
Postural hypotension is the most prominent clinical expression of AN to 
affect the cardiovascular system. It tends to be a late feature, often 
associated with other clinical features of AN. Although postural hypotension 
may be asymptomatic, the main symptoms are dizziness, vertigo or syncope which 
occur on standing but occasionally may also be present when sitting. The 
symptoms are usually transient lasting a few minutes, but sometimes they are 
sustained and cause visual disturbances during which falls or loss of conscious-
ness may result (Rundles, 1945; Keen, 1959; Ellenberg, 1976; Hosking, Bennett 
and Hampton, 1978; Clarke, Ewing and Campbell, 1979). Insulin administration 
may accentuate or produce postural hypotension in healthy subjects, but 
particularly in diabetics with AN (Miles and Hayter, 1968; Page and Watkins, 
1976). 
Painless myocardial infarction may also be a feature of diabetic AN 
(Faerman, Faccia, Milei, et al, 1977) although patients with severe AN may 
develop typical cardiac pain during myocardial infarction (Campbell, Ewing and 
Clarke, 1978). Furthermore cardiorespiratory arrests have been observed in 
relatively young diabetics with severe AN, and sudden death occurred in one 
case (Page and Watkins, 1978). In most cases interference of respiration with 
anaesthesia, drugs or pneumonia occurred, leading to suggestions that the 
arrests were caused by defective respiratory and not cardiovascular reflexes. 
(e) Pupillary Changes 
Reduced pupillary diameter particuarly in the dark and delayed or absent 
reflex to light and diminished hippus have been reported in AN (Rundles, 1945; 
Smith, Smith,. Brown, Fox and Sonksen, 1978). However, no symptoms have been 
reported to ensue. 
(f) Unawareness of Hypoglycaemia 
This feature is common in diabetics with AN whereby loss of the normal 
premonitory signs and symptoms of impending hypoglycaemia occurs (Sussman, Crout 
and Marble, 1963) and may have a profound effect on the lifestyle of the patient. 
4 (iii) AUTONOMIC NEUROPATHY AND HORMONE RELEASE 
Abnormalities in the secretion of a number of hormones has been 
reported in diabetic AN, but the studies have been limited to IDDM. In IDDM with 
obvious clinical features of AN flat plasma IRG responses to insulin hypoglycaemia 
were observed. However, plasma cortisol and plasma growth hormone responses to 
insulin hypoglycaemia were not impaired in these diabetics (Maher, Tanenberg, 
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Greenberg, et al, 1977). In addition arg1n1ne stimulation induced a rise in 
plasma IRG levels in the diabetics with AN. These findings indicated that 
while the capacity to release IRG during hypoglycaemia was lost in AN, IRG 
responsiveness to arginine was maintained. Furthermore growth hormone and 
cortisol responsiveness to hypoglycaemia appeared to be independent of 
autonomic nervous integrity. 
Serum gastrin concentrations were investigated in response to the intragastric 
instillation of food in IDDM. The patients were divided into two groups viz 
those with and those without nausea and vomiting, symptoms of delayed gastric 
emptying, and features of AN (Feldman, Corbett, Ramsey, Walsh and Richardson, 
1979). The results revealed that basal and food-stimulated serum gastrin 
concentrations were two- to threefold higher in both groups of diabetics 
compared to normal subjects. In addition a similar degree of delayed gastric 
emptying was present in the two groups of diabetics. Thus it is possible that 
AN was present in both groups of diabetics; indeed evidence of PN was present in 
half of those subjects without nausea and vomiting and postural hypotension too 
was present in 20% of them. The study of Feldman, et al (1979) suggested that 
in long standing IDDM with either clinical evidence of AN or even PN, auto-
vagotomy may be present which may in turn result in hypergastrinaemia. Although 
the hypergastrinaemia in their patients was not associated with hypersecretion 
of gastric acid. 
Serum PP responses to insulin hypoglycaemia have also been studied in IDDM with 
AN, in whom markedly impaired responses were observed as compared with IDDM 
without AN (Krarup, Schwartz, Hilsted, et al, 1979). However certain of the 
patients without AN who had a long duration of diabetes, also had impaired serum 
PP responses, although not to the same extent as those with AN. Furthermore 
even in the diabetics without AN the impairment of the PP response to hypo-
glycaemia correlated inversely with the threshold of the sense of vibration. 
These data would tend to indicate the existence of undiagnosed AN in at least 
some of the patients in the group without AN. 
Thus AN may be associated with alterations in the release of certain gastro-
intestinal hormones. Moreover, Maher and associates (1977) have postulated that 
there is a relationship between unstable diabetes and AN. Their postulate was 
based on their observation that in patients with AN and unstable diabetes both 
separately (Maher et al, 1977; Reynolds, Molnar, Horwi1z, et al, 1977) and in 
combination (Maher et al, 1977), there was an impaired IRG response to insulin 
hypoglycaemia. 
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Hence single reports on the effect of AN on IRG, PP and gastrin release have 
appeared in the literature. These reports have been limited to studies in IDDM. 
It is apparent that much work is required to evaluate fully the effect of AN on 
gastrointestinal hormone release in other forms of diabetes release and to 
elucidate neuropeptide release in diabetes of all kinds. 
4 (iv) ASSESSMENT OF AUTONOMIC NERVE FUNCTION 
In the last decade a number of tests which are simple, reproducible and 
non invasive have been developed to assess autonomic nerve function. These 
tests have enabled investigators to confirm the presence of AN although 
quantitation of the deficit is not possible at present. Most of the newer tests 
are based on cardiovascular reflexes and by inference they are assumed to 
reflect autonomic nerve change in other systems. The literature pertaining to 
the autonomic function tests which were described prior to the studies under-
taken in this manuscript, is reviewed briefly. 
(a) Tests based on blood pressure 
With standing there is immediate pooling of blood in the legs with a fall 
in blood pressure, but provided there is normal baroreceptor function, this is 
rapidly corrected by peripheral vasoconstriction and tachycardia. Thus, 
Ewing, Campbell, Burt and Clarke (1973) first described the use of postural 
hypotension which was detected using a cuff sphygmomanometer and measuring the 
fall in systolic blood pressure as a measure of AN. These workers defined a 
fall of 30 mm Hg or more in systolic blood pressure as significant. This 
remains one of the simplest methods of detection of possible AN. 
Another simple test which is based on blood pressure responses to sustained 
muscle exercise has been defined. Sustained muscle exercise produces an 
increase in systemic blood pressure and cardiac output which is dependent on 
heart rate but which does not alter peripheral vascular resistance. Ewing, · 
Irving, Kerr, Wildsmith and Clarke (1974) devised a test based on this reflex in 
which a handgrip dynamomanometer, standardized at 30% of the maximum voluntary 
contraction was used together with measurement of blood pressure. They observed 
that there was an abnormally small rise in diastolic blood pressure in diabetics 
with AN. Thus a rise in diastolic blood pressure of 16 mm Hg or more was 
defined as normal, between 11 and 15 mm Hg as borderline and less than 10 mm Hg 
as abnormal (Ewing, Campbell, Burt and Clarke, 1973). This test although being 
effort-dependent is relatively simple and reproducible. 
The third test based on measurement of blood pressure involved applying 
negative pressure to the lower body below the iliac crests which results in 
pooling of blood which in turn elicits cardiovascular reflexes to maintain system 
blood pressure (Brown, Goei, Greenfield and Plassaras, 1966). Diabetics with AN 
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showed a hypotensive response to this manoeuvre despite forearm vaseconstriction 
(Bennett, Hosking and Hampton, 1979). This test, unlike the first 1wo, is time 
consuming, complex and requires special equipment. 
(b) Tests based on heart rate 
Heart rate changes during the Valsalva manoeuvre have been described as a 
test of autonomic function. Tachycardia and peripheral vasoconstriction during 
the valsalva manoeuvre is followed by an overshoot bradycardia and rise in blood 
pressure immediately after the manoeuvre and represent the baroreceptor response 
to the manoeuvre (Levin,1966). Heart rate changes during and after the 
manoeuvre are considered a reliable guide to the haemodyamic events and have 
been used to evaluate responses to the manoeuvre (Elsberg, 1963; Levin, 1966). 
The subject's response to the manoeuvre is expressed as the valsalva ratio i.e. 
the ratio of the longest R-R interval after the manoeuvre to the shortest R-R 
interval during the manoeuvre. In diabetics a ratio of 1.10 or less is 
considered abnormal, 1.11 - l .20 as borderline and greater than 1.21 as normal 
(Ewing, Campbell, Burt and Clarke, 1973; Clarke, Ewing and Campbell, 1979). 
The test is simple but requires patient co-operation and a certain degree of 
effort. 
Beat-to-beat variation in heart rate, which is dependent on parasympathetic 
innervation of the heart (Wheeler and Watkins, 1973) has been used in a test to 
evaluate autonomic function. In the test beat-to-beat variation in heart rate 
was analysed during deep breathing which produces maximum variation in heart 
rate (Wheeler and Watkins, 1973). The test is simple and does not require 
complex equipment. 
Changing from lying to standing produces an integrated reflex response of 
the cardiovascular system which includes alterations in heart rates and blood 
pressure (Johnson and Spalding, 1974) and has been used as a test of autonomic 
function. The test involves measurement of the 15th and 30th RR intervals after 
standing on an ECG recording to give the 30:15 ratio. In normal subjects the 
ratio is greater than 1.03 while in diabetics with AN the ratio isl .00 or less 
(Ewing, Campbell, Murray, Neilson and Clarke, 1978). The test is simple, 
reproducible and requires little patient co-operation. 
(c) Gastric Acid Secretion 
Reduced gastric acid secretion in response to insulin hypoglycaemia in the 
presence of a normal acid secretory response to pentagastrin suggests 
disturbance of vagal integrity (Langer, 1972; Hosking, Moody, Stewart and 
Atkinson, 1975). This may be used as a test for vagal integrity but requires 
special equipment, is invasive and may be uncomfortable for the patient. 
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(d) Impaired Sweating 
Areas of reduced sweating due to sudomotor dysfunction may be elicited by 
dusting the patient with a starch and iodine compound or quinizarin and inducing 
an increase in core temperature by at least 1°c (GLttma,n, 1946; Goodman, 1966). 
This has been used as a test of autonomic integrity but may be cumbersome and 
disagreeable. 
(e) Testicular Pain Sensation 
Reduced testicular pain sensation has been reported in patients with 
impotence and other features of AN (Campbell, Ewing, Clarke and Duncan, 1974) 
and has been suggested as a possible test of autonomic dysfunction. The test 
requires patient co-operation and may indeed prove to be unpleasant. Further-
more it is subjective and difficult to quantitate precisely. 
(f) Drug Tests 
Heart rate responses to various agents such as phenylephrine, atropine and 
propranolol which induce alterations in blood pressure and produce cardiac 
blockade have been evaluated in diabetics with AN (Lloyd-Mastyn and Watkins, 
1975) and poor heart rate responses have been observed. 
The tests are invasive and not as simple as some of those described 
earlier. Local instillation of various drugs with observation of pupil sizes 
may also be useful for assessing autonomic innervation of the pupil. 
Instillation of dilute solutions of hydroxyamphetamine, epinephrine, 
phenylephrine and cocaine may be used to detect the presence of sympathetic 
lesions. Instillation of cholinomimetic drugs such as pilocarpine and 
methacholine may elicit the presence of interrupted parasympathetic innervation 
of the pupil (Moskowitz, 1977). 
Thus a large number of tests have been described whereby autonomic nerve function 
may be determined. Some of the tests evaluate parasympathetic innervation such 
as gastric acid secretory responses and beat-to-beat variation in heart rate. 
Integrity of sympathetic innervation may be determined by the blood pressure 
response to sustained handgrip and assessment of postural _hypotension. In view 
of the patchy involvement of AN which may be manifest by intact sympathetic 
innervation and selective damage of parasympathetic pathways (Lloyd-Mostyn and 
Watkins, 1975), an evaluation of autonomic function therefore requires a variety 
of autonomic function tests. 
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In summary in this section literature pertaining to AN has been reviewed. While 
little has been reported with regard to the pathogenesis of AN, the numerous and 
diverse clinical features of AN have all been well documented. A number of 
tests, for the most part based on cardiovascular reflexes, have been described 
to assist in the confirmation of the presence of AN. Hormonal and biochemical 
effects of AN have been assessed in three reports revealing abnormalities in 
IRG, PP and gastrin release. In addition metabolic sequelae of AN based on 
altered IRG release have been postulated. The increased mortality rate and 
possible metabolic consequences of AN emphasize the necessity for greater under-
standing of this complication of diabetes. 
It is apparent from the literature reviewed thus far that AN may effect gastro-
intestinal hormone secretion and may have relevance in the stability of control 
in these patients. A new exciting field has recently opened with the finding 
that dietary fibre improves glucose tolerance and with suggestions that fibre 
supplementation of diets may have a role to play in the therapy of diabetes. 
However the mechanisms whereby fibre exerts its effect on glucose tolerance are 
not fully understood, although altered gut hormone secretion amongst others 
have been proposed as possible mechanisms. Furthermore it is not known whether 
fibre would have an equally beneficial effect in the presence or absence of AN 
if the fibre-induced effect on glucose tolerance is somehow related to autonomic 
nervous integrity. In the next section existing knowledge of dietary fibre will 
be explored with particular reference to its proposed mechanisms of action and 
its effect in diabetes. 
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SECTION 5 : DIETARY FIBRE 
Introduction 
Dietary or plant fibres have been defined as those portions of edible 
plants that are not digested in or absorbed from the human small intestine 
(Anderson, Midgley and Wedman, 1979). Although a definite classification of 
the multitude of plant fibres cannot be made at present, from a biological 
viewpoint dietary fibres have been divided into: 
(a) Structural fibres 
(b) Gums and mucilages 
(c) Storage polysaccharides 
The structural fibres are components of plant cell walls and include cellulose, 
pectins, lignins and different hemicelluloses. The gums and mucilages serve 
specialized functions for the plant such as repair of injured areas. The 
storage polysaccharides are usually dispersed throughout the endosperm of the 
plant and are stored for later use as energy sources (Anderson and Chen, 1979). 
Epidemiological studies have suggested that fibre depleted diets may play a role 
in the higher prevalence of cancer of the colon and rectum, diverticular 
disease of the colon, varicose veins, haemorrhoids and ischaemic heart disease 
noted in Western societies compared with rural African society (Trowell, 1973; 
Burkitt, Walker and Painter, 1974; Burkitt, 1978). In addition it was suggested 
that fibre depleted diets may play a causative role in the development of 
clinical diabetes (Trowell, 1973; Trowell, 1975; Trowell, 1978). These 
suggestions have precipitated tremendous interest in dietary fibres in recent 
years. 
Various studies have revealed that dietary fibre has a number of effects. 
Indeed in semi and highly purified forms, and as part of high fibre foods 
dietary fibre has been shown to reduce serum cholesterol levels (Jenkins, 
Leeds, Newton and Cummings, 1975; Anderson and Chen, 1979), and serum tri-
glyceride levels in patients with hypertriglyceridaemia (Anderson and Chen, 
1979) and to improve glucose tolerance (Jenkins, Leeds, Gassull, Cachet and 
Alberti, 1977; Jenkins, Wolever, Leeds, et al, 1978; Monnier, Pham, Aguirre, 
Orsetti and Mirouze, 1978; Munoz, Sandstead, Jacobs, Johnson and Mako, 1979). 
In this section literature pertaining to dietary fibre in diabetes and its 
postulated mechanisms of action in improving glucose tolerance is reviewed. 
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5 (i) MECHANISMS OF ACTION 
Dietary fibre is thought to exert its effect on glucose tolerance 
through actions on the gastrointestinal tract. Four mechanisms have been 
postulated. First a delay in gastric emptying may result in a lower absorption 
of carbohydrate. Soluble fibres such as guar and pectin slow gastric emptying 
(Holt, Heading, Carter, Prescott and Tothill, 1979). However whole bran 
appears to accelerate gastric emptying and has a less prominent effect on 
glucose tolerance than the soluble fibres (Anderson and Chen, 1979). Second, 
the gel forming properties of the soluble fibres may result in slower 
absorption of carbohydrate. Fibres such as pectin and guar form gelatinous 
masses in the gut which results in delayed gastric emptying and altered 
intestinal transit time (Anderson, Chen, 1979; Eastwood and Kay, 1979). 
Third, available carbohydrate that is packaged within fibre may be insulated 
from digestive enzymes and may not be digested or absorbed in the small 
intestine. Thus available carbohydrate may escape into the colon and be lost 
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in the faeces or be digested by bacteria (Anderson and Chen, 1979). Fourth, 
altered gut hormone release i.e. GIP and GLI which has been demonstrated with 
fibre supplementation might be responsible for the reduced insulin secretion and 
in some way be related to the improved glucose tolerance (Anderson and Chen, 
1979; Morgan Goulder, Tsiolakis, Marks and Alberti, 1979). 
5 (ii) DIETARY FIBRE IN DIABETES 
Two pieces of epidemiological evidence formed the basis of the theory 
that fibre depleted diets might play a part in the development of diabetes. 
First, rural societies in Africa have diets containing considerably more dietary 
fibre than Western societies and rarely suffer from diabetes (Trowell, 1973). 
Second, the increase in the wheat bran content of bread in Britain during world 
war II was found to be associated with a fall in mortality figures for diabetics 
(Trowell, 1973). 
Numerous studies during recent years have revealed that fibre has a beneficial 
effect on control of diabetes and may have therapeutic value. 
A number of studies have evaluated the acute effect of fibre on glucose tolerance 
and have revealed that fibres has a beneficial effect in the short term. After 
Jenkins, Wolever, Leeds, et al (1978) reported that of six different fibres guar 
produced the greatest flattening of the serum glucose response to oral glucose, 
and pectin too was effective, most further studies were confined to these two 
fibres. Addition of fibre to meals induced a significant reduction in plasma 
glucose concentrations after the meals in IDDM and NIDDM_ (Jenkins, Goff, Leeds, 
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et al, 1976; Morgan, Goulder, Tsiolakis, Marks and Alberti, 1979). Serum 
insulin responses to ingestion of a meal were also reduced in the NIDDM. In 
the latter study GIP responses were reduced as well leading to suggestions that 
fibre may be a useful adjunct in diabetic therapy, and that its effect on 
insulin secretion may be mediated through GIP. 
Further studies have assessed the effect of long term fibre therapy on glucose 
tolerance. One week's therapy with guar resulted in a 10% reduction of mean 
urinary glucose excretion in IDDM and in one diabetic who was treated on dietary 
restriction alone (Jenkins, Wolever, Hockaday, et al, 1977). High fibre diets 
containing 20 g crude fibre maintained for 2 weeks resulted in a marked 
reduction in mean plasma glucose and IRG levels in IDDM, (Miranda and Horwitz, 
1978). High fibre diets containing 15 g crude fibre for 2 weeks resulted in 
significant reduction in fasting plasma glucose levels, discontinuation of 
sulphonylurea therapy in NIDDM and a marked reduction in insulin requirements in 
IDDM on less than 30 units of insulin per day. However, in diabetics requiring 
40-55 units of insulin, fibre induced no change in fasting plasma glucose levels 
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or in insulin requirements (Kiehm, Anderson and Ward, 1976). High fibre, high 
carbohydrate diets for a period of 15 months produced a significant reduction in 
fasting plasma glucose levels and insulin or sulphonylurea requirements in IDDM 
and NIDDM. The reduction in insulin requirements was also noted in a single 
patient on 55 units of insulin per day (Anderson and Ward, 1978). This data 
suggests that fibre need not necessarily be of little value in patients on high 
daily doses of insulin. 
Thus it is apparent that fibre, in either its purified or crude form has 
prominent effects on glucose tolerance in both the short and long term. Indeed 
fibre supplementation of diets may have a place in the therapy of diabetes. 
However, problems may be encountered in the implementation of these diets. The 
first problem concerns the question of palatability, flatulence and altered 
bowel habits. However, Anderson and Ward (1978) reported that despite increased 
flatulence, increased defaecation and initial problems with the large quantities 
of vegetables in the diet, patients tolerated and accepted the diets remarkably 
well. In addition, Jenkins, Wolever, Nineham, et al (1978) described the use of 
guar in crisp bread 11 the first palatable guar formulation therefore represents 
an important advance in food technology". Thus it would appear that high fibre 
diets are acceptable to patients. The second problem concerns the question of 
mineral depletion and vitamin deficiency. In short term studies of 20-38 days 
high fibre diets were associated with increased faecal losses of calcium, 
magnesium, phosphorus, zinc (Reinhold, Faradji, Abadi and Ismail-Beigi, 1976; 
Ismail-Beigi, Reinhold, Faraji and Abadi, 1977) and silicone (Kelsay. Behall and 
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Prather, 1979). In addition reduced plasma concentrations of calcium, 
phosphorus, zinc and iron were noted, but the reductions were sustained in the 
first two alone (Reinhold, Nasr, Lahimgarzadeh and Hedayati, 1973). In contrast 
in a long term study of 5-44 months no depletion of calcium, magnesium, iron or 
fat soluble vitamins were observed (Anderson, Sieling and Ferguson, 1979). These 
data would tend to indicate that fibre may have a deleterious effect on mineral 
balance in the short but not the long term. Further if there is adequate 
mineral intake, mineral balance may not suffer in the long term. However further 
studies are required to fully evaluate the effect of dietary fibre on mineral 
and vitamin balance in the long term. 
A major point of interest with regard to fibre revolves around the mechanisms 
whereby fibre exerts its action on glucose tolerance, because AN in diabetes may 
result in delayed gastric emptying (Ellenberg, 1976; Hosking, Bennett and 
Hampton, 1978) and diabetic enteropathy (Ellenberg, 1964) as described earlier. 
Thus the question that arises is would fibre still exert its well recognized 
effect on glucose tolerance if there was no longer autonomic nervous integrity? 
In this section available literature of dietary fibre has been discussed with 
special reference to its known actions in diabetics and its proposed mechanisms 
of action in altering carbohydrate absorption and metabolism. Fibre in 
different forms has been shown to improve glucose tolerance in the acute 
situation as well as in the long term. In addition fibre supplementation of the 
diet for 2 weeks to 15 months has been responsible for reducing or obviating the 
need for oral hypoglycaemic or insulin therapy in two groups of diabetics. 
However, in one study fibre had no effect on glucose tolerance or insulin 
requirements in patients on more than 40 units of insulin per day, while in 
another study, fibre had a beneficial effect on glucose tolerance insulin 
requirements in a patient on 55 units of insulin per day. Altered intestinal 
transit time secondary to numerous factors and altered gut hormone release have 
been postulated as the mechanisms whereby fibre exerts its action on glucose 
tolerance. While fibre supplementation may seem an ideal adjunct to the 
existing forms of therapy in diabetics, problems such as lack of effect in 
patients on high daily doses of insulin, possible mineral and vitamin depletion, 
and the question of its efficiency in the presence of AN need to be 
investigated. 
SUMMARY 
This review reveals gaps in present knowledge not only of AN and release of the 
five gastrointestinal hormones, but also in the pathogenesis of AN, in autonomic 
nervous regulation of the release of some of the hormones and in the effect of 
diabetes on them. It is apparent that little is known about the pathogenesis of 
AN. Studies have revealed abnormalities in carbohydrate and lipid metabolism in 
peripheral nerves of patients with PN leading to suggestions that metabolic 
factors may be causative in PN. In addition, vascular factors have been 
postulated to be involved in the pathogenesis of PN. Similarities in 
histological studies of peripheral and autonomic nerves in PN and AN 
respectively lend credence to the possibility that PN and AN may share a common 
pathogenesis. Although beyond the scope of this manuscript, further studies 
are required to evaluate the causation of AN and to assess whether PN and AN 
indeed have a common pathogenesis. 
In spite of work having been done concerning autonomic nervous regulation of 
gastrointestinal hormone release, it is evident that hiatuses exist in present 
understanding. It is fairly definite that PP release is regulated, at least in 
part, by vagal cholinergic pathways, but the role of the sympathetic nervous 
system needs to be elucidated. As regards gastrin there seems little doubt that 
vagal cholinergic pathways provide a constant inhibitory effect on its release, 
while it would appear that adrenergic pathways are involved in regulation of 
basal, but not stimulated gastrin release. A great deal of contradictory data 
has been reported on autonomic, and in particular, parasympathetic regulation of 
IRG release. It would appear however that adrenergic pathways modulate basal IRG 
secretion but the true effect of the parasympathetic nervous system on IRG 
secretion needs to be fully evaluated. Early work has revealed that the vagus 
may be involved in mediation of GIP release, but studies are required to fully 
assess parasympathetic and sympathetic modulation of GIP release. Animal 
studies have suggested that SRIF-LI too may be regulated at least in part, by 
autonomic pathways but in this instance too, further studies are required 
before an adequate assessment of the importance of autonomic regulation of 
SRIF-LI release can be made. 
In the reports on the effect of AN on hormone release gastrin, IRG and PP were 
the hormones studied and abnormalities in the secretion of all were found. The 
three studies were limited to IDDM and one stimulation test for each hormone was 
used. The early evidence of autonomic modulation of GIP and SRIF-LI release 
might also indicate that abnormalities in their release would occur in the 
presence of AN. 
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With regard to dietary fibre, considerable evidence has accumulated which 
demonstrates that fibre has a beneficial effect on glucose tolerance in IDDM and 
NIDDM in the short and long term. Indeed fibre supplementation has even resulted 
in a reduction of insulin requirements in patients on moderate daily doses of 
insulin and cessation of oral hypoglycaemic therapy. It is not clear however, 
that fibre would be effective in patients in whom loss of autonomic nervous 
integrity was present. 
Finally, gaps have been revealed in our present knowledge, particularly of the 
pathogenesis of AN, the effect of AN on hormone release, autonomic control of 
hormone release and the efficacy of dietary fibre in the presence of AN. In 
this thesis the effect of AN on gastrointestinal hormone release and the 
relative value of dietary fibre supplementation in the presence of AN are the 
subjects studied. 
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CHAPTER II 
OBJECTIVES OF THE STUDY 
CHAPTER II 
OBJECTIVES OF THE STUDY 
From the literature review it is apparent that gaps in knowledge exist in almost 
every field of study alluded to. Hiatuses were revealed particularly with 
regard to : the pathogenesis of AN, the effect of AN on gastrointestinal hormone 
release, autonomic nervous regulation of the release of certain gastrointestinal 
hormones, the effect of diabetes on gastrointestinal hormone release and the 
efficacy of dietary fibre in the presence of AN. To attempt to fill all these 
gaps is a massive undertaking and well beyond the scope of a single project. 
The primary aim of this work is to provide evidence which may contribute to an 
understanding of the interrelationship between NIDDM, gastrointestinal hormone 
release and the autonomic nervous system. Thus, in an attempt to interrelate 
these aspects, the objectives of this thesis which have been limited to the 
study of five gastrointestinal hormones were as follows:-
First, to compare the basal levels of IRG, PP, gastrin, GIP and SRIF-LI in NIDDM 
with and without AN. 
As has been indicated basal release of the five gastrointestinal hormones may be 
regulated, at least in part, by the autonomic nervous system. If this is indeed 
the case, differences in the basal concentrations of these hormones may be 
apparent in NIDDM with AN as opposed to NIDDM without AN. Also, diabetes per se 
appears to have an effect on the basal release of most of the five gastro-
intestinal hormones. In such a situation the basal concentrations of the 
hormones should be similar in NIDDM with AN and NIDDM without AN but may differ 
from those in healthy subjects. However, should the basal hormone concentrations 
differ in the NIDDM with AN and those without AN, this may have relevance to the 
altered basal hormone release found in NIDDM per se. Thus the second objective 
is to investigate whether abnormalities in basal hormone release found in NIDDM 
could relate to the presence of AN. 
The third objective is to compare stimulated levels of IRG, PP, gastrin, GIP and 
SRIF-LI in NIDDM with and without AN. As stated earlier, not only basal but also 
stimulated release of the five hormones may be regulated, at least in part, by 
the autonomic nervous system. Thus in this situation too, differences 
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in the stimulated concentrations of the five hormones may occur in the NIOOM 
with and without AN. However, altered stimulated secretion of the majority of 
these hormones may also be found in diabetes per se. Thus the stimulated 
concentrations of the hormones may be similar in the NIDDM with and without AN 
but may differ from those in normal people. In the event of a relationship 
between AN and altered stimulated hormone release, and diabetes per se and 
altered stimulated hormone release, however, this may indicate that AN is 
involved in the disturbed stimulated release of the hormones in NIDDM per se. 
Hence the fourth objective is to assess whether AN may contribute to the 
abnormalities found in stimulated release of the five hormones in NIDDM. 
The fifth objective is to determine the existence of a biochemical marker for 
AN. There is little doubt that AN may have unpleasant and even dangerous 
consequences for the patient, e.g. postural hypotension, unawareness of 
hypoglycaemia and sudden cardiorespiratory arrest. At present various clinical 
tests are available to detect AN. The majority of these tests are based on 
cardiovascular reflexes, and testing of gastrointestinal nervous integrity 
relies on the gastric acid secretory response to insulin hypoglycaemia. If 
there is indeed autonomic nervous control of gastrointestinal hormone release 
and if this could be elicited easily and reproducibly, then the response of 
such a hormone may be an accurate marker for gastrointestinal autonomic 
integrity and as such may add a useful test to the armoury of those used for 
investigation of autonomic nervous integrity. 
The final objective is to evaluate whether the beneficial effect of dietary 
fibre on glucose tolerance could be altered by the presence of AN in NIDDM. 
Fibre supplemented diets have been shown to improve glucose tolerance and have 
been suggested to have a role in the therapy of .diabetes. Also suggested is 
the possible dependence for this action of dietary fibre on mechanisms which 
may be related to autonomic nervous integrity such as delayed gastric emptying 
and altered gastrointestinal hormone secretion. If the effect of dietary fibre 
on glucose tolerance is mediated by a factor related to autonomic nervous 
integrity, differences may be apparent in NIDDM with and without AN. However 
the converse may also apply. 
To attain these objectives controlled studies have been designed and undertaken. 
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CHAPTER III 
EXPERIMENTAL DESIGN 
SECTION I : THE SUBJECTS 
Previous reports of hormone concentrations in diabetics have sometimes 
been the result of studies in poorly defined groups, containing perhaps unknown 
numbers of patients with AN. Thus an attempt is made in these studies to 
control strictly the type of diabetic studied, the presence and absence of AN 
and the ·matching of patients. 
I (i) THE TYPE OF DIABETES 
NIDDM formed the patient group for ·study. They were selected because 
of the high proportion of NIDDM attending the Groote Schuur Hospital Diabetes 
Clinic and because they were not treated with insulin and were therefore not 
prone to the formation of antibodies e.g. to PP, which may result from 
treatment with ordinary commercial insulins (Bloom, West, Polak, Barnes and 
. Adrian, 1978; Klaff, Vinik, Berelowitz and Jackson, 1978). 
I (ii) MATCHING OF SUBJECTS 
In all instances groups of subjects who were compared, were either age-
matched or within a similar age range. This was necessary because the concen-
trations of certain hormones are known to rise with increasing age e.g. PP, IRG 
(Berger, Crowther, Floyd, Pek and Fajans, 1978). In addition only males were 
studied in order to exclude sex differences between patients as a possible 
cause for differences in hormone concentrations. Similarly only non-obese 
subjects were studied in order to exclude obesity as a possible factor in 
differences in hormone concentrations. Wherever possible care was taken to 
study patients with a similar duration of diabetes to exclude varying durations 
of diabetes as a possible factor in differences in hormone concentrations. 
I (iii) THE PRESENCE OF AUTONOMIC NEUROPATHY 
As the field of study was the effect of AN on gastrointestinal hormone 
release, it would have been ideal to localize the AN to the gut. However only 
one test has been described which evaluates autonomic function of the gut viz 
gastric acid secretory responses to insulin hypoglycaemia and pentagastrin 
(Hosking, Moody, Stewart and Atkinson, 1975). A battery of 7 other tests were 
therefore added, namely postural hypotension (Ewing, Burt, Williams, Campbell 
and Clarke, 1976), beat-to-beat variation on deep breathing (Wheeler and 
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Watkins, 1973), the Valsalva Manoeuvre (Ewing, Campbell, Burt and Clarke, 1973), 
sustained handgrip (Ewing, Campbell, Kerr, Wildsmith and Clarke, 1974), sweating 
in response to insulin hypoglycaemia (Guttmann, 1940; Editorial, Lancet, 1976). 
testicular sensation (Campbell, Ewing, Clarke and Duncan, 1974) and immediate 
heart rate responses to . standing (Ewing, Campbell, Murray, Neilson and Clarke, 
1978). 
The majority of these tests were based on cardiovascular reflexes and had the 
advantages of simpli~ity, non-invasiveness and reproducibility. Disadvantages 
of some of these tests were their effort dependence e.g. Valsalva and in the case 
of beat-to-beat variation with deep breathing, the fact that this variation 
diminishes over the age of 50 in healthy subjects. The chief disadvantage of the 
tests not based on cardiovascular reflexes was the unpleasantness which may be 
associated with hypoglycaemia. A further disadvantage of the tests was that they 
are not quantitative and cannot precisely localize a lesion of the autonomic 
nervous system. However their prime purpose in this study was to provide an 
overall assessment of the presence of AN and not to localize the lesion. 
There are no specific criteria for the diagnosis of AN. Abnormal 
responses to three or more of the autonomic function tests together with the 
presence of symptoms of AN were defined as the criteria for the diagnosis of AN 
in this study. The criteria for the absence of AN were the lack of symptoms of 
AN and normal responses to all eight autonomic function tests. 
SECTION 2 : THE SCOPE OF THE STUDIES 
Using the patients as outlined above, measurement of their gastro-
intestinal hormone status was undertaken under basal and stimulated conditions. 
2 (i) THE HORMONES 
The hormones were selected primarily on the basis of availability of 
antisera and reliable radioimmunassays. Further reasons for their selection 
relate to their altered release in diabetes per se and/or their at least partial 
dependence on autonomic nervous regulation. The hormones measured initially were 
IRG, PP, gastrin and GIP. SRIF-LI was added to the four hormones only after the 
initial insulin hyperglycaemia test had been carried out. · 
2 (ii) THE TESTS OF HORMONE RELEASE 
In these tests ·whenever possible normal healthy subjects acted as controls 
for the studies. The diabetics were initially considered as a single group 
regardless of the presence or absence of AN, in order to document the 
concentrations of the hormones in the group of NIDDM selected for study. 
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Thereafter an assessment was made as to whether any differences might exist in 
the concentrations of the hormones in the diabetics with and without AN. 
{a) Tests of Basal Hormone Concentrations: 
Studies were designed to evaluate the effect of AN on basal hormone 
concentrations. In the first study, circulating hormone concentrations were 
determined after a 12 hour overnight fast. The second study took cognizance of 
the chronic hyperglycaemia of diabetes and was therefore designed to assess 
whether basal hormone concentrations were related to the level of fasting 
glycaemia. The effects of the acute establishment of fasting normoglycaemia 
· were therefore assessed on basal hormone concentrations. The normalization of 
blood glucose levels was achieved by a continuous overnight insulin infusion, 
using a rapidly acting monocomponent Tisulin. An infusion rate of 0.5-0.8 U/hr 
was considered adequate to produce fasting normoglycaemia in moderately hyper-
glycaemia NIDDM. However in order to ensure a satisfactory fall in blood 
glucose levels over the 12 hr infusion period, blood glucose estimations were 
carried out hourly and the infusion rate altered accordingly. 
Motor dysfunction of the stomach with consequent dilatation and delayed gastric 
emptying, although often asymptomatic, is a feature of diabetic AN (Campbell, 
Heading, Tothill, et al, 1977). This manifestation may contribute to poor · 
diabetic control by the irregular and delayed entry of food into the intestine 
{Kassander, 1958). Therefore the third study was designed in order to exclude 
the possibility that gastric retention may result in continuous stimulation of 
hormone release due to a slow 'leak' of food through the pylorus. The study 
was designed to provide 'slow' drainage of the stomach by overnight gastric 
aspiration to ensure that all subjects had complete emptying of the stomach 
before the estimation of basal concentrations was carried out. 
{b) Provocative Stimulation Tests: 
The ensuing studies involved measurement of the concentrations of 
the five hormones after provocative stimulation. In the first study, hormone 
concentrations were measured in response to the stimulus of insulin hypogly-
caemia. Insulin hypoglycaemia is a known stimulus for the release of IRG 
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{Gerich, Schneider, Dippe, et al, 1974) and PP (Adrian, Bloom, Besterman, et al, 
1977; Marco, Heda and Villaneuva, 1978) while there is conflicting evidence with 
regard to its effectiveness as a stimulus for gastrin release (Stadil, 1974; 
Mcloughlin, Hayes, Buchanan and Kelly, 1978), as also for GIP (Service, Nelson, 
Rubenstein and Go, 1978; Reynolds, Tronsgard, Gibbons, Blix and Rubenstein, 1979). 
The effect of insulin hypoglycaemia on SRIF-LI release was 'not known. Hollander 
in 1946 originally described the insulin test to detect the presence of intact 
vagal fibres after vagal operations for peptic ulcer disease. In his description 
of this test, Hollander suggested that the insulin injection induced hypogly-
caemia, which in turn activated the vagus centre in the medulla resulting in 
stimulation of gastric acid secretion. More recent work has however indicated 
that insulin hypoglycaemia increases circulating catecholamine levels, in 
addition to activation of the vagus nerves (Vendsalu, 1960; Garber, Cryer, 
Santiago, et al, 1979). Indeed the release of certain of the hormones e.g. PP 
(Adrian, Bloom, Besterman, et al, 1977; Schwartz, Holst, Fahr€nkrug, et al, 1979) 
and gastrin (Stadil, 1974), has been shown to be altered in response to hypo-
glycaemia after vagotomy. However, conflicting evidence has been presented with 
regard to the effect of vagotomy on IRG secretion (Bloom, Vaughan and Russell, 
1974; Palmer, Werner, Hollander and Ensinck, 1979). The effect of vagotomy on 
plasma GIP and plasma SRIF-LI responses to hypoglycaemia was not known. 
Nevertheless by using the stimulus of insulin hypoglycaemia, an assessment could 
be made of the effect of autonomic nervous dysfunction on hormone release. The 
diabetics received a larger dose of insulin than the healthy controls because of 
the higher level of fasting glycaemia in the diabetics. 
As the level of fasting hyperglycaemia may influence either the rate of change, 
or the absolute changes in circulating hormone levels in response to a given 
stimulus, a modification to this second study was made and a study was designed 
to evaluate whether the hormone responses to insulin hypoglycaemia were 
dependent on the degree of fasting glycaemia. Thus in the third study the 
effect of fasting normoglycaemia on the hormone concentrations during hypo·· 
glycaemia in the diabetic patients was assessed. Fasting normoglycaemia was 
induced acutely by a continuous insulin infusion. 
In the next study hormone concentrations were measured in response to ingestion 
of a mixed meal. This stimulus was chosen because it is known that IRG (Gerich, 
Lorenzi, Karam, Schneider and Forsham, 1975), GIP (Kuzio, Dryburgh, Malloy and 
Brown, 1974), PP (Adrian, Bloom, Bryant, et al, 1976) and gastrin (Korman, Soveny 
and Hansky, 1971) are all released in response to ingestion of a mixed meal. 
While instillation of intragastric food in the dog is associated with SRIF-LI 
release (Schusdziarra, Rouillier, Harris, Conlon and Unger, 1975), it was not 
known whether ingestion of a mixed meal would induce SRIF-LI release in man. 
Ingestion of a mixed meal containing protein, carbohydrate, fat, minerals and 
fluid, constituents of a normal balanced diet should constitute a good 
' 
physiological stimulus for the release of most gastrointestinal hormones. The 
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second reason for the selection of a mixed meal was related to the fact that 
neural, and in particular vagal, pathways have been implicated in the cephalic 
and gastric phases of PP (Schwartz and Rehfeld, 1977; Taylor, Feldman, Richardson 
and Walsh, 1978; Schwartz, Stenquist and Olbe, 1979), gastrin (Grossman, 1967; 
Soll and Grossman, 1978) and gastric acid (Grossman, 1967; Soll and Grossman, 
1978) responses to food. Thus ingestion of a mixed meal should provide not only 
a good physiological stimulus for hormone release, but also an assessment of the 
integrity of vagal innervation of certain of the hormones. 
2 (iii) FIBRE SUPPLEMENTATION 
The final study was designed to assess whether the effectiveness of 
dietary fibre supplementation on glucose tolerance would be altered by the 
presence of AN in NIDDM. Dietary fibre has been shown to have a beneficial 
effect on glucose tolerance in healthy man as well as diabetics (Jenkins, 
Wolever, Leeds, et al, 1978; Monnier, Pham, Aquirre, Orsetti and Mirouze, 1978; 
Monuz, Sandstead, Jacob, Johnson and Mako, 1979). In addition the use of high 
fibre, high carbohydrate diets has led to a reduction in insulin requirements in 
some !DOM and discontinuation of sulphonylurea therapy in NIDDM (Kiehm, Anderson 
and Ward, 1976; Anderson and Ward, 1978). However it was uncertain whether fibre 
would hae an equally beneficial effect on glucose tolerance in diabetics with and 
without AN. 
Two possible means of assessing the effectiveness of dietary fibre on glucose 
tolerance were considered, namely, addition to glucose in the form of an oral 
glucose tolerance test or by its addition to a mixed meal. The latter was chosen 
as it was felt that a meal would represent the more physiological stimulus. 
The next issue which arose was the selection of the particular fibre or fibres 
to be ·used. Indeed a large number of dietary fibres are available, but in 
reported studies guar and pectin, particularly the former, were the most 
favoured. One major factor in favour of the choice of guar was the report in 
which out of six different fibres it was shown to have the most marked effect on 
postprandial glucose responses in healthy volunteers (Jenkins, Wolever, Leeds, 
et al, 1978). Pectin was also reported to be effective on postprandial glucose 
concentrations (Jenkins, Leeds, Gassull, et al, 1977; Jenkins, Wolever, Leeds, 
et al, 1978). Guar is a galactomannan, a storage polysaccharide, derived from 
the cluster bean Cyamopsis tetragonotoba. Pectin is a constituent of plant and 
cell walls, and thus a structural fibre. 
The dosage of guar and pectin was the next problem. In most previous reports 
10 to 16 g of guar and 10-15 g of pectin were used (Jenkins, Goff, Leeds, et al, 
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1976; Jenkins, Leeds, Gassull, et al, 1977; Jenkins, Wolever, Leeds, et al, 
1978; Morgan, Goulder, Tsiolakis, Marks and Alberti, 1979). In the present 
study 15 g guar and 10 g pectin were tried. The guar was added to 20 g 
cooked oats and the pectin to 20 g honey. However, neither the honey nor the 
oats were found to be palatable after the two fibres were added. The addition 
of 5 g of guar to the cooked oats and 5 g of pectin to the honey of the previous 
standard test meal was found to be quite palatable however and was used in this 
study. Hence the effect of fibre supplementation could be assessed on post-
prandial glucose and hormone concentrations, using the standard test meal 
mentioned earlier as the control. 
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CHAPTER IV 
METHODOLOGY 
SECTION I THE PATIENTS AND THE DIAGNOSIS OF AUTONOMIC NEUROPATHY 
The male NIDDM who attended the Groote Schuur Hospital Diabetes 
Clinic were specifically questioned for the symptoms of autonomic dysfunction, 
such as impotence, diarrhoea, gastric fullness and dizziness on standing. 
Impotence was found to be the most common symptom. Of those questioned, 
fifteen whose only symptom of autonomic dysfunction was impotence, agreed to 
undergo testing in order to confirm the presence of AN. A further 20 male 
diabetics, asymptomatic of AN agreed to undergo the same tests. The patients 
underwent a series of eight autonomic function tests and the diagnosis of AN 
was made if the patients had three or more abnormal responses to the eight 
tests. Only patients who had normal responses to all the tests carried out 
were included in the group without AN. The tests were as follows: 
i) Postural Hypotention: With the subject lying in the supine position, a 
standard sphygmomanometer cuff was attached to the patient's upper arm. The 
systolic blood pressure was recorded and was repeated within 30 seconds of the 
subject assuming the standing position. The procedure was done three times at 
5 minute intervals. Postural hypotension was judged as being present if a fall 
in systolic blood pressure of 30mm Hg or more was present immediately on 
assuming the standing from the supine position, on all occasions (Ewing, Burt, 
Williams, Campbell and Clarke, 1976). 
ii) Beat-to-beat variation on deep breathing: The subject lay in the supine 
position for the duration of the test. A standard electrocardiograph machine 
(Cardiopan 531, Philips) was used. Lead II strips were utilized for measure-
ment of the heart rate. With the electrocardiograph (ECG) recording the rate, 
the patient breathed in and out deeply three times during a 20 second period. 
The beginning of each inspiration and each expiration was recorded on the ECG 
tracing by a marker. The minimum R-R interval for each inspiration and the 
maximum R-R interval for each expiration was measured and the beats per minute 
calculated in each instance. The procedure was repeated twice at 5 minute 
intervals. A mean beat-to-beat variation of less than 10 beats per minute in 
the 3 procedures was defined as abnormal (Wheeler and Watkins, 1973). 
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iii) Valsalva Manoeuvre: The subject was studied in the semi-recumbent position 
and was trained to perform the Valsalva manoeuvre by blowing through a mouth-
piece attached to a sphygmomanometer and maintaining a pressure of 40 mm Hg for 
15 sec. Heart rate changes as measured by the R-R interval variation on a 
continuously recording ECG were used as the index of response. Once the subject 
had mastered the technique, the test was performed with an ECG continuously 
recording the heart rate changes during the manoeuvre and for 15 sec after the 
pressure had been abruptly released. The manoeuvre was performed three times at 
5 minute intervals. The results were expressed as the Valsalva ratio which was 
calculated from the ratio of the longest R-R interval after the manoeuvre to the 
shortest R-R interval during the manoeuvre. A mean valsalva ratio was 
calculated from the ratios of the 3 manoeuvres. A valsalva ratio of 1 .10 or 
less was defined as an abnormal response (Ewing, Campbell, Burt and Clarke, 
1973). 
iv) Sustained Handgrip: After instruction in the use of the handgrip dynamo-
manometer (Stoelting Company), the subject remained seated throughout with their 
dominant arm gripped maximally for a few seconds and this was repeated twice. 
In this way the maximum voluntary contraction (MVC) was obtained by taking the 
highest value of the three contractions. The patient then maintained the hand-
grip at 30% of MVC for 5 minutes, or alternatively for as long as possible, to 
a maximum of 5 minutes. Blood pressure was measured with a sphymomanometer on 
the non-dominant arm. Three basal diastolic blood pressure recordings were 
taken at 5 minute intervals. Further recordings were taken at 1 minute 
intervals during contraction. A rise in diastolic blood pressure of 10 mm Hg or 
less was defined as abnormal (Ewing, Irving, Kerr, Wildsmith and Clarke, 1974). 
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v) Sweating in response to Insulin Hypoglycaemia: The subject was rendered 
hypoglycaemic by a 0.20 U/kg intravenous insulin injection (Actrapid monocomponent 
insulin, Novo Laboratories Industries Ltd) after an overnight fast. Quinizarin 
powder was dusted onto sellotape which was in turn applied to the subject's 
forehead, palms of the hands and soles of the feet. In the presence of sweating 
in response to hypoglycaemia, the powder altered in colour from orange-red to 
purple. Absent or reduced sweat on the lower limbs in comparison with that 
apparent on the forehead was defined as abnormal (Guttmann, 1940: Editoriill, 
Lancet, 1976). 
vi) Testicular Sensation: Testicular sensation was tested only in those 
diabetics complaining of impotence. The subject's scrotum .was held in one hand 
and each testicle was firmly squeezed in turn between the thumb and two fingers 
of the other hand. Pressure was increased until pain was felt. A normal 
response was considered as a peculiar 'sickening' pain on moderate pressure. 
The response was considered diminished if considerable pressure elicited only 
an unpleasant but tolerable discomfort and absent if full pressure evoked no 
response. Diminished or absent testicular sensation in impotent patients was 
defined as abnormal (Campbell, Ewing, Clarke and Duncan, 1974). 
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Table IV.l CLINICAL DETAILS AND INDIVIDUAL RESPONSES TO THE AUTONOMIC FUNCTION TESTS IN THE PATIENTS STUDIED 
No. Name Age Weight Height Duration Therapeutic Postural Beat-to-Beat Valsalva Sustained Sweating Testicula
r Heart rate Gastric 
{yr) (kg) (cm) of diabetes agent used Hypotensiori Variation Handri p Sensation respon:;e Acids 
(yr) 
- --
--
Diabetics with AN 
1 SH 51 75 167 16 chlorpropamide 
+ phenformi n 
N A A N A N A A 
2 RB 52 63 164 2 diet N 
.. A A N A N A N 
3 CT 45 56 161 6 glibenclamide N A A A N N A N 
+ metformi n 
4 WR 45 91 179 6 chlorpropamide 
+ phenformin 
N A N N A A A A 
5 CL 63 84 180 4.5 tolbutamide N N N N N A A A 
6 TW 41 74 180 6' glibenclamide N A N N N N A A I 
+ metformin 
7 JB 47 77 168 8 tclbutamidc 
+ metformi n 
N N A N N A A N 
8 MA 52 63 173 10, chl orpropami de N l A A N A N A N 
+ metformi n 
9 DC 58 94 169 6 chlorpropamide N l N A 
A A N A N 
10 . LP 50 64 168 8 glibenclamide A A A A - A A 
Diabetics without AN 
A JL 46 63 172 5 chlorpropamide N N N N N .. N N 
B DG 35 65 165 
I 5 chlorpropamide N N N N N N I .. N 
! 
C PR 58 63 164 2 glibenclamide N N N N N - N N 
D WN 54 70 171 10 chlorpropamide N N N N N - N N 
+ metformin 
E WG 49 69 167 3 glibenclamide N N 'N N N - N N I + metformin 
F PH 45 86 183 7 chlorpropamide 
+ metformin 
N N N N N - N N 
G EG 59 76 170 8 chlorpropamide N ~ N N N N - N N H PL 45 93 180 3 glibenclamide N N N N N - N N I HK 61 73 178 10 chlorpropamide N N N N N - N N 
+ phenformi n 
J DG 70 76 176 20 chlorpropamide N ~ N N N N - N N K GA 41 81 182 I 5 tolbutamide N N N N - - N L MW 66 80 187 6 chl orpropami de N N N N - - N 
+ metformin 
M AD 52 74 181 7 glibenclamide N N N N - - N 
N PB 54 68 163 4 metformin N N N N - - N
 
0 VE 60 70 179 5 glibenclamide N N N N - - N
 
+ metformin 
p GF 38 67 168 8 glibenclamide N I N N N -
- N 
Q SF 41 84 179 2 chlorpropamide N N N N N - -
R CD 51 60 161 5 chlorpropamide N N N N - - N 
s vv 41 60 168 3 chlorpropamide N N N N - N -
+ metformin 
vii) Immediate heart rate response to standing: The subject lay quietly for 
three minutes, then stood up within 5 seconds and remained motionless for 2 
minutes. The manoeuvre was performed with an ECG continuously recording the 
heart rate and a marker was used to identify the time of standing. The ECG was 
recorded from 30 seconds before standing to 1 minute after standing. The R-R 
intervals at beats 15 and 30 after standing were measured. The results were 
expressed as the 30 : 15 ratio, ie. the length of the R-R interval at beat 30 
divided by the length of the R-R interval at beat 15. A ratio of l .00 or less 
was considered abnormal (Ewing, Campbell, Murray, Neilson and Clarke, 1978). 
viii) Gastric Acids: The subject was tested in the morning on two separate 
occasions, each time after a 12 hour overnight fast. With the subject in a 
semi-recumbent position, on each occasion a radio-opaque nasogastric tube (Rusch, 
West Germany) was passed into the stomach and the correct positioning confirmed 
by radiological screening. Then using constant suction at a pressure of 3 mm 
H2o, the stomach was emptied of any resting gastric juice. Basal secretions were 
collected over the ensuing hour. Thereafter the appropriate stimulation was 
given. On the one occasion an intramuscular injection of 6 )Jg/kg pentagastrin 
(Peptavlon, Imperial Chemical Industries Ltd., Macclesfield, Great Britain) was 
given and gastric juice collected over the next hour. On the other occasion 
0.2 U/kg insulin was given. Gastric juice was collected for the next two hours. 
An abnormal gastric acid response to insulin hypoglycaemia as assessed by 
Hollander's criteria (1946), in the presence of a gastric acid secretory response 
to pentagastrin stimulation was defined abnormal (Hosking, Moody, Stewart and 
Atkinson, 1975). 
It is apparent in Table IV.1 that not all patients underwent the full battery of 
eight autonomic function tests. Patient 10 had such a wide range of abnormal 
·responses to six of the tests that the more cumbersome tests were considered 
unnecessary. Some of the diabetics without AN, who were only utilized to increase 
the numbers for the study on basal plasma IRG secretion had only six of the eight 
autonomic function tests. Again the more complex and cumbersome tests were 
excluded. All the other patients underwent the full battery of tests. On the 
basis of their responses to the eight autonomic function tests, AN was diagnosed 
in ten of the fifteen diabetics who complained of impotence but not in the 
remaining five. These five patients had abnormal reponses ·to less than three of 
the tests and were excluded from the study. In addition nineteen of the twenty 
diabetics who had no symptoms of AN were indeed found to be free of AN, while in 
the one remaining diabetic AN was diagnosed. 
The clinical details and individual responses to the autonomic function tests of 
the ten diabetics with AN and the nineteen diabetics without AN, who were 
included in the ensuing studies, are given in Table IV.1. None of the diabetics 
was obese and the age ranges in the two groups were alike. The normal subjects, 
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also referred to as controls, healthy controls or healthy subjects, who acted 
as controls in the studies were drawn from the laboratory and cleaning staff at 
the University of Cape Town Medical School. They were all healthy non-obese, 
non-diabetic males with no history of any endocrine or other medical disorders 
and with no family history of diabetes mellitus. 
All the studies were approved by the Ethical Review Committee of the University 
of Cape Town. Prior to each test written informed consent was obtained from 
each person after a careful explanation of the nature of the test. 
In the various studies intravenous cannulae were used to enable the withdrawal 
of multiple blood samples. The cannulae were all 19 gauge Wings infusion sets 
(AHSC South Africa (Pty) Ltd) which we.,..·einserted into an antecubital vein and 
kept patent by filling the needle with heparinized saline. 
The studies on hormone secretion were divided into three sections : basal 
hormone concentrations, stimulated hormone concentrations, and the effect of 
fibre supplementation on glucose and hormone concentrations. 
SECTION 2 : BASAL HORMONE SECRETION 
Basal plasma IRG, serum PP, serum gastrin, plasma GIP and plasma 
SRIF-LI concentrations were estimated in diabetics and healthy controls of 
similar ages, divisible into those with AN and those without AN. The effects 
of the acute establishment of fasting normoglycaemia and of complete gastric 
emptying on the basal levels of the five aforementioned hormones were also 
assessed in the diabetics after separation into the two groups. In this and the 
following sections the diabetics included in the studies on the various 
hormones are referred to by the number or letter ascribed to them in Table IV.1. 
Basal plasma IRG concentrations were estimated in twentysix diabetics, eight 
with AN (l,2,3,4,5,8,9 and 10) and eighteen without AN (A,B,C,D,E,F,H,I,J,K,L, 
M,N,O,P,Q,R and S). However the detailed studies on the effect of prior 
normalization of fasting blood glucose levels and complete gastric emptying on 
basal plasma IRG concentrations were conducted in ten diabetics, five with AN 
(1,2,3,4 and 5) and five without AN (A,B,C,D and E). Basal serum PP concen-
trations were studied in 12 diabetics : 6 with AN (2,3,4,5,6 and 7) and 6 
without AN (A,B,C,E,F and G), basal plasma GIP concentrations in 12 diabetics 
6 with AN (1,3,4,5,6 and 7) and 6 without AN (A,B,C,D,E and F), basal serum 
gastrin concentrations in 12 diabetics : 6 with AN (l ,2,3,4,5 and 6) and 6 
without AN (A,B,C,D,F and G), and basal plasma SRIF-LI levels in 12 diabetics 
6 with AN (l,3,4,5,6 and 7) and 6 without AN (A,B,C,D,E and F). 
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Basal plasma IRG, serum PP, plasma SRIF-LI and serum gastrin concentrations 
were estimated in 17 healthy subjects aged 35-62 yr, weighing 61-97 kg and 
166-190 cm in height. Basal plasma GIP concentratbns were estimated in 12 
healthy controls aged 35-55 years, 166-190 cm tall and weighing 61-97 kg. The 
detailed studies were not done in the healthy subjects. 
Basal secretion of the hormones was studied under the following conditions 
A. After a 12 hr overnight fast: 
The diabetics and controls fasted overnight for 12 hr. In the morning at 
08.00 hr an indwelling cannula was inserted and after reclining comfortably for 
half-an-hour a basal blood sample was collected. The next two protocols were 
conducted with the diabetics admitted to a hospital ward. 
B. After a 12 hr overnight insulin infusion: 
Once in the hospital ward, at 20.00 hr, three hr after the evening meal, an 
indwelling catheter was inserted into each arm. The one catheter was used for 
blood sampling and the other to administer a continuous insulin infusion. 2.5 
units of Actrapid insulin was added to 50 ml haemaccel (Behring Institute, West 
Germany). The haemaccel was used in order to prevent the insulin from adhering 
to the syringe walls. The infusion was maintained by a B. Brown infusion pump 
(Apparatebau, Melsungen). The infusion was commenced at 20.00 hr and a rate of 
0.5 - 0.8 U/hr was maintained. With a view to obtaining normalization of 
fasting blood glucose concentrations, blood samples were withdrawn at hourly 
intervals throughout the night, blood glucose estimations were done using 
dextrostix (Ames Company, Miles Laboratories Ltd) and the Ames Eyetone Reflect-
ometer, and the infusion rate adjusted accordingly. In the morning at 08.00 hr, 
the infusion was stopped and basal blood samples collected over thirty minutes. 
C. After overnight gastric aspiration: 
In the evening on the second day of hospital admission, 5 hours after 
eating his evening meal, a radio-opaque naso-gastric tube was passed in each 
diabetic subject. The correct positioning was confirmed radiologically. Two 
hourly gastric aspiration was carried out during the night. In the morning at 
08.00 hr the nasogastric tubes were removed, an indwelling cannula inserted 
and basal blood samples withdrawn. 
SECTION 3 : PROVOCATIVE STIMULATION 
Hormone secretion was examined following provocative stimulation 
in NIDDM who could be sub-divided into the two groups, and in the healthy 
controls. The stimulated secretion of IRG, PP, GIP, Gastrin and SRIF-LI was 
studied according to the following protocols: 
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A. Insulin Hypoglycaemia without prior induction of fasting normoglycaemia 
Plasma IRG, plasma GIP, serum gastrin and serum PP concentrations were 
estimated during insulin hypoglycaemia without prior induction of fasting 
normoglycaemia. However, plasma SRIF-LI responses were not evaluated in this 
study. 
The fifteen diabetics who took part in this study on IRG concentrations 
consisted of the five diabetics with AN included in the preJious study, with an 
additional two diabetics with AN (8 and 9). The diabetics without AN comprised 
four subjects from the previous study (A,C,D and E) plus an additional four 
subjects (F,H,I and J). Serum PP concentrations were estimated in 14 patients, 
two (5 and I) being added to the twelve participants in the previous study. 
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Serum gastrin concentrations were estimated in the same twelve diabetics 
participating previously; while plasma GIP levels were estimated in ten diabetics, 
five with AN (l,2,3,4 and 5) and five without AN (A,C,E,F and I). 
Twelve healthy people aged 35-59 yr, weighing 70-88 kg and 164-182 cm in 
height acted as controls for all the hormones except GIP, for which there were 
seven controls, aged 38-50 yr, 170-186 cm tall and weighing 70-89 kg. 
The insulin hypoglycaemia test was done on an outpatient basis. 
Following an overnight fast, an indwelling catheter was inserted. After half 
an tour at rest in a recumbent position, a basal blood sample was withdrawn. Then 
an intravenous bolus injection of 0.2 U/kg Actrapid insulin was given in the 
diabetics, while 0.1 U/kg insulin was given in the controls. Blood samples were 
withdrawn 20, 40, 60 and 90 minutes after the insulin injection. 
B. Insulin Hypoglycaemia after Induction of fasting normoglycaemia 
The effect of prior normalization of fasting blood glucose concentrations was 
assessed on plasma IRG, serum PP and serum gastrin concentrations during insulin 
hypoglycaemia in the diabetics. On this occasion plasma was also collected for 
SRIF-LI estimations. In ~tew of the lack of effect of hypoglycaemia on plasma 
GIP levels in the preceding study, samples were not collected for GIP estimations 
in this study. Plasma IRG responses were assessed in 5 diabetics with AN 
(1,2,3,4 and 5) and 5 diabetics without AN (A,C,D,E and F). Serum PP responses 
were evaluated in 5 diabetics with AN (2,3,5,6 and 7) and 5 diabetics without AN 
(A,B,C,F and G). Serum gastrin responses were assessed in the same 12 patients 
who took part in the preceding protocol while plasma SRIF-LI responses were 
determined in 5 diabetics with AN (l,3,4,5 and 6) and 5 diabetics without AN 
(A,B,D,E and F). Ten healthy people aged 35-55 yr, 166-180 cm tall and weighing 
73-92 kg acted as controls for the study on SRIF-LI. They underwent the insulin 
hypoglycaemia test described in the preceding protocol. 
The diabetics were admitted to a hospital ward for the study. In the 
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Table IV. 2 CONSTITUENTS OF THE MIXED MEAL 
2 boiled eggs 
250 ml cow's milk 
30 g skim milk powder 
2 slices wholewheat 
bread 
20 g honey 
20 g butter 
Weight 
(g) 
108 
250 
30 
60 
20 
20 
488 
C.I. Church and H.N. Church 
12th ed Rev. 
J.B. Lippincott, 1975 
Philadelphia. 
CHO 
. (g) 
1.0 
12.0 
15.5 
28.2 
15.3 
72 
Proetin 
( g) . 
14.0 
8.5 
10.7 
4.9 
0.1 
0.1 
38.3 
Fat 
(g) 
12.4 
9 .o 
0.1 
2.1 
16.4 
40 
Calories 
166 
165 
107.5 
136.8 
61.2 
148 
784.5 
Food values of Portions commonly, ,µsed. 
evening, at 20.00 hr, three hours after the evening meal, a 12 hr continuous 
insulin infusion was started in each diabetic with a view to establishing 
fasting normoglycaemia. The details of the infusion are described in section 
1.3. The infusion completed, basal blood samples were collected over the 
following thirty min and the insulin hypoglycaemia test described in the 
preceding protocol repeated. 
C. Mixed Meal 
Concentrations of all . of the abovementioned hormones were estimated after 
ingestion of a mixed meal. The study on IRG secretion was conducted in the 
same 10 diabetics, who took part in the detailed studies on basal plasma IRG 
secretion. The studies on PP, gastrin and GIP secretion were carried out in 
the same patients participating in each individual hormone study in the first 
section. SRIF-LI secretion in response to ingestion of a meal was evaluated 
in the same diabetics studied for SRIF-LI in the preceding protocol. Twelve 
healthy subjects aged 33-62 yr, weighing 62-97 kg and 170-186 cm tall acted as 
controls for the study on all the hormones besides gastrin. Six healthy 
subjects aged 35-62 yr, 170-179 cm tall and weighing 61-97 kg acted as controls 
for the study on serum gastrin concentrations. 
The diabetics and controls ate a mixed meal the morning after an overnight 
fast. Simultaneously with the overnight fast, the diabetics had their stomachs 
slowly emptied to ensure complete gastric emptying. 
In the evening, on the second day of admission, five hr after the evening 
meal, a nasogastric tube was passed in each patient and the overnight gastric 
aspiration as described in detail in Section I begun. At 08.00 hr, the naso-
gastric tubes were removed, an indwelling catheter inserted and basal blood 
samples collected over the ensuing 15 minutes. In the healthy subjects the 
study also commenced at 08.00 hrs, with the pbcing of an intravenous catheter 
in an antecubital vein and the collection of basal blood samples over fifteen 
minutes. In all the subjects, after the basal samples were taken, the mixed 
meal, the constituents and caloric contents of which are gi~en in Table IV.2, 
was eaten in ten minutes. One blood sample was taken half-way during the meal 
and further samples were collected 5, 15, 30, 45, 60, 90, 120, 180 and 240 
minutes after completion of the meal. 
SECTION 4 : FIBRE SUPPLEMENTATION 
The effects of fibre supplementation on serum glucose, serum insulin, 
plasma IRG and plasma GIP responses to ingestion of a meal were assessed in six 
diabetics with AN, six age-matched diabetics without AN and in twelve healthy 
controls in the same age range. Patients 1 ,3,4,5,6 and 7 comprised the diabetics 
with AN and patients A,B,C,D,E and F the diabetics without AN. The twelve 
healthy subjects ranged in age from 35-62 yr, were 170-187 cm in height and 
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weighed 60-97 kg. The subjects ingested a test meal on two separate occasions, 
1-2 weeks apart, in each instance after an overnight fast. The test meal was 
the same as that described in Section 3 C and detailed in Table IV.2. In the 
fibre-supplemented meal, 5 g guar was added to the cooked oats which was 
substituted for one slice of bread and 5 g of pectin was added to the honey. 
Otherwise the constituents of the meal were the same as in the test meal. The 
carbohydr~te and caloric contents of the fibre-supplemented meal were 28 g and 
794.5 g respectively. On each occasion in indwelling cannula was inserted, 
basal blood samples withdrawn over 15 min and the meal ingested in 10 minutes. 
One blood sample was collected during the meal and further samples were with-
drawn 5,15,30,45,60,90,l20,l80 and 240 minutes after completion of the meal. 
SECTION 5 COLLECTION OF SAMPLES 
In all the aforementioned studies, blood samples for plasma GIP, 
plasma IRG and plasma SRIF-LI estimations were collected in heparinized test 
tubes containing 1,000 U/ml of Trasylol (Aprotinin, Bayer). The plasma was 
immediately separated by centrifugation and the aliquots were stored at -20°c. 
Blood samples for serum glucose, serum PP, serum insulin and serum gastrin 
estimations were collected in plain glass tubes and allowed to clot. Thereafter 
the serum was separated by centrifugation and the aliquots stored at -20°c for 
later assay. 
SECTION 6 : LABORATORY METHODS 
Serum glucose concentrations were estimated by means of the 
ferricyanide method (Hoffman, 1937; Varley, 1967) using the Technicon Auto 
Analyser I (Technicon Instrument Corporation, Tarrytown, New York). 
Concentrations of the various hormones in blood were measured by specific radio-
illlllunoassays. 
Plasma glucagon immunoreactivity (IRG) was assayed by the method described by 
Faloona and Unger (1974). 
Serum PP immunoreactivity was measured by radioimmunoassay by the method 
described by Sive, Vinik, Van Tonder and Lund (1978). 
Plasma GIP immunoreactivity was estimated by radioimmunoassay using the method 
described by Kuzio, Dryburgh, Malloy and Brown (1974). 
Serum gastrin immunoreactivity was measured by radioimmunoassay using the SORIN 
gastrin radioimmunoassay kit (International CIS). 
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Plasma somatostatin immunoreactivity (SRIF-LI) was assayed by the method 
described by Kronheim, Berelowitz and Pimstone (1978). 
Serum insulin immunoreactivity was measured by radioimmunoassay using the SORIN 
insulin radioimmunoassay kit (International CIS). 
Promblems associated with the SRIF-LI assay: 
The SRIF-LI assay using unextracted plasma developed by Kronheim, Berelowitz and 
Pimstone (1978) was utilized in this study. Kronheim and associates ha.e gone to 
considerable lengths to authenticate this assay and have demonstrated that : the 
integrity of the labelled SRIF can be maintained in unextracted plasma and the 
SRIF-LI measured in this system shared immunological identity with synthetic SRIF 
(Kronheim, Berelowitz and Pimstone, 1978; Kronheim and Pimstone, 1980). However, 
doubt still remains concerning the authenticity of SRIF-LI measured by this 
means. In particular Arimura, Lundqvist, Rothman, et al (1978), and Penman, 
Wass, Lund, et al (1979), have found that plasma SRIF-LI levels measured in 
extracted plasma are much lower than those estimated in unextracted plasma using 
the present assay. These differences may be due to other SRIF-LI like substances 
or to the measurement of different forms of SRIF-LI or non-specific effects in 
unextracted plasma. In particular the antiserum used in the present assay 
appears to be specific for the middle portion of SRIF and may thus measure other 
forms of SRIF such as those recently described. Recently biologically active 
higher molecular weight forms of SRIF have been isolated and structurally 
identified in porcine intestine (Pradayrol, Jornvall, Mutta and Ribet, 1980) and 
porcine and ovine hypothalami (Schally, Huang, Chang, et al, 1980; Brazeau, 
Ling, Esch, et al, 1980) and have been demonstrated to be released from ovine 
stalk median eminence synaptosomes (Dr R.P. Miller, University of Cape Town, 
personal communication). Thus the quantitation of SRIF-LI in plasma will depend 
on the relative crossreactivity of the antisera used with these N terminally 
extended forms of SRIF. Whatever the explanation for the differences it is 
clear that the material measured in unextracted plasma has been at least 
partially specified as SRIF-LI. However, the controversy will remain until 
such time as unequivocal specification of the material measured in unextracted 
plasma as SRIF-LI is demonstrated by its actions in a bioassay. Accepting 
these reservations the SRIF-LI assay using unextracted plasma as mentioned 
earlier, and which appears to measure a substance that is immunologically 
related to synthetic SRIF and is altered in response to physiological stimuli, 
was used in the present studies. 
The details of the laboratory techniques are described in the appendix. 
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SECTION 7 STATISTICAL ANALYSIS 
Statistical analysis of the data was carried out according to the 
methods described by Snedcor and Cochrane (1967). The data on plasma IRG, 
plasma SRIF-LI, plasma GIP, serum PP, serum gastrin, serum insulin and serum 
glucose concentrations were all analysed by means of non-parametric statistical 
tests. The Mann-Whitney U test was used for unpaired data and the Wilcoxon 
Signed Rank test for paired data. The detailed methods of the statistical 
tests are described in the appendix. 
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CHAPTER V 
RESULTS 
In this chapter the results of the studies carried out are given, following the 
same sequence as the preceding chapter. The results are expressed as the mean 
~ the standard error of the mean (SEM). Wherever appropriate, diagrams appear 
on the page opposite the relevant results. On occasion the results are given 
in table form. 
In the sections (a) on basal hormone secretion, 
and 
(b) hormone secretion in response to ingestion of a mixed meal, 
and 
(c) insulin hypoglycaemia, 
the results are initially given for the diabetics considered as a single group. 
Results after subdivision into diabetics with and without AN follow. 
The studies on the various hormones utilized combinations of the patient group. 
However the differences in the comp~sition of the study groups made no 
difference to the glucose and insulin results which were obtained. In order to 
avoid repetition therefore, the glucose and where relevant, the insulin results 
in each section, will be described first. 
SECTION I : BASAL HORMONE SECRETION : EFFECTS OF OVERNIGHT INSULIN INFUSION AND OVERNIGHT GASTRIC ASPIRATION 
I (i) GLUCOSE AND INSULIN 
Diabetics vs Controls 
The 26 diabetics had a significantly higher mean basal serum glucose 
concentration than the 17 healthy subjects (8.2 ! 0.6 vs 4.9 ± 0.2 mmol/1) (p L. 0.01). However the mean basal serum insulin concentrations were similar 
in the diabetics (16.2 ± l.5JJU/ml) and the controis (13.8 ± l .5J.IU/ml). 
Diabetics without AN vs Diabetics with AN 
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The mean basal serum glucose concentrations were similar in the 18 diabetics 
without AN (8.2 ± 0.7 mmol/1) and in the 8 diabetics with AN (8.2 ± 0.9 mmol/1) 
but were elevated relative to the controls. The basal serum insulin concen-
trat i ons too were similar in the diabetics without AN (16 ± 1.3).IU/ml) and those 
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with AN (16.5: 2JJU/ml) and were not different from the controls. 
In the smaller group of patients selected for detailed studies (Table V.l) the 
mean basal serum glucose and insulin concentrations remained similar in the two 
groups of diabetics. 
70 
The overnight insulin infusion reduced the mean basal serum glucose concentrations 
to within the normal fasting range and raised the mean basal serum insulin 
concentrations in both the diabetics with AN and those without AN. There were 
no significant differences between the two groups. 
The overnight gastric aspiration did not alter the mean basal serum insulin or 
glucose concentrations in either group of diabetics. Once again no significant 
differences were apparent between the two groups. 
Comment: 
The diabetics had significant fasting hyperglycaemia but similar basal serum 
insulin concentrations to those of the controls. The diabetics with and without 
AN had similar basal serum insulin and glucose concentrations. The overnight 
gastric aspiration did not alter these concentrations in either group of 
diabetics. The overnight insulin infusion induced fasting normoglycaemia and 
raised the basal serum insulin levels to a similar degree both in the diabetics 
with and without AN. 
45 
FASTING IRG CONCENTRATIONS IN 
ALL MODS (with and without AN) 
AND IN HEALTHY SUBJECTS 
:ft?tiJJNh Il 
.· .· · .. · .. ·.· .. · .. 
DIABETICS NORMAL SUBJECTS 
(Fig. V.l) Basal plasma IRG concentrations in 17 
healthy subjects and 26 diabetics. The 
vertical bars represent the SEM in this 
and all following figures. The asterisk 
indicates p ~ 0.05 difference between 
the two groups. 
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Healthy Controls 
V.2)Basal plasma IRG concentrations in 8 
diabetics with AN, 18 diabetics without 
AN and 17 healthy subjects. Asterisk 
indicates p ~ 0.01 difference between 
the diabetics with AN and the other two 
groups. 
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Table V.2 
Diabetics 
without AN 
Diabetics 
with AN 
Basal plasma IRG concentrations (pmol/1) and the 
effects thereon of overnight insulin infusion and 
overnight gastric aspiration in 5 diabetics with 
AN and 5 diabetics without AN. 
Basal 
(After 
Overnight 
Fast) 
16.2 + 2 • 1 
+ 49.4 5.9* 
After 
Overnight 
Insulin 
Infusion 
+ 18.8 2.9 
+ 48.6 6.4* 
After 
Overnight 
Gastric 
Aspiration 
30.4 + 2.8 
52.1 + 6.4* 
* p<: 0.01 difference between the two groups. 
I (ii) GLUCAGON 
Diabetics vs Controls (Fig. V.l) 
. + The mean basal plasma was 25.3 - 2.8 pmol/1 in the 26 diabetics and 
16.8 ~ 2.5 pmol/1 in 17 healthy controls. The difference was statistically 
significant (p L.. 0.05). 
Diabetics with AN vs Diabetics without AN 
When the diabetics were divided into those with and without AN, 
prominent differences in their basal plasma IRG concentrations became apparent 
(Fig. V.2). In the 18 diabetics without AN, the mean basal plasma IRG level 
was 17.4 ~ 1.3 pmol/1, similar to that observed in the controls. In contrast 
the diabetics with AN had a mean basal plasma IRG level of 43 ~ 4.2 pmol/1, 
significantly higher (p ~ 0.01) than in the diabetics without AN and in the 
controls. 
In 5 diabetics in each group selected for the detailed studies, the 
mean basal plasma IRG concentration was significantly higher (pc( 0.01) in the 
diabetics with AN than in the diabetics without AN (Table V.2). 
The overnight insulin infusion which induced fasting normoglycaemia 
did not alter the mean basal plasma IRG concentrations in either group of 
diabetics. 
The overnight gastric aspiration which was done to ensure complete 
emptying of the stomach, also did not alter the mean basal plasma IRG 
concentrations in either group of diabetics. 
On both occasions the mean basal plasma IRG levels were significantly 
higher (p..:::,. 0.01) in the diabetics with AN than in the diabetics without AN. 
Comment: 
The diabetics had a significantly higher mean basal plasma IRG concentration 
than the healthy controls. However, the mean basal plasma IRG concentration 
in the diabetics without AN was similar to that in the controls, but were 
significantly elevated in the diabetics with AN. Further, neither the over-
night insulin infusion which induced fasting normoglycaemia, nor the over-
night gastric aspiration which ensured complete emptying of the stomach, 
induced any change in the basal plasma IRG concentrations in the diabetics 
with AN and those without AN. 
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Table V.3 
Diabetics 
without AN 
Diabetics 
with AN 
Basal serum PP concentrations (pmol/1) with and 
without prior overnight insulin infusion and 
overnight gastric aspiration in 6 diabetics with 
AN and 6 diabetics without AN. 
Basal 
(After 
Overnight 
Fast) 
47 + 10.8 
After 
Overnight 
Insulin 
Infusion 
35 + 6 
86 + 16.6* 
After 
Overnight 
Gastric 
Aspiration 
+ 48.6 8.8 
52.6 + 1 2 • l 
* p ~0.05 difference between the two groups. 
I (iii) PANCREATIC POLYPEPTIDE 
Diabetics vs Controls 
The mean basal serum PP concentrations were similar in the 12 diabetics (40.6 + 7.7 pmol/1) and the 17 healthy subjects (42.5 ~ 6.3 pmol/1). 
Diabetics without AN vs Diabetics with AN (Table V.3) 
The mean basal serum PP concentrations were found to be similar in the 
two groups of diabetics and were not different from the contols. 
The overnight insulin infusion did not alter the mean basal serum PP 
concentration in the diabetics without AN. In the dinbetics with AN, however, 
there was an increase in the mean basal serum PP level. This increase was not 
significant despite the insulin infusion resulting in an elevation of fasting 
serum PP levels in five of the six diabetics with AN. On this occasion the 
mean basal serum PP concentration was significantly higher in the diabetics 
with AN than in those without AN and also to the controls (p <0.05). 
The overnight gastric aspiration induced an insignificant increase in 
the mean basal serum PP levels in both groups of diabetics. 
The differences between the two groups of diabetics were not 
significant nor were the levels different from the mean basal levels in the 
controls. 
Comment: 
The 12 diabetics and the 17 healthy subjects had similar mean basal serum PP 
concentrations. Diabetics with and without AN had similar mean basal serum 
PP concentrations which were not different from those of the healthy controls. 
Overnight gastric aspiration induced an insignificant rise in mean serum PP 
levels in both groups of diabetics but in neither group was the level 
significantly different from the normal mean basal level. Overnight insulin 
infusion induced an elevation in the mean basal serum PP level only in the 
diabetics with AN. On this occasion the mean basal serum PP concentration 
was significantly higher in the diabetics with AN than in those without AN 
and the controls. 
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Table V.4 
Diabetics 
without AN 
Diabetics 
with AN 
Basal serum gastrin concentrations (pmol/1) with 
and without prior overnight insulin infusion and 
overnight gastric aspiration in 6 diabetics with 
AN and 6 diabetics without AN. 
Basal 
(After 
Overnight 
Fast) 
27.4 + 5. l 
34 + 4 
After 
Overnight 
Insulin 
Infusion 
31.8 + 5 . l 
30.5 + l. 7 
After 
Overnight 
Gastric 
Aspiration 
26. l + 4.8 
26 + l. 3 
I (iv) GASTRIN 
Diabetics vs Controls 
The mean basal serum gastrin concentration was 24.6: 1.9 pmol/1 
in the 17 healthy controls and 30.7 ~ 3.2 pmol/1 in the 12 diabetics. The 
difference was not statistically significant. 
Diabetics without AN vs Diabetics with AN (Table V.4) 
The mean basal serum gastrin concentrations were similar in both 
groups of diabetics, and were not significantly different compared to the 
controls. 
The overnight insulin infusion induced a slight rise in the mean 
basal serum gastrin level in the diabetics without AN and a minor ·fall in the 
diabetics with AN. 
Overnight gastric aspiration did not alter the mean basal serum 
gastrin level in the diabetics without AN, but caused a small fall in the 
diabetics with AN. On all occasions tested, the mean basal serum gastrin 
concentrations were similar in both groups of diabetics and were not different 
from the levels in the healthy subjects. 
Comment: 
The diabetics as a single group or divided into two groups, ie. those with 
and without AN, all had normal mean basal serum gastrin concentrations. 
Furthermore neither the insulin infusion. nor the overnight gastric aspiration 
resulted in a deviation of the mean basal serum gastrin levels from the 
normal range in either group of diabetics. 
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Table V.5 
Diabetics 
without AN 
Diabetics 
with AN 
Basal plasma GIP concentrations and the effects 
thereon of overnight. insulin infusion and over-
night gastric aspiration in 6 diabetics with AN 
and 6 diabetics without AN. 
Basal 
(After 
Overnight 
Fast) 
58.6 + 1 0. 9 
58 + 9 
Plasma GIP 
pmol/1 
After 
Overnight 
Insulin 
Infusion 
65.2 + 1 2 • 1 
77 + 11 • 1 
After 
Overnight 
Gastric 
Aspiration 
73.1 + 13.2 
56.2 + 1 0. 3 
I (v) GASTRIC INHIBITORY POLYPEPTIDE 
Diabetics vs Controls 
The mean basal plasma GIP concentrations were similar in the 12 
diabetics (58.3 ~ 6.8 pmol/1) and in the 12 controls (59.4 ~ 5.0 pmol/1). 
Diabetics without AN vs Diabetics with AN (Table V.5) 
The mean basal plasma GIP concentrations were similar in the 
diabetics without AN and those with AN. 
The overnight insulin infusion did not significantly alter the 
mean basal plasma GIP levels in either group of diabetics. 
The overnight gastric aspiration too did not significantly alter 
the mean basal plasma GIP levels in the two groups of diabetics. In the 
diabetics without AN, there was a small rise in mean basal plasma GIP levels 
after gastric aspiration but not in the diabetics with AN. On all occasions 
the mean basal plasma GIP levels in the two groups of diabetics did not differ 
from those in the healthy subjects. 
ColTdllent: 
The mean basal plasma GIP concentrations were similar in the diabetics and 
controls. Both the diabetics with and without AN had similar mean basal plasma 
GIP concentrations, which were not different to that of the normals. Further-
more, gastric aspiration and insulin infusion did not notably alter the mean 
basal plasma GIP concentrations in either group of diabetics. 
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Table V.6 
Diabetics 
without AN 
Diabetics 
-with AN 
Basal plasma SRIF-LI concentrations (pg/ml) with 
and without prior overnight insulin infusion and 
overnight gastric aspiration in 6 diabetics with 
AN and 6 diabetics without AN. 
Basal 
(After 
Overnight 
Fast) 
215 + 60.4 
236 + 44.8 
After 
Overnight 
Insulin 
Infusion 
162 + 30.2 
203 + 60.9 
After 
Overnight 
Gastric 
Aspiration 
177 + 40.8 
230 + 47 
I (vi) SOMATOSTATIN 
Diabetics vs Controls 
The mean basal plasma SRIF-LI concentration was 225 ~ 36 pg/ml in 
the 12 diabetics and 192.2 ~ 16.1 pg/ml in the 17 healthy controls. The 
difference was not statistically significant. 
Diabetics without AN vs Diabetics with AN (Table V.6) 
The mean basal plasma SRIF-LI levels were similar in the two groups 
of diabetics, and neither were significantly different from that in the 
controls. 
The overnight insulin infusion did not induce any significant 
alteration in the mean basal plasma SRIF-LI concentrations in either of the 
diabetic groups. However there was a slight reduction in the mean basal 
plasma SRIF-LI concentration in both grou·ps. -· 
Similarly, the overnight gastric aspiration induced negligible 
alterations in the mean basal plasma SRIF-LI levels in both groups of 
diabetics. On all occasions, the basal plasma SRIF-LI concentrations in 
the two groups of diabetics remained within the normal fasting range. 
Comment: 
In the diabetics, whether considered as one group or sub-divided into those 
with and without AN, the mean basal plasma SRIF-LI concentrations were 
within the normal range. In addition, neither the overnight insulin 
infusion nor the overnight gastric aspiration induced the basal plasma 
SRIF-LI levels to fall outside the normal basal range in the diabetics with 
AN or in those without AN. 
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Table V.7 
Diabetics 
Diabetics 
without AN 
Diabetics 
with AN 
Summary of the data on basal secretion of the 
five gastrointestinal hormones in the diabetics 
as a single group, the diabetics without AN and 
the diabetics with AN relative to the normal subjects. 
IRG pp GASTRIN GIP SRIF.,.LI 
N N N N 
N N N N N 
N N N N 
'?-4 - elevated 
N normal 
' .. 
SUMMARY: (Table V.7) 
Although the diabetics had fasting hyperglycaemia, their mean basal plasma GIP, 
plasma SRIF-LI, serum PP and serum gastrin concentrations were similar to those 
in the healthy controls. However the mean basal plasma IRG concentrations were 
significantly higher in the diabetics than the controls. 
The mean basal plasma GIP, plasma SRIF-LI, serum PP and serum gastrin 
concentrations were similar in the diabetics with AN and in those without AN, 
and were not different from the mean concentrations in the healthy subjects. 
The basal plasma IRG concentrations presented a different picture from the one 
observed with the aforementioned hormones. There was a significant difference 
in the basal hormone concentrations in the two groups of diabetics. The 
diabetics without AN and the healthy controls had similar mean basal plasma IRG 
concentrations, despite the presence of fasting hyperglycaemia in the former 
group. In contrast the diabetics with AN had a two-fold higher mean basal 
plasma IRG concentration than the diabetics without AN and also the controls. 
The overnight insulin infusion which induced fasting normoglycaemia did not 
alter the mean basal plasma SRIF-LI, plasma GIP or serum gastrin concentrations 
in either group of diabetics and all remained similar to the levels observed in 
the controls. The overnight insulin infusion also did not alter the mean basal 
plasma IRG concentrations in either of the groups of diabetics. Thus the mean 
basal plasma IRG concentration remained twofold higher in the diabetics with AN 
than in those without AN. After the overnight insulin infusion, the mean serum 
PP level rose only in the diabetics with AN and was significantly higher than 
that in the diabetics without AN. 
The overnight gastric aspiration, which ensured complete emptying of the 
stomach, did not induce any deviation from the normal fasting range of the mean 
basal plasma GIP, plasma SRIF-LI, serum PP or serum gastrin levels in the two 
groups of diabetics. The plasma IRG levels too were unaffected by the gastric 
aspiration. Thus once again the mean basal plasma IRG level was twofold higher 
in the diabetics with AN than in those without AN. 
Thus abnormalities in basal IRG secretion were apparent in the diabetics as a 
group and in the diabetics with AN, but not in those without AN. The basal 
secretion of the other hormones remained unaltered either in the diabetics 
per se or in the presence of AN. 
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SECTION 2 : PROVOCATIVE STIMULATION 
A INSULIN HYPOGLYCAEMIA WITHOUT PRIOR INDUCTION OF FASTING 
NORMOGLYCAE MI A 
2 A (i) GLUCOSE 
Diabetics vs Controls (Fig. V.3) 
In the 12 controls serum glucose levels fell rapidly after the 
insulin bolus, from the mean basal level of 5 ~ 0.3 mmol/1 to 1 .7: 1 .1 mmol/1 
at 20 min, rising thereafter. In the 15 diabetics the mean basal serum 
glucose level was 8 ± 0.8 mmol/1, significantly higher than in the controls 
(p~ 0.01). Furthermore, the serum glucose levels fell more slowly and not as 
far as in the controls, with a mean level of 2.9 ~ 0.3 mmol/1 occurring at 
40 min. 
Diabetics without AN vs Diabetics with AN (Fig. V.4) 
The mean basal serum glucose concentrations as well as the serum 
glucose responses to the insulin injection were similar in both groups of 
diabetics and were equally different from those of the controls. In the 8 
diabetics without AN serum glucose fell from the mean basal level of 7.9 ~ 
1.2 mmol/1 to 2.9 ~ 0.3 mmol/1 at 40 min. In the 7 diabetics with AN the mean 
basal glucose level was 8.1 ~ l .1 mmol/1 and fell to 3: 0.3 mmol/1 at 60 min. 
Comment: 
There was significant fasting hyperglycaemia, a delayed fall and higher 
absolute serum glucose levels in the diabetics than the controls. The diabetics 
with and without AN had similar degrees of fasting hyperglycaemia and serum 
glucose responses. 
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2 A (ii) GLUCAGON 
Diabetics vs Controls (Fig. V.5) 
Insulin hypoglycaemia induced a significant rise in plasma IRG 
levels in the 15 diabetics and the 12 controls. The mean basal plasma IRG 
concentration was 30.5 ! 4.2 pmol/1 in the 15 diabetics and 14.9 ~ 2.8 pmol/1 
in the 12 healthy controls. The difference was statistically significant 
(p <0.01). In the healthy controls, plasma IRG concentrations rose 
significantly above basal at 40, 60 and 90 min after the insulin bolus 
(p < 0.01) and a mean peak concentration of 41 .5: 5.4 pmol/1 was attained. 
In the diabetics plasma IRG concentrations only rose significantly above the 
mean basal concentration at 60 and 90 min (p~ 0.01) but the maximum 
incremental rise was similar in the diabetics (20.5: 4.1 pmol/1) and in the 
controls (26.5 ± 3.6 pmol/1). The mean peak plasma IRG concentration was 
51 ! 2.6 pmol/1 in the diabetics. Significant differences between the two 
groups were apparent at 60 and 90 min ( p < 0.01). 
Diabetics without AN vs Diabetics with AN (Fig. V.6) 
In the diabetics without AN plasma IRG concentrations were 
significantly elevated above the mean basal concentration of 18.1 : 1.9 pmol/1 
at 60 and 90 min (Fig. V.20). The mean peak plasma IRG concentration of 
45.7 ! 3.5 pmol/1 (maximum increment 27.5 ~ 4.6 pmol/1) was observed in the 
diabetics without AN. Thus both the mean basal and mean peak plasma IRG levels 
were similar in the diabetics without AN and the controls. The mean basal 
plasma IRG concentration of 44.7 ~ 4.4 pmol/1 in the diabetics with AN was 
significantly higher than in the other two groups (p..:::::. 0.01). Furthermore, 
there was no significant rise in plasma IRG concentrations in response to the 
insulin bolus in the diabetics with AN. In these patients the mean peak plasma 
IRG concentration was 57.1 : 2.5 pmol/1 and the mean maximum increment 12.5 ~ 
5.9 pmol/1. 
Comment: 
The magnitude of the plasma IRG response to the insulin injection was similar 
in the diabetics as a whole and the controls. Diabetics without AN were found 
to have a similar twofold rise in plasma IRG concentrations to that seen in 
the controls. In contrast, the diabetics with AN, who started with a twofold 
higher mean basal plasma IRG concentration than the diabetics without AN and 
the healthy subjects, had a flattened and insignificant rise in plasma IRG 
levels in response to the insulin injection. 
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2 A (iii) PANCREATIC POLYPEPTIDE 
Diabetics vs Controls (Fig. V.7) 
The mean basal serum PP levels were similar in the healthy subjects 
and the diabetics, but the rise in serum PP levels in response to insulin 
hypoglycaemia was significantly greater in the former. In the healthy subjects 
serum PP concentrations rose from the mean basal level of 44.9 ~ 6.5 pmol/1 to 
reach significant elevation above basal from 40 min onwards ( p <.. 0.01), 
although there was a small fall in PP levels after 40 min. The mean peak serum 
PP level of 752.4 ~ 60.l pmol/1, a seventeenfold rise, was attained in the 
healthy controls. In the diabetics serum PP levels rose from 42.4 ± 6.4 pmol/1, 
reaching significant elevation above basal from 40 to 90 min (p .::..0.01). The 
mean serum PP levels attained were significantly lower than those of the 
controls (p < 0.05). The mean peak serum PP level attained in the diabetics was 
409.7 ± 99.9 pmol/1, a tenfold rise and significantly lower than that of the 
controls (p < 0.05). 
Diabetics without AN vs Diabetics with AN (Fig. V.8) 
In the diabetics without AN there was a significant rise in serum 
PP concentrations from the mean basal level of 37.6 ~ 9.3 pmol/1, apparent from 
40 to 90 min (p< 0.01) and the mean peak concentration of 676.9 ± 134.9 pmol/1 
(an eighteenfold rise) was attained. At no time was the PP response in the 
diabetics without AN and the controls different. 
In the diabetics with AN serum PP levels rose from 47.l ~ 9.1 pmol/1, 
reaching significant elevation above basal from 60 to 90 min (p4' 0.01) and 
attaining the mean peak level of 142.5: 35.9 pmol/1 (a threefold rise). There 
was significant impairment of the serum PP response to hypoglycaemia at 40, 60 
and 90 min as well as the mean peak level in the diabetics with AN relative to 
the controls and the diabetics without AN (p< 0.01). 
Comment: 
The diabetics as a whole had a significantly impaired rise in serum PP levels. 
The diabetics without AN had a similar rise in serum PP levels to that of the 
controls, but in the diabetics with AN there was a severely truncated PP rise. 
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in 6 diabetics with and 6 diabetics without AN. 
2 A (iv) GASTRIN 
Diabetics vs Controls (Fig. V.9) 
The mean basal serum gastrin concentrations were 24.9 ! 2~4 pmol/1 
in the 12 controls and 35.6 ~ 3.5 pmol/1 in the 12 diabetics. The difference 
was not statistically significant. In the healthy subjects serum gastrin 
levels rose in response to insu)in hypoglycaemia, reaching significance at 40 
min (p< 0.05). The mean peak concentration of 36.4: 5.3 pmol/1 was noted in 
the controls and was also significantly elevated above the mean basal level 
(p<" 0.01). Although there was a rise in serum gastrin levels after the 
insulin injection in the diabetics too, only the mean peak concentration 
(49.6 ~ 8.8 pmol/1) was significantly elevate·d above basal (p <. 0.05). However 
the mean maximum incremental rises were similar in the diabetics (14 ! 6.9 pmol/1) 
and the controls (11.5 ~ 3.7 pmol/1). 
Diabetics without AN vs Diabetics with AN (Fig. V.10) 
There was only a small and insignificant rise in serum gastrin 
levels in the diabetics without AN, and a· larger but still insignificant rise in 
the diabetics with AN in response to insulin hypoglycaemia. In the diabetics 
without AN serum gastrin levels rose from a mean basal concentration of 30.8 ~ 
5.6 pmol/1 to a mean peak concentration of 38.3 ~ 6.1 pmol/1 (p;>0.05). In the 
diabetics with AN the mean basal level was 40.4: 3.8 pmol/1 and the mean peak 
level 61 : 15.9 pmol/1 (p ~ 0.05). In contrast, the mean maximum incremental 
rise in gastrin levels was slightly higher in the diabetics with AN (20.7 ~ 
13.2 pmol/1) than the similar rises of 7.4 ! 4.3 pmol/1 in the diabetics without 
AN and 11.5: 3.7 pmol/1 in the controls. 
Comment: 
There was a significant serum gastrin response to insulin hypoglycaemia in the 
controls. Although the response in the diabetes and the controls were not 
notably different only the mean peak serum concentration was significantly 
elevated above basal in the former. There was an insignificant rise in serum 
gastrin levels in response to the insulin injection in the diabetics with and 
without AN. The maximum incremental serum gastrin increases were not different 
in either group of diabetics relative to the controls. 
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2 A (v) GASTRIC INHIBITORY POLYPEPTIDE 
Diabetics vs Controls (Table V.8) 
There was no significant alteration in plasma GIP levels after 
the insulin injection in either the diabetics or the controls. 
Diabetics without AN vs Diabetics with AN (Table V.9) 
Insulin hypoglycaemia induced no significant alteration in GIP 
levels in either group of diabetics. 
Comment: 
Insulin hypoglycaemia failed to induce any significant alteration in plasma 
GIP concentrations in the healthy controls, the diabetics as a whole, or 
~fter subdivision into those with AN and those without AN. 
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81a 
Table V .10 
Sununary of the ~esponses of the four gastrointestinal 
I 
hormones to insulin hypoglycaemia in the healthy 
subjects, the diabetics as a single group, and after 
subdivision into those with AN and those without AN, 
relative to responses in the healthy controls. 
IRG pp GIP GASTRIN 
Healthy subjects 
Diabetics 
Diabetics 
without AN 
Diabetics 
with AN 
N 
N 
N 
h 
N · 
significant response 
no significant response 
normal 
i_!l]pa ired 
+ 1r 
significant response only in mean 
peak concentration 
SUMMARY (Table V.10) 
The diabetics as a group had fasting hyperglycaemia before PP, a delayed fall 
and higher absolute serum glucose levels during insulin hypoglycaemia than the 
healthy subjects. In the latter, insulin hypoglycaemia induced significant 
increases in the concentrations of circulating IRG, PP and gastrin but not GIP, 
while in the former significant increases in serum PP, plasma IRG concentrations 
and the mean peak serum gastrin were noted. However only in the case of PP was 
the response in the diabetics significantly impaired relative to the controls. 
On subdivision of the diabetics, differences in the response to hypoglycaemia 
of certain of the hormones became apparent, despite a similar degree of fasting 
hyperglycaemia and similar rates and extents of decline in serum glucose levels 
in the two groups of diabetics. Insulin hypoglycaemia induced significant 
increases in plasma IRG, and serum PP but not serum gastrin or plasma GIP 
concentrations in the diabetics without AN. In all cases the responses were 
not different from those in the controls. In the diabetics with AN only serum 
PP levels rose notably in response to hypoglycaemia. However, significantly 
impaired serum PP and plasma IRG responses were evident in the diabetics with AN. 
Thus insulin hypoglycaemia was not a stimulus for GIP release in any group. 
Abnormalities in PP secretion alone were detected in the diabetics as a whole. 
However the diabetics with AN had abnormal serum PP and plasma IRG responses to 
hypoglycaemia. The latter findings could not be accounted for by differences in 
fasting hyperglycaemia or glucose responses to hypoglycaemia in the diabetics 
with and without AN. 
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(Fig.V.11) The effect of prior induction of fasting normoglycaemia by an 
overnight insulin infusion on serum glucose responses to 
insulin hypoglycaemia in 5 diabetics without AN (left) and 5 
diabetics with AN (right). Serum glucose responses to insulin 
hypoglycaemia after prior induction of fasting normoglycaemia 
in the abovementioned diabetics (top). 
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INSULIN HYPOGLYCAEMIA AFTER INDUCTION OF FASTING NORMOGLYCAEMIA 
IN DIABETICS WITH AND WITHOUT AN 
GLUCOSE (Fig. V.11) 
The overnight insulin infusion resulted in a marked reduction in 
the mean basal serum glucose levels as well as a more rapid fall and a greater 
degree of hypoglycaemia in response to the insulin injection in both groups of 
diabetics. On this occasion the mean basal serum glucose level was 4.8 ! 0.4 
mmol/1 falling to 1.6 ! 0.3 mmol/1 at 40 min in the diabetics without AN. In 
the diabetics with AN the mean basal serum glucose concentration was 5.4 ! 0.3 
mmol/1 falling to 2 ! 0.3 mmol/1 also at 40 min. The mean basal serum glucose 
levels and the glucose responses on this occasion were not different in the 
two groups of diabetics and further approximate::ithe corresponding levels in 
the healthy controls. 
Comment: 
The overnight insulin infusion induced fasting normoglycaemia and a more rapid 
and greater hypoglycaemia response to the insulin injection in the diabetics 
with and without AN. The alterations induced were comparable in the two groups 
of diabetics and their responses now corresponded with that of the healthy 
controls. 
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(Fig. V~l 2) The effect of prior induction of fasting normyglycaemia by an 
overnight insulin infusion on plasma IRG responses to hypo-glycaemia in 5 diabetics without AN (left) and 5 diabetics 
with AN (right). Asterisks indicate p < 0.01 rise above the 
mean basal concentrations. Triangle indicates p ~0.01 difference between the two tests. Plasma IRG responses to insulin hypoglycaemia after prior induction of fasting normo-glycaemia in the abovementioned diabetics. Asterisks indicates p ~0.01 difference between the two groups. Triangles indicate p < 0.01 rise above the mean ba~al concentrations. 
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2 B (ii) GLUCAGON (Fig. V.12) 
The overnight insulin infusion which ensured fasting normoglycaemia, 
induced a marked improvement in the plasma IRG response to insulin hypoglycaemia 
in both groups of diabetics. In the diabetics without AN plasma IRG levels rose 
from 19.4: 2.3 pmol/1 to reach a mean peak concentration of 66.4 ! 18.6 pmol/1; 
significant elevation (p <: 0.01) above the basal level was noted at 40, 60 and 
90 min. In contrast, in the initial test in the diabetics without AN, plasma 
+ + IRG levels rose from 19.1 - 1.7 pmol/1 to a peak of 44.3 - 4.1 pmol/1 but 
significant elevation (p <. 0.01) above basal occurred later at 60 and 90 min. 
In the diabetics with AN in the second insulin test, plasma IRG levels rose from 
the mean basal concentration of 48.6 ~ 6.3 pmol/1 to reach a mean peak 
concentrat i on of 92.4 ~ 16.6 pmol/1, with significant elevation (p,< 0.01) above 
basal being noted at 40, 60 and 90 min. In the initial insulin test in contrast, 
there was no significant elevation in plasma IRG levels above the mean basal 
concentration of 45.4 ~ 5.9 pmol/1, the mean peak concentration being 60.2 ~ 3.0 
· pmol/1 (p~ 0.05). Thus there was no longer an impaired rise in plasma IRG 
levels in response to hypoglycaemia in the diabetics with AN. 
Comment: 
Thus the overnight insulin infusion, while not altering the basal plasma IRG 
levels, resulted in a marked improvement in the plasma IRG responses to 
insulin hypoglycaemia in both groups of diabetics. Furthermore in the 
diabetics with AN the rise in IRG levels in response to insulin hypoglycaemia ) 
was no longer impaired. 
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by an overnight insulin infusion on serum PP responses to 
insulin hypoglycaemia in 5 diabetics without AN (left) and 5 
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between the two tests and triangles p ..( 0.01 rise above the mean 
basal concentrations.Serum PP responses to insulin hypoglycaemia 
after induction of fasting normoglycaemia in the abovementioned 
diabetics. Asterisks indicate p <0.01 difference between the 
two groups and triangles p<" 0.01 rise above the mean basal 
concentrations (top). 
2 B (iii) PANCREATIC POLYPEPTIDE (Fig. V.13) 
The overnight insulin infusion altered the serum PP response to 
insulin hypoglycaemia in the diabetics with AN but not those without AN. In 
the diabetics without AN serum PP levels rose from 39.7: 12.6 pmol/1 to the 
mean peak concentration of 800: 154.2 pmol/1 in the initial test and in the 
second from 33.4 ± 7 to 756.7 ± 109.6 pmol/1. The only difference was the 
more rapid rise in the second test when significant elevation above the basal 
level was noted from 20 min and PP levels stated falling from 40 in place of 
60 min. 
In contrast there was a significant increase in the mean basal 
serum PP level as well as in the PP response to hypoglycaemia in the diabetics 
with AN during the test after the overnight insulin infusion. The mean basal 
serum PP levels were 49.5 ± 12.7 and 81 .7: 19.6 pmol/1 in the first and 
second tests respectively. Significantly higher serum PP levels were noted 
from 40 to 90 min in the second test compared to the first. In addition there 
was a more rapid response and the mean peak level rose from 167.6 ± 46.3 to 
275.7: 67.3 pmol/1 (p4'. 0.01). However the diabetics with AN still had a 
significantly impaired serum PP response relative to those without AN (p<. 0.01). 
Comment: 
Although the basal serum PP levels as well as the PP response to hypoglycaemia 
were significantly greater in the diabetics with AN, when the hypoglycaemia 
was preceded by the overnight insulin infusion, they still had significantly 
impaired PP responses to hypoglycaemia relative to the diabetics without AN 
(threefold vs twentytwofold rise). In both groups of diabetics there was a 
more rapid rise in serum PP levels when insulin hypoglycaemia was preceded by 
the overnight insulin infusion. 
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2 B (iv) GASTRIN (Fig. V.14) 
After the overnight insulin infusion there was a more prominent 
gastrin response to insulin hypoglycaemia in both groups of diabetics. In 
the diabetics without AN serum gastrin levels rose significantly from the 
+ + mean basal level of 31 .8 - 5.1 pmol/1 to a mean peak concentration of 47.6 
11.7 pmol/1 (p <0.01). In the initial insulin hypoglycaemia test, there 
was no significant elevation above the basal serum gastrin level in the 
diabetics without AN. Although the diabetics with AN had a slightly lesser 
gastrin response in the second compared to the initial test, the rise in 
serum gastrin levels was significant, contrasting with the insignificant rise 
in the first test. In the diabetics with AN the mean basal serum gastrin level 
was 30.5: 1.7 pmol/1 and rose significantly (p 4(.0.01) to the mean peak 
level of (44.9: 2.5 pmol/1). The rise in serum gastrin leves on this 
occasion was similar in the two groups of diabetics. 
Comment: 
When the overnight insulin infusion, with its resultant normalization of 
fasting blood glucose levels, preceded the insulin hypoglycaemia test, 
serum gastrin levels rose significantly in both groups of diabetics. 
This finding contrasted with the insignificant responses when basal 
hyperglycaemia had been present. 
86 
86a 
275 
E 
-CJ' 
• 0.. 
' 
125 O 20 40 60 90 
,:_.. • - # 
TIME (min) 
··-o•o. -- ... I ·~-"' 
(Fig. V.15) Plasma SRIF-LI responses to insulin hypoglycaemia 
in 10 healthy subjects and 10 diabetics. 1he 
insulin hypoglycaemia was preceded by the induc-
tion of fasting normoglycaemia in the diabetics. 
Asterisks indicate p <. 0.05 rise above the mean 
basal concentrations. 
_J 
I 
LL · 
-0:-lf)E 
~-;; 
u, a. 
ro 
-0.. 
1·- -- ... 
I 
J· 
,t- _ .... 
~ ;~-- .,.._ . · ·-. 
350 
250 
200 
150 . ,· /I' DIABETICS 
I. 
;11/" ', / with AN -1 
--~_-y,,,, - . ', _]---
. - I 
10° o~----::t20:::-----4:-1::o--"""'5"""0------'90 
Time (min) 
(Fig. V.16) 
Plasma SRIF-LI responses to insulin hypoglycaemia 
preceded by the induction of fasting normogly-
caemia in 5 diabetics with AN and 5 diabetics 
without AN. 
2 B (v) SOMATOSTATIN 
In view of the fact that plasma SRIF-LI concentrations were not 
estimated in the initial insulin hypoglycaemia test, a comparison of plasma 
SRIF-LI response to the two insulin hypoglycaemia tests could not be carried 
out. Therefore the plasma SRIF-LI responses to the second test will be given 
in the diabetics and controls as well as in the diabetics with and without AN. 
Diabetics vs Controls (Fig. V.15) 
Insulin hypoglycaemia induced a significant rise in plasma 
SRIF-LI concentrations in the controls but not in the diabetics. In the 
+ controls plasma SRIF-LI levels rose rapidly from the mean basal level of 174 
23.5 pg/ml to reach significance at 20 min, remaining thus until 60 min 
(p ~ 0.05), but by 90 min basal le/els had almost been regained. In the 
diabetics there was no notable rise in plasma SRIF-LI concentrations above the 
+ mean basal level of 158 - 21 .4 pg/ml-
Diabetics without AN vs Diabetics with AN (Fig. V.16) 
Neither the diabetics without AN nor those with AN had a 
significant rise in plasma SRIF-LI levels in response to insulin hypoglycaemia. 
In the diabetics without AN the mean basal plasma SRIF-LI levels was 170 ~ 35.6 
pg/ml and there was only a minor rise in plasma SRIF-LI levels thereafter. 
+ In the diabetics with AN the mean basal plasma SRIF-LI concentration was 146 
26.7 pg/ml and once again no notable rise was observed in response to hypo-
glycaemia. However the plasma SRIF-LI response in the diabetics without AN 
tended to be similar to that of the controls whilst the diabetics with AN 
tended to have a flatter response. 
Comment: 
In the controls, but not in either group of diabetics, a significant increase 
fn plasma SRIF-LI levels was observed in response to insulin-induced hypo-
glycaemia. However the diabetics with AN tended to have a slightly flatter 
plasma SRIF-LI response. 
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Table V. 11 
Diabetics 
without AN 
Diabetics 
with AN 
(healthy 
subjects 
Summary of the data on the responses of the four 
gastrointestinal hormones to insulin hypoglycaemia 
preceded by an overnight insulin infusion in the 
diabetics with and without AN, relative to their 
responses and those of the healthy subjects in the 
initial insulin test. 
IRG pp GASTRIN SRIF-LI 
I/N N I/N 
I/N I/N 
1' significant response 
I significantly improved response 
N normal response 
.J, impaired response 
7 no significant response 
) 
SUMMARY (Table V. 11) 
The overnight insulin infusion resulted in the establishment of fasting 
normoglycaemia and a more rapid and greater degree of hypoglycaemia in 
response to the insulin bolus in both groups of diabetics, compared to 
the first test. 
In the diabetics without AN the plasma IRG and serum gastrin, but not serum 
responses to insulin hypoglycaemia, were significantly increased when hypo-
glycaemia was preceded by the overnight insulin infusion. Furthermore on 
this occasion no notable differences were apparent in the responses of any 
of the hormones in the diabetics without AN compared to the controls. 
In the diabetics with AN the overnight insulin infusion resulted in significant 
plasma IRG and serum gastrin responses to hypoglycaemia compared with their 
insignificant responses in the initial test. Furthermore normalization of the 
previously impaired plasma IRG response ensued. However serum PP responses 
remained significantly impaired relative to the diabetics without AN and the 
controls. 
Plasma SRIF-LI concentrations were not estimated in the initial insulin hypo-
glycaemia test thus preventing an evaluation of the effect of the prior over-
night insulin infusion or its responses to hypoglycaemia. Thus only the 
plasma SRIF-LI responses to the test after prior overnight insulin infusion 
can be commented on. 
Although insulin hypoglycaemia induced a significant rise in plasma SRIF-LI 
levels in the controls, this was not the case in the diabetics as a whole or 
in those with and without AN. Thus insulin hypoglycaemia preceded by an 
overnight insulin infusion was associated with correction of the impaired 
plasma IRG response to hypoglycaemia in the diabetics with AN. However, 
their impaired serum PP response remained uncorrected. 
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2·.C ( i) 
INGESTION OF A MIXED MEAL 
GLUCOSE AND INSULIN 
Diabetics vs Controls 
The mean basal serum glucose concentration was significantly higher 
in the diabetics (9.l ~ 0.9 mmol/1) than in the controls (5.1 : 0.1 mmol/1) 
(p <. 0.01). Furthermore (Fig. V.17) the diabetics had a significantly greater 
rise in serum glucose levels after the meal than in the controls. The peak 
serum glucose concentration was 5.9: 0.2 mmol/1 in the healthy subjects 
compared with 12.5 ± 1.1 mmol/1 in the diabetics (p<.0.01). 
The mean basal serum insulin levels were similar in the diabetics 
and the controls. In the controls serum insulin levels rose from a mean basal 
level of 12.8 :!: l.6JJU/ml to a peak of 49.6 ± 6.9JIU/ml. In the diabetics, 
serum insulin levels rose from a mean basal concentration of 14.3 ! 1.9 JJU/ml 
to apeak of 38.2 :!: 6.4JJU/ml. The diabetics had significantly lower serum 
insulin levels at 15 and 30 min after completion of the meal relative to the 
controls (p<.0.05). (Fig. V.18) 
Diabetics without AN vs Diabetics with AN 
The mean basal serum glucose concentrations were not significantly 
different in the diabetics with AN (10.l :!: 1.7 mmol/1) and in those without AN 
(8 ± 0.7 mmol/1). There was also a similar degree of fasting hyperglycaemia 
in the two groups of diabetics relative to the controls. · In addition the rise 
in serum glucose concentrations after the meal was significantly greater in 
both groups of diabetics than in the controls. However, the diabetics with AN 
had a lesser rise in serum glucose levels than the diabetics without AN. The 
maximum incremental rise in serum glucose levels was 1.5: 0.1 mmol/1 in the 
diabetics with AN, significantly lower than that of 5.3 ± 0.4 mmol/1 in the 
diabetics without AN (p <0.01). (Fig. V.19) 
The mean basal serum insulin levels were similar in the two groups 
of diabetics and were not different from the controls. In the diabetics with-
out AN serum, insulin levels rose from 12.7 :!: l .3JJU/ml to a peak of 43.3 :!: 
10.8J1U/ml at 90 min, decreasing gradually thereafter(Fig. V.20). Compared 
to the normal subjects the diabetics without AN had significantly lower serum 
insulin concentrations at 15 and 30 min (p< 0.01). In the diabetics with AN 
serum insulin levels rose from 15.8: 3.7JJU/ml to a peak of 39 ± 7.6JJU/ml 
at 180 min; their response was similar to that in the diabetics without AN and 
was not different from the insulin response in the controls. 
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in 5 diabetics with and 5 diabetics without AN. 
Comment: 
The diabetics had fasting hyperglycaemia and a greater hyperglycaemic response 
to the meal than the controls. The diabetics and controls had similar basal 
serum insulin levels, but the diabetics had an impaired insulin response to 
the meal. The diabetics with AN had a slightly greater degree of fasting hyper-
glycaemia than those without AN,but the former had a significantly lesser serum 
glucose response to the meal. The serum insulin responses were similar in those 
with and without AN,but the latternad an impaired early response compared to 
the controls. 
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2 C (ii) GLUCAGON 
Diabetics vs Controls (Fig. V.21) 
The mean basal plasma IRG concentration was 36.2: 6.2 pmol/1 in 
the 10 diabetics and 16.8 ± 2.9 pmol/1 in the 12 healthy subjects. The 
difference was statistically significant (pL. 0.01). In addition the 
diabetics had an exaggerated plasma IRG response to the meal. In the diabetics 
. plasma IRG levels rose significantly (p < 0.05) 5 min after completion of the 
91 
meal and remained so for 4 hr. The mean peak concentration of 58.2 ± 10.4 pmol/1 
(maximum increment 22.4 ± 6.3 pmol/1) occurred at 30 min. In the healthy 
controls plasma IRG levels rose significantly (p < 0.05) 15 min after the meal; 
the peak concentration of 24.6 ± 4.3 pmol/1 (maximum increment 9.4 ± 1.9 pmol/1) 
was noted at 3 hr but levels remained elevated for 4 hr~ 
Diabetics without AN vs Diabetics with AN (Fig V.22) 
The mean basal plasma IRG concentration was 20.4 ~ 2.8 pmol/1 in the 
diabetics without AN, similar to that in the healthy controls, but significantly 
lower than that of 52.1 ± 6.4 pmol/1 in the diabetics with AN (p~ 0.01). In 
the diabetics without AN significant elevation (p<. 0.01) in mean plasma IRG 
levels was first observed during the meal and was maintained for 4 hr. The 
peak IRG concentration of 46.2 ± 11.8 pmol/1 (maximum increment 26.8 ± 10.4 
pmol/1) was noted at 15 min. Despite starting at a significantly higher mean 
basal level, the diabetics with AN had an IRG response similar to that seen in 
the diabet·cs without AN. However, in the diabetics with AN the peak 
concentration of 79.9 ± 20.3 pmol/1 (maximum increment 28 ± 16.6 pmol/1) occurred 
later, after 4 hr. The plasma IRG response to the meal were similarly 
exaggerated in the two groups of diabetics relative to the healthy controls. 
Comment: 
The diabetics considered as a single group had a significantly greater rise in 
plasma IRG levels after the meal than the healthy subjects. The diabetics with 
and those without AN had a similarly exaggerated plasma IRG response to the 
meal despite the fasting hyperglugonaemia in the former. 
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2 C (iii) PANCREATIC POLYPEPTIDE 
Diabetics vs Controls (Fig. V.23) 
As illustrated in Fig. V.23 ingestion of the mixed meal induced a 
prominent and comparable rise in serum PP concentrations in the 12 diabetics 
and the healthy controls. Serum PP concentrations rose rapidly and significantly 
in the healthy subjects from the mean basal level of 46.5 ! 7.9 pmol/1 to 
232.2 ~ 36.4 pmol/1 during the meal, increasing further to a peak of 363.5: 
36.2 pmol/1, 15 min after completion of the meal. Thereafter serum PP levels 
fell to the level of 235.3 ~ 29.5 pmol/1 at 45 min, which was significantly 
lower than the peak concentration (p<. 0.01). Serum PP concentrations again rose 
significantly (p< 0.01) to 336.8 ! 49.4 pmol/1 at 120 min, and remained 
significantly elevated above the basal concentration for the duration of the 
study (p<' 0.01). In the 12 diabetics serum PP levels also rose rapidly and 
significantly (p,< 0.01) from the mean basal concentration of 50.6 ! 7.2 pmol/1 
to 185.3 ~ 43.l pmol/1 during the meal, increasing to reach 300.6: 35.6 pmol/1 
at 5 min. The serum PP levels fluctuated thereafter, falling gradually but at 
240 min were still s·ignificantly elevated above basal (p < 0.01). However there 
was no true biphasic PP response in the diabetics unlike in the controls, while 
the time taken to reach the mean peak concentration was not significantly 
different in the diabetics (20.8 ! 6.2 min) and the controls (11.3 ! 2.2 min). 
Diabetics without AN vs Diabetics with AN (Fig. V.24) 
In the diabetics without AN there was a prompt and significant 
increase in serum PP levels, which became manifest during the meal (p<:: 0.01), 
similar to the controls. Serum PP levels rose from 37.1 ! 8.8 pmol/1 to 363.1 
~ 32.5 pmol/1 at 5 min, thereafter remaining significantly elevated until 
240 min (p < 0.01). There was no true biphasic PP response to the meal in the 
diabetics without AN, in whom the time taken to reach the mean peak concentra-
tion was 8.3 ~ 4.4 min, similar to that in the controls. In the diabetics with 
AN there was a delayed early rise in serum PP levels compared to the controls 
and the diabetics without AN. Serum PP levels rose from the mean basal level 
of 52.6 ! 12.1 pmol/1, reaching significance 5 min after completion of the meal 
(p <.0.01). The serum PP levels increased gradually to 352 ! 74.9 pmol/1 and 
remained significantly elevated above basal until 240 min. As in the diabetics 
without AN, there was no true biphasic PP response to the meal in the diabetics 
with AN. However, the time taken to reach the mean peak concentration was 
23.4 ~ 4.1 min in the diabetics with AN, significantly delayed relative to the 
diabetics without AN (p <. 0.05) and the controls (p '- 0.01). 
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Comment: 
Ingestion of the mixed meal resulted in a comparable rapid, and marked increase 
in serum PP levels in the controls and the diabetics when considered as a 
single group. However only in the controls was the postprandial rise in serum 
PP levels biphasic. The diabetics without AN had a similar rise in serum PP 
levels to that seen in the controls. In contrast, in the diabetics with AN the 
early rise in serum PP levels was significantly delayed, but the magnitude of 
the rise was not impaired. 
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2 C (iv) GASTRIN 
Diabetics vs Controls (Fig. V.25) 
The mean basal serum gastrin concentrations were similar in the 12 
diabetics (26.1 ± 2.4 pmol/1) and in the healthy controls (23.4 ± 2.4 pmol/1). 
There was a rapid rise in serum gastrin levels in the controls, reaching 
significance (p~ 0.01) within 5 min of completion of the meal and remaining 
thus for 4 hr. In the diabetics,significant elevation above the mean basal 
serum gastrin level was first noted at 15 min and also remained elevated for 
4 hr. The magnitude of the rise in serum gastrin concentrations was similar 
in the diabetics and the controls; the peak concentration was 42.7 ± 6.5 pmol/1 
in the former and 49.8 ± 5.3 pmol/1 in the latter group. · 
Diabetics without AN vs Diabetics with AN (Fig. V.26) 
No prominent differences in the serum gastrin levels were found 
when the diabetics were divided into those with and without AN. The mean basal 
serum gastrin concentration was 26.l : 4.8 pmol/1 in the diabetics without AN 
and 26 ± 1.3 pmol/1 in the diabetics with AN, similar to each other as well as 
to the healthy controls. Furthermore the rise in serum gastrin levels after 
the meal was similar in both groups of diabetics as well as in the controls. 
In the diabetics without AN serum gastrin concentrations rose within 5 min of 
completion of the meal, thereafter pla~aued and by 4 hr fasting levels had 
almost been regained. In these subjects though, because of the large standard 
errors, significant elevation (p "-0.01) above basal levels was noted only at 
5, 120 and 180 min. The peak serum gastrin concentration of 41 .4: 8.6 pmol/1 
was observed at 15 min. There was a slightly delayed rise in serum gastrin 
levels in the diabetics with AN, but a significant rise (p ~ 0.01) was observed 
15 min after completion of the meal. Thereafter serum gastrin levels gradually 
increased to reach a peak of 48.6: 14.4 pmol/1 at 3 hr. 
Comment: 
The magnitude of the rise in serum gastrin levels after the mixed meal was 
similar in the diabetics and controls. The diabetics with AN and without AN 
had similar serum gastrin responses to the meal, which ~re not significantly 
different from that of the controls. 
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Plasma GIP responses to ingestion of a mixed meal in 
6 diabetics with and 6 diabetics without AN. Asterisks 
indicate p <::.0.05 difference between the two groups. 
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2 C (v) GASTRIC INHIBITORY POLYPEPTIDE 
Diabetics vs Controls (Fig. V.27') 
Mean basal plasma GIP concentrations were similar in the 12 
diabetics and the healthy controls. In the healthy subjects the mean basal 
, 
plasma GIP concentration was 59.4 ! 5 pmol/1; after ingestion of the meal 
plasma GIP levels rose significantly and rapidly, a rise was exhibited at 
5 min and was sustained for 4 hrs (pL. 0.01). The peak plasma GIP concentration 
of 229.6 ! 19.9 pmol/1 occurred after 2 hrs in the controls. There was also a 
rapid rise in plasma GIP levels after the meal in the diabetics; by 5 min plasma 
GIP levels were significantly elevated above the mean basal concentration of 
64.7 ! 8.4 pmol/1 and the rise was maintained for 4 hrs (p L.... 0.01). However the 
magnitude of the plasma GIP response was lower in the diabetics, significantly 
so for the last 2! hrs of sampling (p<. 0.05). The peak GIP concentration was 
158.2 ! 20.9 pmol/1 in the diabetics. 
Diabetics without AN vs Diabetics with AN (Fig. V.28) 
Differences in the plasma GIP response to the mixed meal were also 
noted when the diabetics were separated into those with and without AN. However 
the mean basal plasma GIP concentrations were similar in the two groups of 
diabetics as well as in the controls. In the diabetics without AN there was a 
rapid rise in plasma GIP levels from the mean basal concentration of 73.1 ~ 
13.2 pmol/1, to reach significance at 5 min, remaining significantly elevated 
until 2 hr (p <:, 0.01). The peak level of 229: 37.7 pmol/1 occurred at 1 hr. 
The plasma GIP response to the meal was similar in the diabetics without AN and 
the controls. However, in the diabetics with AN there was an initially delayed 
and significantly impaired (p ~ 0.05) plasma GIP response after completion of 
the meal, compared to the healthy controls and the diabetics without AN. In 
the diabetics with AN, plasma GIP levels rose from the basal level of 56.2 + 
10.3 pmol/1 to the peak concentration of 119.6: 30.5 pmol/1 at 90 min which 
was significantly impaired (p <.0.05) relative to the peak concentrations noted 
in the diabetics without AN and the healthy subjects. 
Comment: 
95 
Plasma GIP levels rose significantly after ingestion of the meal in the diabetics 
and the healthy subjects but the rise in the diabetics was impaired. The latter 
diabetics without AN had a similar postprandial GIP response to the controls. 
The diabetics with AN however, had an initially delayed and impaired GIP response 
relative to the diabetics without AN and the controls. 
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2 C (vi) SOMATOSTATIN 
Diabetics vs Controls (Fig. V.29) 
The mean basal plasma SRIF-LI concentrations were similar in the 
healthy controls (191 ± 21.7 pg/ml) and in the 10 diabetics (185 ~ 27.7 pg/ml). 
The plasma SRIF-LI levels fell significantly during the meal and rose gradually 
after completion of the meal in the controls, reaching significant elevation 
above basal initially at 5 min and then again at 45 min, then again remaining 
elevated for 4 hrs (p<. 0.05). The peak concentration of 318 ~ 53.6 pg/ml 
(maximum increment 126.3: 36.9 pg/ml) occurred at 120 min. In the cfu.betics, 
plasma SRIF-LI levels rose more rapidly after the meal reaching significance at 
5 min, fluctuating thereafter. The peak concentration of 276 ! 53 pg/ml 
(maximum increment 90 ~ 34.5 pg/ml) was noted at 90 min and was significantly 
elevated above basal. At all times after 5 min plasma SRIF-LI levels were 
lower in the diabetics than the controls. 
Diabetics without AN vs Diabetics with AN (Fig. V.30) 
No prominent differences in the postprandial SRIF-LI concentrations 
became apparent when the diabetics were subdivided. The mean basal plasma 
96 
SRIF-LI concentrations were similar in the diabetics without AN (180 ! 49.8 pg/ml) 
and the diabetics with AN (191 ! 31 .6 pg/ml), and were not different from the 
value in the controls. In the diabetics without AN there was a small early rise 
and a larger late rise in plasma SRIF-LI levels, however significant elevation 
above the basal concentration was only noted at 120 and 180 min (p~.0.01). The 
peak concentration of 308 ! 90.4 pg/ml (maximum increment 128 ! 56.5 pg/ml~ 
occurred at 90 min in the diabetics without AN. There were no 
significant differences in plasma SRIF-LI levels after the meal between the two 
groups of diabetics, or in either group compared to the controls. However there 
was no notable rise in plasma SRIF-LI levels after the meal in the diabetics 
with AN. In these patients the peak concentration of 243 ~ 63 pg/ml which 
constituted a maximum incremental rise of 52: 38.2 pg/ml also occurred at 
90 min. 
Comment: 
Ingestion of the mixed meal induced a significant increase in plasma SRIF-LI 
levels in the controls and the diabetics. Only in the diabetics without AN was 
the rise in plasma SRIF-LI levels significantly different from basal. 
Nevertheless no significant differences were apparent in the magnitude of the 
rise in plasma SRIF-LI concentrations between the two groups of diabetics. 
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Table V. 12 
Healthy 
subjects 
Diabetics 
Diabetics 
without AN 
Diabetics 
with AN 
Sununary of the Responses of the five gastrointestinal 
hormones to ingestion of the mixed test meal in the 
healthy subjects, the diabetics as a single group, 
the diabetics without AN and the diabetics with AN. 
IRG pp GASTRIN GIP 
N N 
N N N 
D N 
~ significant response 
++ exaggerated response 
N normal response 
d) impaired response 
D delayed response 
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SUMMARY (Table V.12) 
· The diabetics as a group had fasting hyperglycaemia and greater hyperglycaemic 
responses after ingestion of the mixed meal than the controls. The plasma IRG 
concentrations followed a similar pattern. In the diabetics there was fasting 
hyperglucagonaemia and an exaggerated rise in plasma levels after the meal 
compared to the controls. In contrast the serum gastrin and plasma SRIF-LI 
levels before and after the meal were similar in the diabetics as a group and 
the controls. However in the diabetics, the rise in plasma GIP levels after 
the meal was impaired, as was the rise in serum insulin levels, relative to the 
tontrols. 
' Several differences in the glucose and hormone responses to the mixed meal 
l 
became apparent when the diabetics were divided into those with AN and those 
without AN. The level of fasting hyperglycaemia was generally slightly higher 
in the diabetics with AN relative to the diabetics without AN. However the 
diabetics without AN had a greater rise in glucose levels after the meal than 
the diabetics with AN. The .two groups of diabetics had similarly exaggerated 
plasma IRG responses compared to the controls. The serum gastrin and plasma 
.. SRIF-LI responses to the meal were similar in both groups of diabetics and were 
. '
not different from the controls. The rise in serum insulin levels was also 
similar in the two groups of diabetics, but there was an early impaired rise in 
the diabetics without AN compared to the controls. In contrast there was an 
initially delayed and a significantly impaired increase in plasma GIP levels 
after the meal in the diabetics with AN relative to the diabetics without AN 
and the controls, in whom the GIP response was similar. In addition there was 
a significantly delayed early rise in serum PP levels after the meal in the 
diabetics with AN compared to the controls and those without AN. 
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SECTION 3 FIBRE SUPPLEMENTATION 
3 (i) GLUCOSE (Fig. V.31) 
Controls 
In the healthy subjects, the mean basal serum glucose concentration 
was 5 :!:' 0.1 mmol/1 before the fibre supplemerted meal and 5.1 :!: 0.1 mmol/1 before 
the test meal. When fibre was added to the meal there was a smaller rise in 
serum glucose levels and a prolonged depression below the basal level for over 
2 hrs. The mean area under the serum glucose curve was 24 ± 21.5 mmol/1 240 
min after the fibre supplemented meal, significantly lower than that of 135.7 + 
54.6 mmol/1 240 min observed after the test meal (111.7% change p ~0.05). 
Diabetics without AN 
Fibre supplementation also had a profound effect on the rise in 
postprandial glucose concentrations in the diabetics without AN. In these 
patients, the mean basal serum glucose concentration was 8.2 ± 0.6 mmol/1 
before the test meal and 9.2 ± 2.2 mmol/1 before the fibre-supplemented meal. 
The difference was not statistically significant. With the addition of fibre 
to the meal, there was a marked diminution in the serum glucose concentrations 
throughout the 4 hr of sampling. In addition there was a 61% reduction 
(p~ 0.01) in the mean area under the glucose curve after the fibre 
supplemented meal (372.9 ± 97.l mmol/1 240 min) compared to the test meal 
(972.l ± 124.4 mmol/1 240 min). 
Diabetics with AN 
In the diabetics with AN, fibre supplementation had little effect 
on the rise in serum glucose levels after ingestion of the meal. The mean 
basal serum glucose concentrations in these patients were similar before the 
fibre-supplemented meal (12.1 ~ 2.0 mmol/1) and before the test meal (11.5 ± 
1.2 mmol/1). There were no significant differences in the rise in the serum 
glucose levels after the fibre supplemented meal compared to the test meal. 
The mean area under the glucose curve was 673 ± 119.4 mmol/1 240 min after the 
test meal and 573 :!: 193.6 mmol/1 240 min after the meal with fibre, only a 
15% fall (p > 0.05). 
Comment: 
Fibre supplementation of the meal was associated with a significant reduction 
in the serum glucose concentrations in the diabetics without AN and the 
controls, but no notable alteration was observed with fibre supplementation in 
the diabetics with AN. 
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3 (ii) INSULIN (Fig. V.32) 
In the healthy subjects the mean basal serum insulin concentrations 
were similar before the test meal with added fibre (14.8 ~ 1 .3JJU/ml) and 
before the test meal alone (13.7 ~ 1 .7 JJU/ml). The serum insulin response was 
marginally lower after the fibre supplemented meal, compared to the test meal, 
but no significant differences were noted at any of the sampling times. The 
mean area under the insulin curve was 4662.8 ! 431.7 JJU/ml 240 min after the 
test meal and 4389.5 ± 749.5.J.JU/ml 240 min after the meal with added fibre, a 
6% change which was not statistically significant. 
Diabetics without AN 
99 
In the diabetics without AN too, the mean basal serum insulin 
concentrations were similar before the fibre-supplemented meal (13.7 ~ 1.7 JJU/ml) 
and before the test meal (12.7 ± 1.3JJU/ml}. The addition of fibre to the meal 
did not alter the early insulin response but lowered, albeit insignificantly, 
the mean serum insulin levels after 30 min. Fibre supplementation reduced the 
mean area under the insulin curve by 26.2% (3622 ± 1003.2j1U/ml 240 min vs 
4908 ± 1299. 5 JIU/ml 240 min) ( p > 0. 05). 
Diabetics with AN 
The mean basal serum insulin concentrations in the diabetics with 
AN were also similar before the fibre supplemented · (l8 ± 3.3_JJU/ml) and the 
test meal (15.8 ! 3.7 JJU/ml). The addition of fibre to the meal did not alter 
the serum insulin response in these patients. The mean area under the insulin 
curve was 4344 ~ 1002.8)-JU/ml 240 min after the test meal and 3954 ! 1183.2 
JJU/ml .240 min after the meal with added fibre, a 9% diminution (p> 0.05). 
Comment: 
Addition of fibre to the test meal had a minimal effect on the postprandial 
insulin concentration~ in the controls and the diabetics wtth AN. In spite 
of a 26% reduction in the mean area under the serum insulin curve in the 
fibre supplemented meal in the diabetics without AN, the reduction was not 
significant. 
3 (iii) GLUCAGON (Fig. V.3] 
Fibre supplementation had different effects on the plasma IRG 
responses to the mixed meal in the normal subjects and the diabetics. 
Controls 
The mean basal plasma IRG concentration in the healthy subjects was 
similar before the fibre supplemented meal (19.4 ± 2.8 pmol/1) and the test 
meal (16.8 ± 2.9 pmol/1). With the addition of fibre to the meal, there was a 
smaller rise in plasma IRG levels throughout the sampling time, although the 
differences were significant only at 180 and 240 min. The mean area under the 
IRG curve was 1917: 442.7 pmol/1 240 min after the test meal and 767 ± 420.ll 
pmol/1 240 min after the addition of the fibre to the meal, a 60% and 
significant diminution (p < 0.05). 
Diabetics without AN 
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In the diabetics without AN, the addition of fibre did not 
effectively alter the plasma IRG response to the meal. In these patients the 
mean basal plasma IRG concentration was 18.4 ± 2.5 pmol/1 before the fibre 
supplemented meal and 21 .l ~ 2.4 pmol/1 before the test meal. The difference 
was not significant. Although the initial rise in plasma IRG levels was lower 
after the fibre supplemented meal, the differences were not significant and 
indeed the levels for the last 3 hrs of the test were similar on both occasions. 
The mean area under the IRG curve was 3340: 1072.7 pmol/1 240 min after the 
test meal and 2349.l : 381.8 pmol/1 240 min after the meal with added fibre, 
and constituted a 30% reduction. However the reduction was not statistically 
significant. 
Diabetics with AN 
In the diabetics with AN, the mean basal plasma IRG concentrations 
were similar before the fibre supplemented (57.l ~ 10.l pmol/1) and the test 
meals (48.5 ± 6.2 pmol/1). With the addition of fibre to the meal, the rise in 
plasma IRG levels was lower throughout almost the entire sampling time. However, 
at no point were the differences in mean plasma IRG levels after the test and 
fibre supplemented meals significantly different. Addition of fibre to the meal 
reduced the mean area under the plasma IRG curve from 5744.3 ± 1728.8 to 1557.7 
- 1566.7 pmol/1 240 min i.e. a change of 72.9%, which was not statistically 
different. 
Comment: 
Fibre supplementation of the meal induced a significant reduction in the rise in 
plasma IRG levels in the controls but not in the diabetics without AN. 
Although plasma IRG levels were lower after the fibre supplemented meal in the 
diabetics with AN, the reduction was not statistically significant. 
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3 (iv) GASTRIC INHIBITORY POLYPEPTIDE (Fig. V.34) 
Controls 
The mean basal plasma GIP concentrations in the normal subjects 
were similar before the fibre supplemented meal (68.3 ~ 5.9 pmol/1) and the 
test meal (59.4 ~ 5 pmol/1). There was a lower early and late rise in plasma 
GIP levels after completion of the fibre supplemented meal. Although there 
was a .22% reduction in the mean area under the GIP curve, with the addition 
of fibre to the meal, the reduction was not significant (33945 ! 2633.4 vs 
26397.4 t 3754.7 pmol/1 240 min). 
Diabetics without AN 
In the diabetics without AN too, ,the plasma GIP concentrations were 
similar before the meal with added fibre (74.3 ! 12.5 pmol/1) and the test 
meal (73.1 ! 13.2 pmol/1). In these patients although the initial rise in 
plasma GIP levels was similar after ingestion of the test meal with and 
without added iibre, from 15 to 60 min the GIP levels were lower after the 
fibre supplemented meal. According to the mean area under the GIP curve, the 
addition of fibre to the meal reduced the GIP response by 10.5% (23208.2 + 
4792.2 vs 20782.9 ± 3224.8 pmol/1 240 miaj (p> 0.05). 
Diabetics with AN 
The mean basal plasma GIP concentration was 62.9 ~ 3.5 pmol/1 before 
the meal with added fibre and 56.2 ~ 10.3 pmol/1 before the test meal in the 
diabetics with AN. In these patients the plasma GIP response was similar after 
ingestion of the two meals although marginally higher after the meal with 
added fibre. Indee~ the mean ~rea under the GIP curve was 14245.3 ~ 5522.9 
pmol/1 240 min after the fibre supplemented meal and 11806.9 ~ 3364.5 pmol/1 
240 min after the test meal, a 20.7% rise (p.> 0.05). 
Comment: 
Fibre supplementation led to a reduction in the plasma GIP concentration after 
the test meal in the controls and diabetics without AN, but in neither group 
was the reduction in the mean area under the GIP curve significant. In the 
diabetics with AN there was a small increase in GIP levels after the fibre 
supplemented meal. 
102 
102a 
Table V. 13 
Summary of the data on the effect of fibre 
supplementation on glucose and hormone 
responses to ingestion of a mixed meal in 
12 healthy subjects, 6 diabetics without AN 
and 6 "diabetics with AN. 
Glucose Insulin IRG GIP 
Healthy controls 
Diabetics 
without AN 
Diabetics 
with AN 
-7 
significantly reduced 
no significant change 
impaired response 
SUMMARY (Table V.13) 
In the healthy subjects fibre supplementation of the meal induced a significant 
reduction in the serum glucose and plasma IRG responses to meal ingestion. 
However, there were only minor associated reductions in the serum insulin and 
plasma GIP responses. 
In the diabetics without AN the serum glucose response to the mixed meal was 
significantly reduced. No significant alterations in the plasma IRG, serum 
insulin or plasma GIP responses were found in diabetics without AN. 
In sharp contrast to the controls and the diabetics without AN, addition of 
fibre to the meal in the diabetics with AN did not alter the serum glucose 
response to food ingestion. Furthermore, fibre supplementation induced only 
minor insignificant changes in the serum insulin, plasma GIP and plasma IRG 
concentrations after the meal. · 
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SUMMARY OF CHAPTER V: 
The first section deals with basal hormone secretion. The only abnormality 
detectable in the diabetics as a whole was a significantly elevated basal 
plasma IRG concentration compared to the controls. After division of the 
diabetics significant fasting hyperglucagonaemia was also the other abnormality 
detected in the diabetics with AN. Neither the overnight insulin infusion nor 
the overnight gastric aspiration significantly altered the mean basal concen-
trations of any of the hormones in either group of diabetics. 
The second section deals with the effects of insulin hypoglycaemia on hormone 
release. Insulin hypoglycaemia was not a stimulus for GIP secretion. The 
diabetics as a group had a normal plasma IRG, an impaired serum PP and a non 
significant serum gastrin response to hypoglycaemia. When the diabetics were 
subdivided, no abnormalities were detected in hormone secretion in response to 
hypoglycaemia in the diabetics without AN. In contrast impaired plasma IRG and 
serum PP responses were observed in the diabetics with AN despite similar basal 
glucose levels and similar serum glucose responses in the diabetics with and 
~ithout AN. 
In the third section results are given of the effect of prior establishment of 
fasting normoglycaemia on hormone secretion during insulin hypoglycaemia. This 
manoeuvre ensured correction of the plasma IRG but not the serum PP response to 
hypoglycaemia in the diabetics with AN. In addition there was improvement in 
the serum gastrin and plasma IRG responses in the diabetics without AN and the 
former also improved in the diabetics with AN. Further, both groups of 
diabetic~ as well as the diabetics as a whole had an insignificant rise in 
plasma SRIF-LI levels in response to hypoglycaemia, in comparison with the 
significant rise in the controls. 
In the fourth section results of the glucose and hormone response to ingestion 
of a mixed meal are given. In the diabetics considered as a single group, 
exaggerated piasma IRG responses, normal serum PP, serum gastrin and plasma 
SRIF-LI responses occurred, while impaired plasma GIP responses were observed. 
The diabetics with AN had impaired plasma GIP, delayed serum PP and smaller 
serum glucose responses to food ingestion relative to the diabetics without AN. 
In the final sectio~ the results of the study on fibre supplementation of the 
mixed meal are given. Fibre was found to have no effect on the postprandial 
rise in serum glucose concentrations in the diabetics with AN, in sharp 
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contrast to the diabetics without AN and the controls, where a prominent 
reduction wa~ apparent. In addition serum insulin and plasma GIP response 
to the meal were unchanged by fibre in either of the three groups, but fibre 
significantly reduced the plasma IRG response in the healthy controls. 
Thus it is apparent that abnormalities in basal and stimulated hormone 
secretion occur in diabetics per se and particularly in diabetics with AN. 
In addition it is apparent that fibre benefits glucose tolerance only in the 
absence of AN. 
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CHAPTER VI 
DISCUSSION 
In this chapter we will discuss our findings on the effect of AN on basal and 
stimulated hormone release in NIDDM; the possibility of the existence of a 
hormonal marker for AN, and whether fibre supplementation of a meal would have 
a similar effect on glucose tolerance and hormone secretion in the presence or 
absence of AN. In order to avoid repetition, literature which has been 
discussed in earlier chapters will be referred to by page number and will not 
be discussed in detail unless immediately relevant. 
SECTION l : THE DIAGNOSIS OF AUTONOMIC NEUROPATHY 
The clinical features of AN are numerous and diverse and include sweating 
abnormalities, intermittent nocturnal diarrhoea, constipation, bladder problems, 
impotence and postural hypotension (pages 37-39). However, many of these 
features are non-specific. In these studies, the only symptom of autonomic 
dysfunction elicited from the diabetics was that of impotence and its non-
specificity as a feature of AN was confirmed by the finding that only 10 of the 
15 diabetics complaining of impotence, were found on testing to have AN. 
Previously the non specific nature of many of the symptoms of AN, together with 
the complex nature of the tests of autonomic nerve 
in their interpretation due to the lack of control 
diagnosis of AN being made by exclusion. However, 
decade of a new generation of simple, reproducible 
tests has greatly facilitated the diagnosis of AN. 
function and the difficulty 
data, often led to the 
the description in the last 
and generally non-invasive 
In addition it has become 
apparent that abnormal responses to autonomic function tests may occur in the 
absence of symptoms of AN (Murray, Ewing, Campbell, Neilson and Clarke, 1975; 
Gunderson and Neubauer, 1977), as was observed in patient No. 2 in this study. 
Further, these newly described tests have confirmed the patchy involvement of 
AN where patients have been found to have normal responses to some tests, yet 
abnormal responses to others (Bennett, Hosking and Hampton; 1975). Intact 
sympathetic jnnervation in the presence of severe parasympathetic damage has 
been reported previously (page 43) and was observed in patient No. 5 in these 
studies. Therefore a battery of tests assessing both sympathetic and para-
sympathetic involvement should be used in any evaluation of autonomic function. 
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In these studies AN was said to exist if abnormal responses to three or more of 
the eight autonomic function tests were present. This was an arbitrary 
decision as a case could be made for the diagnosis of AN if a single abnormal 
response to autonomic function testing was detected, for some degree of 
impairment of neural function is likely to have been present in such a 
situation. Although at present there is no real means of quantifying the 
degree of AN, it might be assumed that the more abnormal responses found on 
testing, the more severe the autonomic dysfunction. Indeed, the grounds for 
the selection of three or more abnormal responses rested primarily on the 
desire to evaluate the effect of fairly severe AN on hormone secretion in the 
NIDDM. 
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SECTION 2 : BASAL HORMONE SECRETION 
2 (i) GLUCOSE AND INSULIN 
Fasting hyperglycaemia with normal basal serum insulin levels, as 
observed in the diabetics as a whole in this study, are well recognized features 
of NIDDM. However, the similarity in basal serum insulin and glucose 
concentrations in the diabetics with and without AN has not been reported 
previously in NIDDM. 
The significant increase in basal serum insulin levels after the overnight 
infusion in the two groups of diabetics, together with the fasting normo-
glycaemia achieved in both groups, suggest~ a lack of insulin resistance in 
these patients. The effect of overnight gastric aspiration on serum insulin 
and glucose concentrations has not been reported previously. However, the 
lack of effect noted in this study may indicate that either delayed gastric 
emptying was not present in those with AN or alternatively that the delay was 
not great enough to alter either basal serum glucose or insulin concentrations. 
2 (ii) GLUCAGON 
The finding of an elevated basal plasma IRG level in the NIDDM as a 
whole, relative to the healthy subjects is in agreement with reports by numerous 
workers (page 26). However, basal plasma IRG levels similar to those in 
healthy subjects have also been reported in NIDDM (page 26). 
The striking feature of this study was that the diabetics with AN had 
significantly elevated basal plasma IRG levels compared to the diabetics without 
AN and the control subjects, in whom similar levels occurred. This has not been 
reported previously. As all diabetics were male, of similar ages, had similar 
degrees of obesity, similar durations of diabetes and similar fasting glucose 
levels, these factors must be discounted as causes of the differences in basal 
plasma IRG levels compared in the two groups of diabetics. Further overnight 
gastric aspiration failed to alter the basal plasma IRG levels compared in 
either group. This latter observation would tend to exclude delayed gastric 
emptying (page 37), as a cause for the elevated basal plasma IRG levels in the 
diabetics with AN. In addition the 12 hr insulin infusion failed to reduce the 
fasting plasma IRG levels in either group of diabetics. Thus the difference in 
basal plasma IRG levels in the two groups of diabetics might best be explained 
by a loss or impairment of the neural innervation of the alpha cell in the 
diabetics with AN, there being no other differences between the two groups which 
might account for their differing basal plasma IRG levels. 
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The mechanism of the elevated basal plasma IRG levels in the diabetics with AN 
is uncertain. Recent evidence has led to the belief that the parasympathetic 
nervous system exerts little effect on basal IRG release (pages 15-16). Howeve~ 
the diabetics with AN had mixed sympathetic and parasympathetic neuropathy and 
sympathetic pathways appear to influence basal IRG release (page 16)~ Thus 
interruption of the sympathetic regulation of basal IRG release and in 
particular loss of the inhibitory alpha adrenic tone might be the underlying 
cause for the elevated basal plasma IRG levels in the diabetics with AN. 
·Although there can be little doubt that fasting hyperglucagonaemia, either 
relative (ie. elevated in relation to the prevailing glucose levels) or absolute 
{ie. significantly elevated as compared to healthy controls) may be a feature of 
NIDDM, the mechanism thereof is poorly understood. Theories which have been 
advanced include insulin deficiency, impairment of the action of endogenous 
insulin or an abnormality of intracellular carbohydrate metabolism (Day and 
Anderson, 1973), abnormal secretion of IRG and/or GLI (Pek, 1977) or abnormal 
intra-islet paracrine relationships (Unger and Orci, 1976). To these AN should 
be added, as in the present study, the marked fasting hyperglucagonaemia in the 
diabetics with AN, in the face of the relative fasting hyperglucagonaemia in 
those without AN, conferred absolute fasting hyperglucagonaemia on the whole 
group of diabetics. Thus it is possible that undiagnosed AN might have been an 
underlying pathogenetic factor of the observed fasting hyperglucagonaemia which 
has previously been reported in NIDDM. The mechanism of relative fasting 
hyperglucagonaemia as observed in the diabetics without AN remains conjectural. 
2 (iii) PANCREATIC POLYPEPTIDE 
The observation of normal basal serum PP levels in the diabetics 
considered as a single group in this study is in accord with a previous report 
in NIDDM (page 29). In addition the similarity in basal serum PP levels in the 
diabetics with and without AN is in agreement with the finding in IDDM with and 
without AN (Krarup, Schwartz, Hilsted, et al, 1979). 
The latter observations may suggest that autonomic dysfunction does not have a 
prominent effect on basal PP release. However, this conflicts with available 
evidence suggestive of an effect of neural influences on basal PP release. 
Schwartz, Strenquist, Olbe and Stadil (1979) argued that the spontaneous 
secretion of PP is regulated mainly by tonic vagal activity. Their argument 
was based on the findings that atropine and benzilonium both suppressed basal 
PP release. Further, that truncal vagotomy normalized basal serum PP concen-
trations in duodenal ulcer patients with the highest pre-operative levels 
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(Schwartz, Rehfeld, Stadil, et al, 1976). However, the lack of effect of 
vagotomy on normal pre-operative basal serum PP levels (Adrian, Bloom, Besterman, 
et al, 1976; Schwartz, Rehfeld, Stadil, et al, 1976; Taylor, Feldman, Richardson 
and Walsh, 1978) may indicate that vagal activity is not the sole regulator of 
basal PP release. Indeed adrenergic influences too alter basal PP release 
(page 19). Thus the normal basal serum PP levels in the diabetics with AN may 
have been due to combined defective sympathetic and parasympathetic innervation 
of basal PP release. Alternatively, there may have been residual neural function 
in these patients or it may be that neural influences are not of prime importance 
in regulation of basal PP release. 
In the present study a 12 hr overnight insulin infusion did not significantly 
alter the mean basal serum PP level in the 6 diabetics without AN (PP levels rose 
in 3 and fell in 3 patients). In contrast there was a rise in basal serum PP 
levels in 5 of the 6 diabetics with AN, leading to a mean concentration 
significantly above that of the healthy controls and the diabetics without AN. 
This latter observation tends to contradict numerous reports for which there is 
no apparent explanation (pages 29-30). The mean basal serum glucose levels were 
only insignificantly higher in the diabetics with AN than in those without, both 
initially and after the insulin infusion, providing no explanation of the 
increase in basal serum PP levels in the former. However, it is possible that 
the acute fluctuation in blood glucose levels produced an acute alteration in 
the glucose sensitive metabolic pathways in certain autonomic nerves, resulting 
in improved conduction of the vagus nerve and unrestrained defective alpha 
adrenergic activity, causing the observed increased basal serum PP levels. 
In the present study there was an insignificant rise in serum PP levels after 
overnight gastric aspiration in both groups of diabetics. Thus the possible 
existence of delayed gastric emptying did not have a prominent effect on basal 
serum PP concentrations in the diabetics with AN. The small rise in mean serum 
PP levels after aspiration in both groups of diabetics might have been due to 
the mere presence of the nasogastric tube in the stomach, which interacted with 
receptors in the gastric wall. 
2 (iv) GASTRIN 
There appears to be a paucity of existing knowledge concerning gastrin 
release in NIDDM and the normal basal levels observed in the diabetics as a 
whole in this study have not been reported previously. However, twice to three-
fold elevated basal serum gastrin concentrations relative to healthy subjects 
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have been reported in long-standing IDDM who were thought to have AN . (Feldman, 
Corbett, Ramsay, Walsh and Richardson, 1979). 
In this study, by contrast, the diabetics with and without AN had similar and 
normal basal serum gastrin levels, which remained unaltered by the prior 
establishment of fasting normoglycaemia and the overnight gastric aspiration. 
Thus the presence of fasting hyperglycaemia and the possible existence of a 
slow leak of food through the pylorus played no part in the normal basal serum 
gastrin concentrations in the patients with AN. 
In view of the evidence of neural regulation, both sympathetic and vagal 
· cholinergic (pages 19-21) on basal gastrin release, the reason for the normal 
basal serum gastrin concentrations in the diabetics with AN is unclear. 
However, combined sympathetic and vagal cholinergic dysfunction might result in 
normal basal serum gastrin concentrations. Alternatively residual neural 
function in these patients would produce the results observed. Indeed the 
difference in the effect of AN on basal serum gastrin concentrations in the 
NIDDM in this study and the IDDM in Feldman, et al 's study, might have been due 
to selective vagal impairment in their patients. 
2 ( V) GASTRIC INHIBITORY POLYPEPTIDE 
The finding of normal basal plasma GIP levels in the diabetics 
considered as a single group in the present study, none of whom were obese, is 
in accord with previous findings in non-obese NIDDM (page 31). However, 
comparable and normal basal plasma GIP levels in the diabetics With and without 
AN noted in this studY, have not been reported previously. Similarly the lack 
of effect of an overnight insulin infusion and overnight gastric aspiration on 
basal plasma GIP levels observed in the diabetics with and without AN have not 
been reported. These findings indicate that fasting hyperglycaemia_ did not 
alter basal GIP release in either group and that the possible existence of 
delayed gastric emptying did not alter basal GIP release in those with AN. 
The present findings indicate that basal GIP secretion is unaltered in the 
presence of AN in NIDDM. However, an explanation of this is hindered by a lack 
of knowledge of the effect of the autonomic nervous system on basal GIP release. 
In the only report available a threefold elevation in fasting plasma GIP levels 
was described in patients after truncal vagotomy (page 22), leading the author 
of the report to suggest that intact autonomic innervation seemed to be 
import ant for the basal con t rol of GIP cells. The present findings, taken in 
conjunction with the patients' responses to the autonomic function tests and 
111 
the prominent effect AN had on stimulated PP levels, tends to mitigate against 
their suggestion. 
2 (vi) SOMATOSTATIN 
Controversy surrounds the measurement of SRIF-LI in unextracted plasma, 
particularly as the levels measured are higher than those measured in extracted 
plasma. Thus the basal plasma SRIF-LI concentrations found in the present study 
were similar to those previously reported in unextracted plasma in man (Kronheim, 
Berelowitz and Pimstone, 1978), but were much higher than those found in 
extracted plasma in man (Penman, Wass, Lund, et al, 1979). However, similar 
forms of stimulation resulted in a significant increase in plasma SRIF-LI levels 
in both extracted and unextracted plasma, which will be discussed later. Thus 
while there may be some doubt with regard to the measurement of SRIF-LI in 
unextracted plasma, the fact that the SRIF-LI measured by this method shares 
immunological identity with synthetic SRIF (Kronheim, Berelowitz and Pimstone, 
1978) and is found to increase after stimul~tion, as is that measured in 
extracted plasma, suggests that some form of SRIF-LI is being measured in our 
system. Furthermore, measurement of different somatostatin moeities, antisera 
differences and losses incurred during extraction may be responsible for the 
different levels found in the two methods. 
In the present study the diabetics considered as a single group and the healthy 
subjects had similar basal plasma SRIF-LI levels. Furthermore, the diabetics 
with and without AN had comparable basal plasma SRIF-LI levels, which did not 
differ from those of the healthy controls. The former observation contrasts 
with the significantly elevated basal plasma SRIF-LI levels reported in alloxan 
diabetic dogs compared to normal dogs, (page 33). This disparity is likely to 
be due to differing SRIF-LI secretion in insulin-deficient and non insulin-
deficient forms of diabetes. 
In the present study the overnight insulin infusion did not alter basal plasma 
SRIF-LI levels in the diabetics with AN and those without AN. In contrast it 
was reported that reinstitution of insulin therapy in insulin deprived alloxan 
diabetic dogs reduced their elevated basal plasma SRIF-LI Tevels, but to levels 
still significantly higher than those of control dogs (page 33). These 
observations tend to reaffirm the differences in SRIF-LI secretion in insulin 
deficient and non-insulin deficient diabetes, and the similarity in basal 
SRIF-LI release in the diabetics regardless of the presence of AN. Overnight 
. 
gastric aspiration too did not alter basal plasma SRIF-LI levels in either the 
diabetics with AN or those without AN, suggesting that the possible existence 
of delayed gastric emptying had no effect on basal SRIF-LI in the former. 
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The observation of similar and normal basal plasma SRIF-LI concentrations in the 
diabetics with and without AN tends to suggest that autonomic dysfunction does 
not have a major effect on basal SRIF-LI release. This is supported by the 
findings of a lack of effect of atropine on basal plasma SRIF-LI levels in the 
dog (Schusdziarra, Rouiller, Harris and Unger, 1979), and on SRIF-LI release 
from the isolated canine pancreas (page 23). The suggestion is contradicted by 
the finding that vagotomy in the dog resulted in significant elevation of basal 
plasma SRIF-LI levels (page 23). In addition in the isolated perfused canine 
pancreas beta adrenergic blockade abolished SRIF-LI release stimulated by beta 
adrenergic agonism (page 23). 
In view of the data indicating neural mediation of basal SRIF-LI release, the 
lack of effect of AN on this release is surprising. However, it may well be 
that neural influences are not of prime importance in regulation of basal 
SRIF-LI release in man. Alternatively the neuropathy may not have been severe 
enough to cause a noticeable effect on basal SRIF-LI release. 
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SECTION 3 PROVOCATIVE STIMULATION 
A INSULIN HYPOGLYCAEMIA 
3 A (i) GLUCOSE 
Although the absolute nadir serum glucose concentration in the 
initial insulin hypoglycaemia test was lower in the healthy controls than the 
diabetics as a whole, or after division into those with and without AN, the 
actual fall in serum glucose concentrations was greater in the diabetics. This 
indicated sensitivity to insulin administration in the diabetics. However the 
dosage of insulin given to the diabetics was twice that given to the controls. 
This larger dose was administered in order to produce an adequate degree of 
hypoglycaemia in the diabetics. Indeed although the absolute nadir serum glucose 
concentrations were higher in the diabetics, the vast majority experienced 
symptoms of hypoglycaemia, comparable to those of the controls. This observation 
suggests that the features associated with hypoglycaemia may be induced by 
factors other that a nadir serum glucose concentration of less than 2.8 mmol/1. 
The serum glucose responses to insulin administration in the diabetics with and 
without AN were similar. Had the release of the counter-regulatory hormones 
such as growth hormone, the catecholamines and IRG been impaired in the diabetics 
with AN, a delayed recovery from hypoglycaemia might have ensued. Although IRG 
release was impaired in the diabetics with AN in the initial insulin hypogly-
caemia test, but not when hypoglycaemia was preceded by the overnight insulin 
infusion, there was no impairment in the recovery from hypoglycaemia on either 
occasion. This observation may suggest that the release of the other counter-
regulatory hormones was unaltered in the diabetics with AN in this study. This 
would in turn account for the unimpaired recovery from hypoglycaemia. 
The third major point of the study was the fact that the overnight insulin 
infusion normalized the glucose responses to the insulin bolus in both groups 
of diabetics. This indicates an equivalent degree of sensitivity to short term 
insulin therapy regardless of the presence of AN in the diabetics studied. 
3 A (ii) GLUCAGON 
The prominent plasma IRG response to insulin hypoglycaemia observed 
in the healthy subjects in the present study confirmed present beliefs (page 55). 
Previous reports of plasma IRG responses to insulin hypoglycaemia in diabetics 
have been limited to IDDM. Impaired responses have been reported in IDDM, 
unstable IDDM and IDDM with AN (page 27). 
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In contrast to these reports in IDDM, the NIDDM considered as a single group in 
this study did not have an impaired plasma IRG response to insulin hypoglycaemia, 
nor indeed did those without AN. This finding suggests that impaired plasma IRG 
responses to insulin hypoglycaemi~ are not a feature of NIDDM. Indeed it would 
appear that the existence of fasting · hyperglycaemia and a higher nadir serum 
glucose level did not induce an abnormal plasma IRG response to hypoglycaemia in 
the NIDDM compared with the controls. 
When in ' this study the diabetics with AN were found to have an impaired plasma 
IRG response to the initial insulin hypoglycaemia test, various factors which 
may possibly have been implicated in this impaired response were evaluated. 
There were no differences in age, degrees of obesity, degrees of fasting hyper-
glycaemia, the level of hypoglycaemia attained, expressed either as absolute 
values or as percentage change from basal, o.r in the rate of fall in serum 
glucose levels to account for the different plasma IRG responses in the two 
groups of diabetics. After exclusion of the abovementioned factors it seemed 
likely that the impaired IRG response in the diabetics with AN might be explained 
on the basis of defective neural regulation of IRG release. In agreement with 
this suggestion was the observation that impaired IRG responses to hypoglycaemia 
were present in IDDM with AN (Maher, Tannenberg, Greenberg, et al, 1977). 
However, when insulin hypoglycaemia was repeated after prior establishment of 
fasting normoglycaemia, the plasma IRG response improved in both groups of 
diabetics. Furthermore the plasma IRG response was no longer impaired in the 
diabetics with AN. Thus it would appear that factors other than the autonomic 
innervation of the alpha cell play the major role in the regulation of the IRG 
response to insulin hypoglycaemia. This is supported by recent evidence 
indicating that neural mechanisms are probably unimportant in mediation of the 
IRG response to hypoglycaemia (pages 15-16). 
The exact mechanism whereby IRG release is stimulated by insulin hypoglycaemia 
remains unknown, but the rate of fall of blood glucose levels or hypoglycaemia 
per se may be the initiator of IRG release. It may well be that hypoglycaemia 
is such a potent alpha cell stimulus that it overrides neural control of the 
alpha cell. If that is the case, the impaired plasma IRG responses to hypo-
glycaemia observed in IDDM with AN (Maher, Tannenberg, Greenberg, et al, 1977) 
might have been related to the presence of unstable diabetes. This suggestion 
is based on the following. Unstable IDDM were reported to have impaired IRG 
responses to insulin hypoglycaemia (Reynolds, Nolnar, Horwitz, et al, 1977) and 
most of the IDDM with AN had unstable diabetes, while in none of the IDDM 
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without AN was their diabetes unstable. Therefore there would appear to be 
different situations with regard to IRG responsiveness to hypoglycaemia in IDDM 
and NIDDM. Further, the improvement in the plasma IRG responses to hypoglycaemia 
in both groups of diabetics after the overnight insulin infusion in the present 
study may have been due to the greater degree of absolute hypoglycaemia attained. 
3 A (iii) PANCREATIC POLYPEPTIDE 
The stimulatory effect of insulin hypoglycaemia on PP release in man 
is well recognized (page 55) and was confirmed in the healthy subjects in this 
study. However, PP responses to insulin hypoglycaemia have not previously been 
reported in NIDDM in who~when considered as a single group, impaired responses 
were noted. 
In IDDM, impaired serum PP responses to hypoglycaemia have been found in patients 
without AN and greatly impaired responses in patients with AN (Krarup, Schwartz, 
Hilsted, et al, 1979). In the IDDM without AN impairment of the PP response to 
hypoglycaemia wa·s related to duration of diabetes, as well as to increased 
threshold of vibratory sensation. This probably indic~es the existence of 
undiagnosed AN in the patients with a longer duration of diabetes, as their 
patients with a short duration of diabetes had a normal serum PP response to 
hypoglycaemia. Similarly the truncated serum PP responses to hypoglycaemia 
observed in the NIDDM as a whole in this study appeared to be due to the over-
riding effect of the markedly impaired responses in the diabetics with AN, 
particularly as the magnitude of the rise in serum PP levels was similar in the 
diabetics without AN and the control subjects. 
In the present studies the diabetics with AN had a significantly impaired rise 
in serum PP levels during hypoglycaemia relative to the diabetics without AN. 
This impairment occurred regardless of whether hypoglycaemia was preceded by the 
establishment of fasting normoglycaemia. Indeed there appeared to be an 
improvement in the magnitude of the rise in serum PP levels in the diabetics 
with AN when hypoglycaemia was preceded by the establishment of fasting normo-
glycaemia. However their basal serum PP levels were higher on this occasion and 
they still had only a threefold rise in serum PP levels, which remained 
significantly impaired relative to the diabetics without AN. The uniformly 
impaired rise in serum PP levels in the diabetics with AN compared to those 
without AN could not be explained by any differences in the two groups, in whom 
chronic pancreatitis, which may also induce impaired serum PP responses to 
insulin hypoglycaemia (page 30) had been excluded, other than the presence of 
autonomic dysfunction in those with AN. This suggestion is in agreement with 
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the study in IDDM by Krarup et al, and in keeping with the vagal cholinergic 
mediation of this aspect of PP release (page 17). Furthermore the likely 
mechanism of the impaired serum PP responses to insulin hypoglycaemia in the 
diabetics with AN is defective vagal cholinergic activity. Once again this 
suggestion is in line with the conclusions reached by Krarup and associates. 
In order to determine the possible value of the PP response to insulin hypogly-
caemia as a marker for AN, an assessment was made of correlations between the 
patients' PP responses to hypoglycaemia and their responses to the individual 
criteria used to determine the presence or absence of AN. However, the degree 
of impairment of the PP responses did not correlate with the individual absolute 
criteria of autonomic dysfunction in the patients. The PP response 
to both the initial hypoglycaemia test and the test preceded by the establishment 
of fasting normoglycaemia was uniformly impaired in all patients who had AN, and 
normal in those .without AN. Thus it is pos~ible that the PP responses to insulin 
hypoglycaemia might have been an additional marker of AN, in the small number of 
patients studied. The inability to correlate the PP response to hypoglycaemia 
with the other indices of AN in this study might possibly have been due to the 
qualitative nature of the latter. These data suggest that the impairment of the 
PP response to hypoglycaemia may prove to be a quantitative marker of AN. 
3 A (iv) GASTRIN 
Insulin hypoglycaemia has not been reported as an unequivocal 
stimulus for gastrin release in healthy man (page 55), but proved to be a 
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stimulus in the control subjects in this study. The effect of insulin hypogly-
caemia on gastrin release has not previously been reported in diabetics and their 
response when considered as a single group in this study was similar to that of 
the controls, but only the mean peak serum gastrin concentration was significantly 
elevated above basal. The reason for this is unclear but may relate to greater 
variability in the serum gastrin responses in the diabetics. 
Recently it has been shown that vagal intactness is not a prerequisite for the 
gastrin response to hypoglycaemia (page 20). Whereas, infusion studies have 
suggested that the rise in serum gastrin levels in response to hypoglycaemia may 
at least in part be mediated via beta adrenergic pathways (page 21). Thus it is 
apparent that in diabetes complicated by autonomic dysfunction an altered gastrin 
response could occur. However, in the present study the diabetics with and 
without AN had similar gastrin responses to insulin hypoglycaemia whether 
preceded by the overnight insulin infusion or not, although when the test was 
preceded by the insulin infusion, the serum gastrin response to hypoglycaemia 
became significant in both groups. This improvement was probably related to the 
greater degree of hypoglycaemia attained in the second test. 
The mechanism of the normal gastrin response to hypoglycaemia in the diabetics 
with AN is unclear, but there are a number of possibilities which are similar to 
those discussed earlier with regard to the normal basal gastrin release in these 
patients. 
3 A (v) GASTRIC INHIBITORY POLYPEPTIDE 
The major observation of this study was the notable failure of 
insulin hypoglycaemia to induce an alteration in plasma GIP levels in any of the 
subjects studied. Prior to the commencement of these studies the effect of 
insulin hypoglycaemia on GIP release had not been determined, but recently two 
contradictory reports on this subject have appeared (page 55). In the first 
Service, Nelson, Rubenstein and Go (1978) described a significant rise, ie. 78 ± 
40 pg/ml in plasma GIP levels in healthy subjects in response to insulin hypo-
glycaemia. In the second report hypoglycaemia induced by the same dose of 
insulin as used in the first report, failed to significantly alter GIP levels in 
healthy subjects and IDDM (Reynolds, Tronsgard, Gibbons, Blix and Rubenstein, 
1979). There is no ready explanation for the contradictory reports . . However 
the findings in this study support those of Reynolds et al. In addition it 
would appear that vagal activation and catecholamine release induced by insulin 
hypoglycaemia have little effect on GIP release in man. 
3 A (vi) SOMATOSTATIN 
In this study insulin hypoglycaemia induced a significant rise in 
plasma SRIF-LI levels in the healthy subjects, but not the diabetics as a whole. 
Although insulin hypoglycaemia in the latter was preceded by the induction of 
fasting normoglycaemia. The reason for the differential effect in the controls 
and the diabetics is not clear, although it may not be important in view of the 
fact that the response in the latter was not significantly different from that 
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of the former. In a recent report the stimulatory effect of insulin hypogly-
caemia on SRIF-LI secretion in healthy subjects has been confirmed by Wass, Penman, 
Medbak, et al (1980). However plasma SRIF-LI responses to hypoglycaemia have not 
been reported previously in diabetics. 
In the diabetics with and without AN the rise in plasma SRIF-LI levels during 
hypoglycaemia was insignificant in both cases, but the response seemed to be 
flatter in those with AN. The significance of this finding is uncertain in view 
of the small groups studied and the lack of knowledge with regard to the 
mechanisms whereby insulin hypoglycaemia induce SRIF-LI release. It is possible 
that significant differences in the SRIF-LI responses in the diabetics with and 
without AN might be apparent if larger groups were studied. Such a finding 
would tend to support a neural role in mediation of the SRIF-LI response to 
hypoglycaemia. 
B THE MIXED MEAL 
3 .B (i) GLUCOSE AND INSULIN 
The exaggerated rise in serum glucose concentrations and impaired 
serum insulin responses following ingestion of the meal in the diabetics 
considered as a single group in this study, are a well recognized feature of 
NIDDM. 
The major point of interest in this study was the delayed and significaritly 
lower serum glucose response in the diabetics with AN compared to those without 
AN, while their postprandial insulin responses were similar. There are a number 
of possible explanations for the lower serum glucose response in the diabetics 
with AN. They include a delay in gastric emptying, which has previously been 
reported in diabetic AN (page 37). This was not investigated in the present 
study. Second, defective innervation of the small intestine which may result in 
defective absorption and/or altered gut hormone release. There is no evidence 
for defective innervation of the small intestine in these patients, but altered 
gut hormone release e.g. GIP or SRIF-LI, might have been involved. 
In view of the fact that the insulin response to food ingestion may be partially 
neurally mediated (Woods and Porte, 1974; Young and Landsberg, 1977), 
it was interesting to note the similar serum insulin responses to the meal in the 
diabetics with and without AN. This observation may indicate that neural factors 
are not of prime importance in mediation of the insulin response to food 
ingestion. Alternatively, that the neuropathy was not severe enough to induce 
any alteration in the insulin response in these patients. 
3 B (ii) GLUCAGON 
The small, but significant, rise in plasma IRG levels noted after 
ingestion of the mixed meal in the healthy subjects in the present study is in 
agreement with a previous report (page 56). Further the exaggerated rise in 
plasma IRG levels observed in the ten diabetics in this study has also been found 
after a mixed meal in IDDM (page 27). However, the similarly exaggerated plasma 
IRG responses to the mixed meal in the diabetics with and without AN observed in 
this study have not previously been described. 
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Although the groups studied were small, the latter findings suggest that 
autonomic dysfunction does not alter the plasma IRG response to food. Further-
more the findings tend to suggest that factors other than the integrity of the 
autonomic nervous system might be primarily responsible for the food-induced rise 
in plasma IRG levels. The latter suggestion is supported by the fact that only a 
cephalic phase of IRG release in response to food has been identified, and then 
only in the dog (page 15) and the calf (Edwards and Vaughan, 1978). Whereas 
other factors are known to play a prominent role in meal-induced IRG release, 
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such as protein or fat which cause release of IRG (Unger and Orci, 1979), 
gastrointestinal hormones such as GIP,which are released after ingestion of a meal 
and have IRG-stimulating activity, may be the enteric signal to the alpha cell 
(Unger and Orci, 1979): 
3.8 (iii) PANCREATIC POLYPEPTIDE 
The biphasic release of PP following ingestion of a mixed meal 
observed in the healthy subjects in this study is in agreement with a previous 
report (page 17). However, the similarity in the serum PP responses to ingestion 
of the meal in the diabetics as a whole and the controls in this study contrasts 
with the exaggerated serum PP responses to a protein meal in diabetics previously 
reported (page 30). However the previous report did not define the type of 
diabetic studied. Furthermore their patients had a greater degree of fasting 
hyperglycaemia than those of the present study. 
Of major interest in this study was the delayed early PP peak in the diabetics 
with AN compared to the diabetics without AN and the controls, particularly in 
view of the evidence of a dependence of this phase on vagal cholinergic path-
ways (pages 17-18). All six diabetics with AN had vagal neuropathy as evidenced 
by their impaired PP responses to hypoglycaemia and abnormal responses to the 
autonomic function tests which assessed vagal integrity. Thus it seems likely 
that the delayed early rise in serum PP levels noted in these patients was due 
to the presence of vagal neuropathy. Although the fact that the magnitude of 
the early rise in serum PP levels was not impaired in these patients suggests 
residual vagal function and that the neuropathy was not severe enough to effect 
this phase of PP release in its entirety. 
It is generally believed that an interaction of humoral and chemical stimuli 
and vagal activity mediate the prolonged second phase of PP release after food 
and it has been suggested that mechanisms other than neural are dominant in 
controlling this phase (page 18). In the diabetics with and without AN, there 
was no significant difference in their second phase of PP release, which 
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supports the aforementioned suggestion. 
3 .B ( i v) GASTRIN 
Gastrin responses to meal ingestion have not previously been reported 
in NIDDM, but the diabetics as a whole and the healthy subjects had insignificantly 
different serum gastrin responses in this study. 
The diabetics with and without AN also had similar serum gastrin responses to the 
meal, and their responses did not differ from those of the controls. This latter 
observation contrasts with a report in IDDM. Feldman, Corbett, Ramsey, Walsh and 
Richardson (1979) studied gastrin responses to the intragastric installation of 
homogenized food in two groups of long-standing IDDM. Their two groups of 
patients were supposed to comprise one group with AN and one group without AN. 
However, both groups of patients were found to have vagal neuropathy and in 
addition had twice to threefold higher food-stimulated serum gastrin concentra-
tions than the normal controls. 
In the light of the report in the IDDM with AN and the evidence of vagal but not 
adrenergic (pages 20-21) mediation of gastrin release in response to food, the 
mechanism of the normal serum gastrin responses in the diabetics with AN in this 
study is unclear. However, the likely explanation is the presence of residual 
vagal function in these patients. 
3 B (v) GASTRIC INHIBITORY POLYPEPTIDE 
The observation of an impaired plasma GIP response to the mixed meal 
in the diabetics as a whole in this study differs from the findings of other 
workers. Besterman, Sarson, Turner and Bloom (1978) observed normal plasma GIP 
responses to a test meal in NIDDM, similar to the diabetics without AN in this 
study , whilst Ebert and Creutzfeldt (1978) reported exaggerated GIP responses 
after a test meal in NIDDM. The diabetics in the present study comprised an 
equal number of subjects with and without AN and only the former subgroup was 
characterized by an impaired plasma GIP response to the meal. Thus it appears 
likely that the diabetics with AN conferred an impaired plasma GIP response on 
the entire group. The normal plasma GIP responses reported by Besterman et al, 
and noted in the diabetics without AN on the one hand, and the exaggerated 
plasma GIP responses observed by Ebert et al on the other, might be explained by 
the presence of obesity in the patients studied by Ebert et al. Alternatively, 
antisera differences may be the explanation for the differing results. 
The most interesting feature of this study was the impaired plasma GIP response 
to the meal in the diabetics with AN. This finding suggests that autonomic 
dysfunction may have altered the sensitivity of the GIP cell to the meal. 
However, studies evaluating neural regulation of food-stimulated GIP release 
have reported findings comparable with either the effects of atropine per se or 
a neural dependence of GIP release (page 22). Thus the impaired plasma GIP 
responses in the diabetics with AN might have been due to other factors. Ebert, 
Creutzfeldt, Brown, Frerichs and Arnold (1976) suggested that the GIP response 
to a meal was dependent on at least two factors: the rate of absorption of 
nutrients and the capacity of the beta cell for insulin secretion. Insulin 
secretion was similar in the diabetics with and without AN, thus excluding 
altered insulin secretion as the cause for the impaired GIP response in the 
former. Although having slightly higher basal serum glucose levels, the 
diabetics with AN had lower postprandial glucose responses than the diabetics 
without AN. Thus the impaired plasma GIP response to food ingestion might, in 
fact, have been related to altered absorption of nutrients, although glucose 
was the only nutrient measured. In support of this suggestion was the report by 
Creutzfeld, Ebert, Arnold, Frerichs and Brown (1976) in which significantly 
impaired plasma GIP responses to a mixed meal were noted in patients with mal-
absorption due to coeliac disease. Their patients had significantly lower 
glucose and insulin responses compared with controls. Patients with chronic 
pancreatitis and fat malabsorption in contrast, had exaggerated GIP responses to 
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a mixed meal, which was postulated to be due to endocrine (insulin) insufficiency 
(Ebert, Creutzfeld, Brown, Frerichs and Arnold, 1976). Thus it would appear that 
impaired plasma GIP responses to food ingestion may be related solely to poor 
absorption of glucose. Indeed it is attractive to suggest that there is defective 
absorption of nutrients, in particular glucose, in diabetics with AN in order to 
explain their impaired plasma GIP responses to food ingestion. Had changes in fat 
levels been measured the problem might have been nearer resolution. The 
mechanism of the defective absorption of nutrients in turn may have been related 
to delayed gastric emptying, as alluded to earlier. 
3 B (vi) SOMATOSTATIN 
The stimulatory effect of meal ingestion on SRIF release noted in the 
healthy subjects in this study has recently been confirmed by Wass, Penman, 
Dryburgh, et al (1980). However SRIF-LI release following a meal has not 
previously been reported in diabetics. In the present study plasma SRIF-LI 
responses to meal ingestion were similar in the diabetics considered as a single 
group and the healthy controls. This finding contrasts with the report of a 
delayed but ultimately higher rise in plasma SRIF-LI levels in alloxan diabetic dogs 
after protein-fat meals (page 33). The discrepancy in the findings of the two 
studies, like that for the basal SRIF-LI concentrations, is likely to be related to 
the different forms of diabetes studied. 
The major point of interest in the present study was that the plasma SRIF-LI 
responses to the meal were not significantly different in the diabetics with and 
without AN although the responses in the former group tended to be flatter, . 
particularly compared to the controls. 
The precise mechanism whereby ingestion of a mixed meal induced stimulation of 
SRIF-LI release is unknown. Cephalic factors have not been identified as yet 
and would tend to be excluded by the present findings. Animal experiments have 
revealed a gastric phase for SRIF-LI release (page 23). In addition the 
existence of an intestinal phase of the SRIF-LI response to food , mediated by 
gut hormones, nutrients and neural pathways has been suggested by Schusdziarra, 
Rouiller, Pietri, et al (1979). Thus two phases have been identified in the 
SRIF-LI response to ingestion. However the lack of significant differences in 
the response in the two groups of diabetics may suggest that in man neural 
factors are probably not of prime importance in mediation of the SRIF-LI response 
to food. 
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SECTION 4 FIBRE SUPPLEMENTATION 
These studies confirm the observation that fibre added to meals 
lowers the postprandial rise in serum glucose concentrations in normal subjects 
and NIDDM and further confirm that fibre improves glucose tolerance (pages 46-
47). Although the effect of fibre on glucose tolerance in diabetics with AN has 
not previously been reported, our findings indicate that improvement in glucose 
tolerance is observed only in the absence of AN in NIDDM. 
The reason for the lack of effect of fibre supplementation on the serum glucose 
responses to food ingestion in the diabetics with AN is not clear. However, it 
is conceivable that one or another of the mechanisms which have been postulated 
to explain the effects of fibre on glucose tolerance (page 46) may not be fully 
operative in the presence of AN. Deiayed gastric emptying is a well recognized 
feature of diabetic AN (page 37), although not assessed in the present study as 
stated earlier. Nevertheless it is possible that the diabetics with AN already 
had asymptomatic delayed gastric emptying which could not be further delayed by 
fibre. This suggestion has subsequently been confirmed (Dr M. Rosman of the 
University of Cape Town, personal communication). 
Significantly smaller rises in serum glucose levels following ingestion of a 
mixed meal were documented earlier in this work in diabetics with AN compared 
to those without AN. This observation may indicate the presence of altered 
absorption of nutrients in the diabetics with AN, which may be secondary to 
delayed gastric emptying or defective innervation of the small intestine. At 
this stage it is uncertain whether altered nutrient absorption may occur in 
diabetic AN per se and may thus negate the postulated fibre-induced delayed 
nutrient absorption. 
Intestinal transit time may be reduced in diabetics with AN affecting the bowel 
(Scarpello and Sladen, 1978). In addition delayed gastric emptying per se may 
result in prolonged transit times in these patients. Hence it is possible that 
the lack of effect of fibre in the diabetics with AN may be related to 
intestinal transit time, which was already slowed by the pr-esence of AN. 
It is apparent from our studies that diabetics with AN may have altered gut 
hormone release. Altered IRG (Maranda and Horwitz, 1978; Munoz, Sandstead, 
Jacob, Johnson and Mako, 1979), GIP (page 47) and GLI release (Morgan, Goulder, 
.Tsiol ak is, Mark~ ·and Alberti, 1979) have been reported with fibre supplemen-
tation. However in this study, only IRG secretion was significantly altered by 
fibre and then only in the healthy subjects, although reduced plasma GIP 
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concentrations, albeit statistically insignificant, were noted in the healthy 
subjects and both groups of diabetics. While it is possible that altered gut 
hormone release may play a part in mediation of the fibre-induced effects on 
glucose tolerance, the lack of significant changes in their release in the 
diabetics without AN, despite the observed improvement in glucose tolerance, 
makes this unlikely. In addition it seems unlikely that the lack of effect of 
fibre in the diabetics with AN was related to the existence of altered gut 
hormone secretion. 
After due consideration of the various mechanisms proposed to explain the effect 
of fibre on glucose tolerance, the presence of existing delayed gastric emptying 
in the diabetics with AN appears to be the most likely cause for the lack of 
effect of fibre in this group of subjects. 
A further point of interest in the present study was that in contrast to 
previous reports in NIDDM (Jenkins, Goff, Leeds, et al, 1976) and healthy 
subjects (Jenkins, Leeds, Gassull, Cachet and Alberti, 1977; Morgan and 
associates, 1979) there was no associated reduction in serum insulin responses 
with fibre supplementation of the test meal. However, Munoz and co-workers 
(1979) also found that in healthy subjects, fibre supplemented diets did not 
alt~r serum insulin responses to meal ingestion. The reason for the disparity 
in fibre-induced insulin secretion in the various studies is not clear, but 
there are a number of possible explanations. The first relates to the type of 
fibre used. Guar and pectin administered either separately or together were 
used in the studies by Jenkins, Goff, Leeds, et al; Jenkins, Leeds, Gassull, et 
al; Morgan et al and in present study, while Munoz and co-workers used various 
sources of dietary fibre. The second explanation relates to the report of 
significantly reduced GIP secretion in association with significantly diminished 
insulin secretion with fibre supplemented meals by Morgan et al. They suggest 
that GIP may be involved in the fibre-induced effects on insulin secretion. 
Thus the lack of effect of fibre on insulin secretion in the present study might 
have been due to the lack of significant alteration in GIP secretion. The third 
possible ex~lanation relates to the different dosages of fibre used. In the 
present study 5 g each of guar and pectin were used. Morgan and co-workers gave 
10 g guar only, Jenkins and co-workers used 14.5 g guar and 10 g pectin and 16 g 
guar and 10 g pectin in different studies and Munoz and co-workers administered 
26 g each of various fibres. Thus it is apparent that real differences exist in 
the dosages of fibre administered in the various studies. It might therefore be 
of value to determine the effects of increasing doses of fibre, since it is 
probable that the effect of fibre on insulin secretion and glucose tolerance is 
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dose-dependent. Although cognisance was taken of reports in the literature in 
which guar and pectin were administered, the relatively low dosages of 5 g of 
each were selected for this study because of their palatability. The doses of 
the two fibres in the meal were gradually reduced from 15 g each until the meal 
became palatable. However, in spite of the relatively low quantities of fibre 
used, marked reduction in serum glucose levels were observed in the absence of 
a prominent effect on insulin secretion. This suggests that fibre might exert 
its effect on glucose tolerance independent of altered insulin secretion. 
There seems to be little doubt that dietary fibre has a beneficial effect on 
glucose tolerance in both healthy subjects and diabetics. A reduction in 
insulin requirements in IDDM and obviation of the need for oral hypc:glycaemic 
therapy in NIDDM have been reported with fibre-supplemented diets (page 47). 
However, high fibre diets were not universally successful in IDDM on relatively 
high doses of insulin (page 47) and fibre was not effective in the present study 
in NIDDM with AN. Thus although further studies are required to fully elucidate 
the mechanisms whereby fibre improves glucose tolerance and to assess the reason 
for its lack of effect in diabetics with AN, dietary supplementation with fibre 
may have a real role in the management of diabetes, even in the presence of AN. 
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COLLATION OF DATA ON INDIVIDUAL HORMONES 
The prime purpose of these studies was to provide evidence which might contribute 
to an understanding of the inter-relationship between NIDDM, gastrointestinal 
hormone release and the autonomic nervous system. The various studies carried 
out however, revealed some interesting features of the individual hormones, a 
short summary of which follows 
(i} GLUCAGON 
The data revealed that IRG release stimulated by insulin hypoglycaemia and 
a mixed meal was unaltered by the presence of AN in NIDDM, but that basal IRG 
release was affected. This data suggested selective involvement of the basal 
unstimulated alpha cell by AN. The lesion in the autonomic innervation of the 
alpha cell which was most compatible with the abnormal basal IRG release in these 
patients, was loss of the inhibitory alpha a~renergic influences on basal IRG 
release. 
The possible consequences of the significant fasting hyperglucagonaemia in the 
diabetics with AN depends on two main factors. First, the importance of IRG in 
the induction of metabolic abnormalities observed in diabetics. Second, the 
relative importance of abnormal basal only as opposed to abnormal basal and 
stimulated IRG secretion in the induction of metabolic abnormalities. 
(ii} PANCREATIC POLYPEPTIDE 
The PP data revealed normal basal PP release except after the 
establishment of fasting normoglycaemia, an impaired serum PP response to hypo-
glycaemia and a delayed early serum PP response to the mixed meal in the 
diabetics with AN. These findings indicate that stimulated and to a lesser 
extent basal PP release were affected by autonomic nervous dysfunction in the 
patients studied. 
These findings provide confirmatory evidence for a prominent neuroregulatory 
role in the mediation of PP release. However, the data also suggests that the 
various facets of PP release are governed by neural pathways, but to varying 
degrees. The lesion in the autonomic innervation of PP release most 
compatible with the abnormalities in it's stimulated release was loss or 
impairment of vagal cholinergic integrity. In contrast defective alpha 
adrenergic activity might have been involved in the single instance of abnormal 
basal PP release. 
The consequences of the abnormal PP release in the diabetics with AN are 
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uncertain and will largely depend on the physiological functions uncovered for 
this newly described hormone . 
. (iii} GASTRIN 
The data revealed that AN did not induce any major alterations in basal 
or stimulated gastrin release. This might have been due to the presence of 
residual neural function in the patients and the possibility that a greater 
degree of neural impairment may be required before an effect on gastrin release 
is observed. 
(iv} GASTRIC INHIBITORY POLYPEPTIDE 
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The data revealed that basal GIP release was unaffected by AN, while 
food-induced GIP release was affected in these patients. These data might have 
suggested selective involvement of stimulated GIP release by autonomic dysfunction. 
However, the impaired GIP response to food ingestion in the diabetics with AN was 
probably secondary to defective glucose absorption and not due to defective 
neural innervation of GIP release. As yet the consequences of the impaired 
stimulated GIP release in the diabetics with AN are unknown. 
(v} SOMATOSTATIN 
The data revealed a lack of effect of AN on all facets of SRIF-LI release 
studied. However the fact that flatter, albeit insignificantly so, SRIF-LI 
responses to the mixed meal and insulin hypoglycaemia were observed in the 
diabetics with AN than in those without AN, may indicate that significant 
differences would appear if larger groups were studied. Furthermore whether 
SRIF-LI release from nerves is altered in the presence of AN and the consequences 
thereof remain to be determined. 
CHAPTER VII 
CONCLUSIONS 
CHAPTER VII 
CONCLUSIONS 
The major purpose of this thesis was to provide evidence which might contribute 
to an understanding of the interrelationship between NIDDM, gastrointestinal 
hormone release and the autonomic nervous system. 
Thus it was attempted to : 
a) evaluate the effect of AN on the release of certain gastrointestinal hormones 
in NIDDM. The hormones studied were IRG, PP, gastrin, GIP and SRIF-LI. 
b) assess whether any of the abnormalities in the release of these gastro-
intestinal hormones described in NIDDM could be accounted for by undiagnosed AN. 
c) evaluate whether the PP response to hypoglycaemia could be used as a bio-
chemical marker for AN, and finally, 
d) assess whether the action of dietary fibre on glucose tolerance would be 
altered in the presence of AN. 
To these ends studies were designed, formulated and conducted. The results 
revealed abnormalities in the release of certain of the hormones studied. The 
major findings were in the NIDDM with AN. 
i) significantly elevated basal plasma IRG concentrations which were not 
correctable by the prior establishment of fasting normoglycaemia or by 
complete gastric emptying. 
ii) significantly elevated basal serum PP concentrations only after the 
establishment of fasting normoglycaemia. 
iii) an impaired plasma IRG response to hypoglycaemia which was corrected by 
the prior induction of fasting normoglycaemia by an overnight insulin 
infusion. 
iv) an impaired serum PP response to hypoglycaemia which was not corrected 
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by the prior establishment of fasting normoglycaemia. 
v) a delayed early serum PP peak after ingestion of a mixed meal. 
vi) an impaired plasma GIP response to ingestion of the mixed meal. 
vii) a lack of effect of fibre supplementation on serum glucose concen-
trations and hormone responses following ingestion of a mixed meal. 
These were all new findings. 
In all the diabetics studied, ie in the combined group of patients with and 
without AN it was found that : 
i) basal plasma IRG concentrations were significantly elevated. 
ii) · the serum PP response to insulin hypoglycaemia was impaired. 
iii) the plasma GIP response to ingestion of the mixed meal was impaired. 
The findings revealed that an interrelationship does exist between NIDDM, gastrointestinal hormone release and the autonomic nervous system. Further that AN does have an effect on the release of certain of the hormones studied, 
although many of the precise mechanisms are not fully understood as yet. Certain abnormalities in the release of the gut hormones in NIDDM may be related to the presence of undiagnosed AN. In addition serum PP responses to hypo-glycaemia may be a biochemical marker for AN in NIDDM. Finally in NIDDM the 
effect of dietary fibre on glucose tolerance is altered in the presence of AN. 
Therefore these findings suggest that the discrepancies in hormone release 
reported in diabetes in the literature may be related to variable numbers of patients with undiagnosed AN in the study groups. Further studies may shed 
more light on this suggestion and may reveal involvement of AN in various of the other as yet unexplained biochemical abnormalities found in patients with diabetes. 
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CHAPTER VII I 
SUGGESTED DIRECTIONS FOR FUTURE RESEARCH 
CHAPTER VIII 
SUGGESTED DIRECTIONS FOR FUTURE RESEARCH 
The present findings have reinforced the belief that many facets of diabetes 
mellitus are poorly understood. Furthermore the meaning of these findings in 
terms of biochemical sequelae and patient care remain uncertain. Further 
studies are needed to provide a better understanding of these factors. 
Suggested directions for future research would include the following : 
i) To provide a better understanding of the precise underlying mechanisms 
for the abnormalities in gastrointestinal hormone release revealed in the 
presence of AN. Disturbed release of certain gut hormones has now been 
demonstrated in IDDM and NIDDM with AN. A more complete understanding of 
the autonomic nervous regulation of the gut hormones may shed some light 
on the precise mechanisms involved. Studies in patients with autonomic 
nervous dysfunction not secondary to diabetes, such as familial 
dysautonomia may also be of value in this regard. 
ii) To provide a more complete understanding for the lack of effect of dietary 
fibre on glucose tolerance in the presence of AN in NIDDM and to evaluate 
whether the long term effects of fibre may also be altered in the presence 
of AN. If the precise mechanism for the lack of effect of fibre noted in 
the NIDDM with AN could be identified and countered, fibre supplementation 
may prove to be beneficial even in the presence of AN. This together with 
a study of the long term effects of fibre supplementation in diabetics 
with AN might have relevance in the therapy of diabetes. 
iii) To evaluate PP as a quantitative marker for AN. Although numerous 
clinical tests are available to detect the presence of AN, there appears 
to be no ready means of quantifying the degree of AN. A quantitative 
marker of AN would enable identification of patients at risk from the 
increased mortality as a result of AN. Improved control of diabetes and 
close medical attention may result in an improved outlook for these 
patients. 
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iv) To extend the studies of the five hormones to include aspects of their 
release, as well as to other gut hormones, with regard to the effect of 
AN thereon and the possible effect of undiagnosed AN on abnormalities in 
their release found in diabetes per se. Studies on the 24 hr profile of 
th~ various gut hormones may provide valuable evidence of the effect of 
AN on the daily secretory pattern of the hormones. 
v) To determine whether AN has any important metabolic sequalae in NIDDM. 
An association between instability of diabetic control and AN has been 
suggested for IDDM but whether the same holds for NIDDM is uncertain. 
Studies on 24 hr profiles of blood glucose, free fatty acids, triglyrides 
and amino acids in the presence and absence of AN may shed some light on 
the issue. 
vi) To evaluate a possible effect of AN on neuropeptide release,which may 
have relevance to certain of the abnormalities demonstrated in gut hormone 
release in AN. An effect of AN on neuropeptide release may have greater 
relevance in terms of the overall functioning of the gastrointestinal 
tract, particularly with regard to motility, absorption, endocrine and 
exocrine secretion on a nutrient homeostasis. 
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APPENDIX A 
BIOCHEMICAL METHODS 
1. MEASUREMENT OF SERUM GLUCOSE (Hoffman, 1937; Varley, 1967) 
Principle: Potassium ferricyanide is reduced to ferrocyanide by glucose in 
alkaline solution and measured by an autoanalyser (Technicon Autoanalyser I) 
Reagents: (a) Cyanide-saline diluent, 0.5% sodium cyanide in 0.9% sodium 
chloride with 0.5 ml Brij 35/1. 
(b) Alkaline ferricyanide: 0.03g potassium ferricyanide, 20 g 
anhydrous sodium carbonate, 9 g sodium chloride /1 with 0.5 ml Brij 35/1. 
Standards: Standards were prepared to cover the ranges 25 - 400 mg glucose/ 
100 ml and 50 - 800 mg glucose/100 ml. 
Procedure: The sensitivity of the method was increased by the inclusion of 
sodium cyanide in the saline diluent. The standard Auto analyser technique 
utilizing dialysis to remove non-reducing substances was employed. Absorption 
was recorded at 420 mu and the results calculated from the recorded peak 
heights. 
2. RADIOIMMUNOASSAYS 
2 (0) Principles of Radioimmunoassay (Yalow and Berson, 1971) 
The general principles of radioimmunoasay may be illustrated by the 
following reactions: 
Ag* + Ab 
+ 
·Ag 
~~ 
Ag* - Ab 
Ag Ab 
where Ag* = radioactively labelled antigen 
Ab = specific antibody 
Ag* - Ab= labelled antigen - antibody complex 
Ag = unlabelled antigen 
Ag - Ab= unlabelled antigen - antibody complex 
The principle of radioimmunoassay is based on the competition of radio 
labell ed antigen with unlabelled antigen for a limited amount of antibody. 
Separation of the bound from free labelled antigen may be accomplished by a 
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number of methods. For example, charcoal is used in the IRG, SRIF-LI and gastrin assays. The charcoal adsorbs the free unbound labelled antigen which is then counted in an automatic gamma spectrometer. Separation methods which precipitate the antibody-bound label are also made use of. These include polyethylene glycol (PEG) which is used in the PP assay and microfiltration, 
used in the insulin assay. 
CALCULATIONS 
All samples and standards are assayed in duplicate. In addition duplicate 
tubes containing the total radioactivity added are counted (TC) and duplicated 
tubes are set up to determine the non specific binding (NSB). 
The maximum binding (BO) in the absence of unlabelled Ag is calculated thus: 
BO 
TO = 
BO - NSB 
TC - NSB 
and chosen to be between 40 - 60%. 
X 100 
The percentage binding of standards and unknowns is calculated as below: 
% = binding 
s 
TC 
- NSB 
- NSB 
where S = radioactivity of standards and unknowns. 
A standard curve is constructed by plotting percentage binding of the 
reference standards. The percentage binding of the unknown samples are 
calculated and the hormone concentration read off the graph. 
The basic requirements for a radioimmunoassay are therefore: 
1. unlabelled antigen 
2. labelled antigen 
3. antibody 
4. a method for separation of bound from free antigen. 
2 (i) Radioimmunoassay of Glucagon (IRG) (Faloona and Unger, 1974) 
The assay used was modified from that described by Faloona and Unger (1974). The modifications were as follows: 
a) alteration of the quantities of reagents placed in assay tubes and a 
final volume of 1 ml as opposed to 1 .2 ml. 
b) incubation was for 3 as opposed to 4 days. 
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c) horse not sheep serum was used in the separation. 
d) incubation with charcoal was reduced from 45 to 20 min. 
Reagents 
{a) Antiserum : The antiserum {30k) was raised in rabbits against beef-pork 
pancreatic glucagon and purchased from Dr R. Unger. The cross-reactivity with 
GLI was< 4% and with GIP, VIP, cholecystokin octapeptide, substance P, Leu 
Enkephalin and SRIF < 1%. The final dilution of the antiserum in the radio-
immunoassay was 1:40,000. 
{b} Standards: The reference standards used were pure porcine pancreatic IRG 
obtained from Eli Lilly Laboratories, Indianappolis, U.S.A. The unlabelled 
anti gen was reconstituted on the day of assay and dluted to give standards of 
5, 10, 20, 50, 100, 200, 500 pg IRG. 
{c) 1251 IRG: The above pure porcine pancreatic IRG was labelled with 1251 
by the technique of Greenwood, Hunter and Glover (1936). The label was 
purified on a 30 x 0.7 cm Sephadex QAE A25 anion exchange column in 0.08 M 
TRIS HCl - sodium chloride buffer, pH 8.6. 
(d) Assay buffer: The buffer used was 0.2M glycine in O.lM sodium chloride, 
pH 8.8, containing 0.25% human serum albumen, 1% normal rabbit serum and 5% 
trasylol. 
Procedure 
600 pl assay diluent, 200.)Jl standard or unknown sample, 100).Jl antiserum and 
lOO)Jl 1251 IRG (7000 counts per minute; cpm} were incubated in plastic 
disposable tubes for 72 hr at 40c. Separation of antibody-bound from free 1251 IRG was accomplished using 500yl 0.5% charcoal (Sigma Chemical, USA) and 
0.25% dextran T70, mixing and incubating for 20 min at 4°c. The tubes were 
then centrifuged at 1.2 x 103 g, the supernatant decanted and the pellet with 
free 1251 IRG was counted in a Packard automatic gamma spectrometer for either 
10 mi n or 10,000 counts. 
Results 
The sensitivity, taken as the lowest amount of IRG that caused a significant 
displacemen t of 1251 IRG (p.( 0.01} (Feldman and Rodbard, 1971 ), was 6 pmol/1. 
The i nter-assay coefficient of variation was 15.9 (n = 9). 
The i ntra-assay coefficient of variation was 14.1 % (n = 10}. 
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2 (ii} 
Reagents 
Radioimmunoassay of Pancreatic polypeotide (PP) (Sive, Vinik, 
Van Tonder and Lund, 1978 .= · 
(a) Antiserum: The antiserum which was raised in a rabbit against purified 
hPP (Lot 615-10548-248-19), was a generous gift from Dr R.E. Chance of Eli 
Lilly Laboratories, USA. There was no cross-reactivity of the antiserum with 
monocomponent insulin, glucagon, GIP or human gastrin l. The antiserum was 
used in a final dilution of 1:100,000. 
(b) Standard: Highly purified hPP (Dr R.E. Chance) was used as standard. 
(c) 1251 bPP: bPP was iodinated using the Chloramine-T method (Greenwood, 
Hunter and Glover, 1963) and purified on a 0.9 x 50 cm. Sephadex G-50 
superfine column. 
(d) Assay Buffer: The buffer was a 0.04M sodium phosphate buffer, pH 7.4, 
containing l g human albumen, 1% normal rabbit serum and 0.2 g merthiolate 
and 6 g sodium chloride. 
Procedure 
The assay tubes con ta i ni ng 700 Jll buffer, l 00 )Jl anti serum and l 00 JJl standard 
or sample were incubated in duplicate at 40c for 48 hr. 1251 bPP (5000 cprn) 
in 100)11 buffer was added and the tubes incubated for a further 24 hr. 
Separation of antibody bound from free 125 I bPP was carried out by addition of 
1 ml of 25% PEG to the tubes. 
Results 
The sensitivity of the assay was 4 pmol/1. 
The inter-assay coefficient of variation was 14% at 50% of the maximum binding 
(n = 10). 
The intra-assay coefficient of variation was 9%. 
2 (iii) Radioimmunoassay of Gastrin 
The Sorin gastrin kit (Sorin Biomedica, Gruppo Radiochimica, Italy) 
was used for all radioimmunoassays. 
Reagents 
All reagents were supplied in the Sorin gastrin kit. 
(a) Antiserum: The antiserum was raised in rabbit against human gastrin 
conjugated to bovine serum albumen. The cross-reactivity of the antiserum 
with cholecystokinin octapeptide was 10%, with caerulein< 5% and with 
bombesim, insulin, IRG and VIP~ 1%. 
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(b) Standards: The reference standard was synthetic human gastrin - I (l - 17). 
(c) 1251 Gastrin: The above synthetic human gastrin I was used for labelling. 
(d) Assay Buffer: The buffer was a 0.02M veronal buffer pH 8.2 - 8.6 
Procedure 
700.)Jl buffer, 100)11 sample or standard, 100 jll 1251 Gastrin (10,000 cpm) and 
lOOJJl antiserum were added to assay tubes in duplicate. The tubes were mixed 
and incubated at 2 - 6°C for 24 hr. Before separation lOOJJl inactivated 
horse serum was added to all standard tubes. Separation of antibody bound from 
free 1251 Gastrin was achieved by the addition of charcoal and centrifugation 
at 1.2 x 103g for 15 min. The radioactivity in the charcoal pellet was counted 
in a gamma spectrometer for either 10 min or 10,000 counts. 
Results 
The sensitivity of the assay was 8 pmol/1. 
The inter-assay coefficient of variation was 17.2% (n = 10). 
The intra-assay coefficient of variation was 6.8% (n = 10). 
2 (iv) Radioimmunoassay of Gastric Inhibitory Polypeptide (GIP) (Kuzio, 
Dryburgh, Malloy and Brown, 1974) 
The assay used was modified from that described by Kuzio, et al (1974). 
The modifications were as follows: 
(a) Sephadex QAE - A25 column was used in place of a Sephadex G - 15 column 
in the purification of 1251 GIP. 
(b) The incubation volume was increased to 1 ml in place of 0.5 ml and the 
preincubation period increased to 72 hr. 
(c) The separation of bound from free 1251 GIP was accomplished using 25% 
PEG instead of charcoal. 
Although the materials used in the assay were the same as those used in the 
assay reported by Kuzio, et al, difficulties encountered in establishing a 
stable, reproducible assay resulted in major modification~ being made. 
Reagents 
(a) Antiserum: Antiserum (GPOl) for the assay was obtained from Dr J.C. Brown 
and was used in a final dilution of 1:35,000. 
(b) Standards: The reference standard used was guinea pig GIP (EG 111) 
received from Dr J.C. Brown. 
(c) 1251 GIP: The above guinea pig GIP (EG 111) was used for labelling. 
5 )Jg GIP (in 50 J.11 0.5 M phosphate buffer, pH 7 .5) was reacted with 1.0 mCl 
Sodium 1251 (Radiochemical Centre, Amersham) using lOJJg chloramine T. The 
reaction was terminated after 10 sec by the addition of 20JJl of 0.24% sodium 
metabisulphite. 50.JJl 1% Potassium Iodide and 10 Jll lM TRIS were added before 
applying to the 30 x 0.7 cm Sephadex QAE - A25 column and eluted with 0.03 M 
TRIS/Sodium chloride buffer pH 8.6 at 10 ml/hr. l ml fractions were collected 
and the fractions showing the greatest immunoreactivity and least damage were 
used in the assay. 
(d) Buffer: The assay buffer was 0.04M phosphate, pH 7.4 with added 1% 
normal rabbit serum, 0.25% human serum albumen and 5% trasylol. 
Procedure 
700JJ1 assay buffer, 100)11 sample or standard and 100)11 a'ntiserum were 
placed in a tube and prehcubated at 4°C for 72 hr. After 72 hr 100)11 1251 
GIP (5,000 cpm) was added and the mixture incubated at 4°C for a further 24 hr. 
Separation of antibody bound from free 1251 GIP was accomplished using 1 ml of 
25% PEG. Plasma content was equalized by the addition of aged charcoal treated 
human plasma to standards and water to sample tubes. The tubes were 
centrifuged at 1.8 x 1039 for 45 min, the supernatant decanted and the PEG 
precipitate counted in a spectrometer for a minimum of 10 min or 10,000 counts. 
Results 
The sensitivity of the assay was 29.4 pmol/1. 
The inter-assay coefficient of variation was 9% (n = 8). 
The intra-assay coefficient of variation was 8% (n = 9). 
2 (v) 
Reagents 
Radioimmunoassay of Somatostatin (SRIF-LI) (Kronheim, Berelowitz 
and Pimstone, 1978 
(a) Antiserum: Antibodies to somatostatin were produced in rabbit in response 
to immunization with cyclic somatostatin conjugated by carbodiimide conden-
sation to Haliotis sp. haemocyanin (Goodfriend, Levine and Fasman, 1964). The 
antiserum showed no cross-reactivity with a wide range of hypothalamic 
peptides, posterior pituitary neurohormones, pituitary and gut hormones and 
neurotransmitters. The antiserum (S16) was used in the assay at a final 
dilution of 1:125,000. 
(b) Standard: The reference standard used was synthetic cyclic somatostatin 
(AY24910) obtained from Dr E. Polakm'I, Ayerst Laboratories. 
138 
(c) 1251 SRIF: N - tyrosylated - somastostatin obtained from Dr D.H. Coy, 
was labelled with 1251 by the Greenwood-Hunter-Glover technique (1963). The 
label was purified on a 5 x l cm Whatman CM52 cellulose column. 
(d) Buffer: The assay buffer was 0.5% bovine serum albumen O.OlM 
sodium phosphate in 0.15M sodium chloride, pH 7.8 with 0.05M disodium 
ethylene-diamine-tetra-acetic acid (EDTA). The final buffer pH of the buffer 
was 5.6. 
Procedure 
200 JJl buffer, 100 ).11 antiserum, 100 J.Jl 1251-tyr' - somatostatin (4,000 to 
6,000 cpm) and 100 JJl reference standard in serial dilutions or sample were 
incubated in tubes at 4°c for 20 hr. Separation of antibody-bound from free 
label was achieved using 500 JJl 0.1 % charcoal (NORIT 11 A11 ) coated with 0 .. 01 % 
dextran in phosphate buffer saline in the p(esence of lOOJJl inactivated horse 
serum (Wellcome), incubated for 40 min at 4°c. The tubes were centrifuged at 
2.5 x 10
3
g for 20 min at 4°C and the radioactivity in the charcoal pellet 
counted in a gamma spectrometer for a minimum of 10 min or 10,000 counts. 
Results 
(a) The sensitivity of the assay was approximately 10 pg/tube. 
(b) The intra-assay coefficient of variation was 17.4% at 400 pg/ml (n = 23). 
(c) The inter-assay coefficient of variation was 19.2% at 480 pg/ml (n = 8). 
2 (vi) Radioimmunoassay for Insulin (IRI) (Sorin Biomedica, Gruppo 
Radiochimica, Italy) 
The Sorin insulin radioimmunoassay kit was used in the present 
studies. 
Reagents 
These were all contained in the Sorin Insulin Radioimmunoassay kit. 
(a) Antiserum: Insulin antibodies were obtained by pre-reacting human 
insulin antiserum raised in guinea pigs with an anti-serum pig gamma globulin 
serum raised in rabbits. The cross-reactivity of the antiserum with pro-
insulin was 7% and with glucagon and C-peptide < 1%. 
(b) 
(c) 
(d) 
Standards: Human insulin was used as the reference standard. 
1251 I 1 . nsu ,n: Labelled insulin was provided. 
Buffer: Lyohilized buffer of sodium phosphate, EDTA sodium salt and 
bovi ne albumen was dissolved in distilled water to obtain a solution of pH 7.4. 
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Procedure 
100 JJl sample or standard and lOOJJl antiserum were incubated in assay tubes 
at 2 - s0c for 6 hr. Thereafter lOOJJl 1251 Insulin was added and the tubes 
were incubated for a further 18 hr at 2 - soc. Separation was carried out 
by microfiltration using a phosphate buffer, the filter disc was transferred 
to a counting tube and the radioactivity measured in a gamma spectrometer. 
Results 
The sensitivity of the assay was 2yU/ml. 
The inter-assay coefficient of variation was 12.8% (n = 10). 
The intra-assay coefficient of variation was 8.6% (n = 10). 
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APPENDIX B 
STATISTICAL METHODS 
All statistical analysis cf data was performed using the appropriate 
programme for a Hewlett-Packard Computer, model 9830A according to the 
method described by Snedcor and Cochran · (1967). 
l. The Mean: = X 
l 
n 
X 
where x = the observations 
E = the sum of 
n = the number of observations. 
2. Standard Error of the Mean (SEM) 
for n <.30 SEM =J E (x - -x) 2 
n - 1 
3. Wilcoxan Signed-Ranked Test (paired data) : 
As the data did not fit a normal distribution curve, a non parametric 
method of analysis was applied to all results obtained -
i) for each matched pair, determine the signed (!) difference (d) 
between the two values. 
ii) Rank the d's without respect to sign. With tied d's, assign 
the average of the tied ranks (ie. first 3 tied) rank 
(l + 1 + 3)/2 = 2; next rank = 4. 
iii) Affix to each rank the sign (~) of the d which it represents. 
iv) Determine T = the smaller of the sums of the like-signed ranks. 
v) n = total no. of d's with a sign (excludes d = 0). 
vi) for nC:::.25, critical T values are read from the appropriate 
tables for n degrees of freedom and significance. 
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4. The Mann Whitney U test (for unpaired samples). 
i) All observations in the groups for comparison are put in a 
single array. 
ii) Ranks are then assigned to the combined array. With tied 
ranks the average of the ranks is given. 
iii) The rank numbers in the group that has the smaller sum are 
added. 
iv) The smaller sum of ranks, Tis referred to the appropriate 
table to determine significance. 
When the samples are of unequal size (n,, n2), an extra step 
is required: 
i) 
ii) 
iii) 
Find the total T1 of the ranks of the sample that has 
the smaller size, say n1 
Compute T2 = n, (n, + n2 + 1) - T1 
Then T = the smaller of T and T and is read off the 2 
appropriate table. 
5. Levels of Significance: 
Values of p were determined from the appropriate tables for the 
Mann Whitney U test and the Wilcoxan Signed-Rank test. 
Two tailed tests were used in the determination of p, and where 
p was greater than 0.05 (p.> 0.05) the differences were not 
regarded as significant. 
/ 
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